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Abstract 
 
Endothelial  inflammation  leading  to  vascular  dysfunction  is  a  major  contributor  to  the 
development  of  atherosclerosis.    The  release  of  adenosine  at  sites  of  inflammation 
represents  an  endogenous  mechanism  for  limiting  excessive  inflammation  and  tissue 
damage.  The  majority  of  the  anti-inflammatory  effects  of  adenosine  are  mediated  by 
signalling  through  the  A2AAR  and  activation  of  the  A2AAR  has  been  shown  to  be 
protective  in  numerous  models  of  inflammatory  disease.    Little  is  known  about  the 
molecular  mechanisms  behind  these  effects.    However,  in  vitro  studies  using  cultured 
endothelial cells indicate that signalling through the A2AAR can suppress activation of the 
NFkB and JAK/STAT proinflammatory signalling pathways.  NFkB appears to be primed 
for activation in atherosclerosis-prone regions of the aorta indicating that suppression of 
NFkB signalling may protect against the development of atherosclerosis.  In this study, the 
role of the A2AAR in regulating NFkB and JAK/STAT signalling pathway activation in the 
aorta  was  studied  using  A2AAR-deficient  mice  subjected  to  an  LPS-induced  model  of 
septic  shock.    In  response  to  LPS  treatment,  these  mice  displayed  markedly  elevated 
plasma  levels  of  the  pro-inflammatory  cytokines  TNFa,  IL-6,  IL-1b  and  GMCSF 
compared to wild-type mice.  Consistent with this finding, heightened activation of the 
NFkB  and  JAK/STAT  pathways  was  detected  in  aortic  protein  samples  from  A2AAR-
deficient mice as demonstrated by increased levels of the phosphorylated forms of IkBa 
and STAT1.  However, expression of the NFkB and STAT1-regulated genes ICAM-1, 
VCAM-1 and TAP-1 was unaffected indicating the involvement of compensatory negative 
feedback mechanisms.  These findings confirm a role for the A2AAR in regulation of pro-
inflammatory signalling in the aorta.  Further analysis of mechanisms which mediate this 
response may reveal new targets for therapeutic intervention to suppress inflammation in 
inflammatory disorders such as atherosclerosis. 
While the wide range of anti-inflammatory and tissue-protective responses elicited by the 
A2AAR have been well documented, the molecular regulation of the A2AAR has been less 
well studied.  The presence of several serine and threonine residues in the extended C-
terminal tail of the A2AAR suggests that it may be regulated by phosphorylation events 
occurring in this region.  Indeed, the canine A2AAR is phosphorylated in response to PKC 
activation.  Interestingly, several proteins have recently been identified as being able to 
interact  with  the  C-terminal  tail  of  the  A2AAR.    However,  how  these  interactions  are 
regulated is not known.  One of the aims of this study was to characterise phosphorylation 3 
of the human A2AAR and to determine whether this could provide a means for regulating 
the binding of C-terminal interacting proteins.  This was examined using human umbilical 
vein endothelial cells infected with recombinant adenovirus encoding the human A2AAR.  
It was found that phosphorylation of the human A2AAR could be induced in HUVECs by 
treatment with PMA or by stimulation of endogenous histamine H1 receptors.  This was 
due  to  activation  of  PKC,  as  phosphorylation  was  inhibited  by  the  PKC  inhibitor 
GF109203X and by depletion of PKC following chronic treatment with PMA.  Treatment 
of  cells  with  the  calcium-chelating  agent  BAPTA/AM  did  not  inhibit  PMA-induced 
phosphorylation  indicating  that  a  calcium-insensitive  isoform  of  PKC  was  responsible.  
Meanwhile an siRNA-mediated  gene silencing approach confirmed that  PKCe was not 
responsible  indicating  the  involvement  of  either  PKCd  or  PKCq.    Previously  reported 
interactions between the A2AAR and TRAX and 14-3-3t were confirmed in vitro by GST 
pull-down assay.  Binding of 14-3-3t to the A2AAR appeared to be unaffected by treatment 
of  HUVECs  with  PMA.    However,  A2AAR  complex  formation  with  TRAX  was 
significantly reduced in samples from PMA-stimulated cells.  These findings indicate that 
PKC-mediated phosphorylation may represent a means of regulating which proteins can 
interact with the C-terminal tail of the A2AAR.  This may allow the A2AAR to initiate 
distinct  signalling  pathways  depending  on  the  cellular  context  in  order  to  achieve  the 
appropriate response. 
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1  Introduction 
1.1 Vascular inflammation 
1.1.1 Inflammation 
The process of inflammation is the immediate response of tissues to cellular injury or 
infection  and  is  essential  for  the  maintenance  of  tissue  homeostasis  and  mediation  of 
immune responses.  Clinically, inflammation is characterised by heat, pain, swelling and 
redness, symptoms caused by increased blood flow to the affected area, leakage of fluid 
into  tissues  and  the  accumulation  of  activated  leukocytes.    The  actions  of  cytotoxic 
lymphocytes and inflammatory mediators serve to remove pathogens and damaged tissues, 
clearing the way for healing and restoration of function (Murphy et al., 2008). 
Inflammation  is  initiated  on  activation  of  the  innate  immune  system  by  microbes  or 
damaged  cells.    Macrophages  and  neutrophils  have  germline-encoded  cell  surface 
receptors that recognise patterns of molecules that are common to many pathogens and the 
products released from damaged or dying cells.  Receptor ligation triggers phagocytosis 
and induces changes in gene expression such as an increase in production of cytokines and 
other  inflammatory  mediators  which  recruit  and  activate  neutrophils  and  other 
lymphocytes  (Han  and  Ulevitch,  2005).    Inflammation  can  also  be  triggered  through 
activation of the complement cascade as the first component, C1q, can interact directly 
with the surface of certain pathogens.  Complement is a series of proteases which  act 
sequentially to produce fragments that are involved in clearing pathogens either through 
opsonisation or by direct lysis.  The cleavage events also produce fragments including C3a, 
C4a and C5a which are inflammatory mediators (Tomlinson, 1993). 
1.1.2 The role of the vascular endothelium 
A  crucial  site  in  the  development  of  the  inflammatory  response  is  the  vascular 
endothelium, a single-celled layer that forms the lining of all blood vessels (Hurairah and 
Ferro, 2004; Michiels, 2003).  In one capacity the vascular endothelium acts as a barrier 
between  blood  and  neighbouring  tissues,  allowing  the  exchange  of  nutrients  while  in 
normal conditions, limiting the passage of blood cells and plasma proteins.  In addition, the 
endothelium  plays  a  critical  regulatory  role  in  many  processes  required  for  vascular Gillian R Milne, 2008    Chapter 1, 20 
homeostasis including maintenance of vascular tone, humoral coagulation, angiogenesis 
and inflammation (Hurairah and Ferro, 2004; Michiels, 2003). 
Endothelial cells of the microvasculature are the site of some of the first events in the 
inflammatory response (Muller, 2003).  On activation by pathogens or damaged cells in 
tissues, mast cells, macrophages and neutrophils produce cytokines such as interleukin (IL) 
-1, IL-6 and tumour necrosis factor-a (TNFa) and other inflammatory mediators such as 
histamine  and  bradykinin  which  act  on  local  blood  vessels  to  stimulate  vasodilatation, 
increase vessel wall permeability and activate the endothelium to express cell adhesion 
molecules.  These bind reciprocal molecules on circulating lymphocytes, causing them to 
adhere to the endothelium before migrating to the site of injury attracted by an increasing 
concentration gradient of chemotactic cytokines such as macrophage chemotactic protein 
(MCP-1;McEver,  2001).    As  well  as  these  local  effects,  cytokines  produced  by 
macrophages  and  neutrophils  stimulate  endothelial  and  fibroblast  cells  to  trigger  a 
secondary wave of cytokine secretion.  These act systemically to activate the “acute phase 
response” with results such as induction of fever and changes in levels of proteins secreted 
by the liver such as C-reactive protein (CRP), complement proteins and fibrinogen which 
contribute to non-specific defences (Baumann and Gauldie, 1994). 
1.1.3 Activation of the endothelium and leukocyte recruitment 
The migration of leukocytes from the vascular system to a site of injury or infection is a 
key event in the process of inflammation.  Inflammatory mediators including the cytokines, 
IL-1, IL-6 and tumour necrosis factor-a, play a central role in recruiting large numbers of 
neutrophils and monocytes to sites of infection and initiating innate and adaptive immune 
responses (Murphy et al., 2008).  The process of leukocyte recruitment follows a series of 
well-characterised steps which result in their adhesion to the endothelium, extravasation 
and  migration  into  tissues.    In  response  to  inflammatory  mediators,  local  small  blood 
vessels become dilated which increases blood flow and slows the course of circulating 
lymphocytes,  allowing  them  to  make  contacts  with  vascular  endothelial  cells  before 
adhering to and crossing the endothelium (Muller, 2003; figure 1.1). 
The endothelium is not normally adhesive and so for interactions between cells to occur, it 
must be activated to express adhesion molecules.  The first to appear are the selectins  Gillian R Milne, 2008    Chapter 1, 21 
Figure 1.1 Recruitment of leukocytes to sites of inflammation 
The process of leukocyte recruitment follows a series of well-characterised steps which 
result  in  their  adhesion  to  the  endothelium,  extravasation  and  migration.    Initially, 
leukocytes roll along the endothelium as a result of weak and reversible interactions 
between P-selectin and E-selectin on endothelium and sulphated sialyl-Lewis
x moieties 
of leukocyte glycoproteins such as P-selectin glycoprotein-1 (PSGL-1).  Chemokines 
such as macrophage chemotactic protein-1 (MCP-1) and IL-8 then activate b-integrins 
including  leukocyte  function  associated  antigen  (LFA-1)  and  Mac-1  on  leukocytes, 
which allows them to make firmer contacts with receptors such as intracellular adhesion 
molecule-1 (ICAM-1) on the endothelium.  Following adhesion, leukocytes transmigrate 
out  of  the  blood  vessel  between  or  through  endothelial  cells  with  the  help  of  other 
molecules such as platelet-endothelial-cell adhesion molecule-1 (PECAM-1) and CD99.  
In order to cross the basement membrane, leukocytes secrete matrix metalloproteinase 
enzymes and migrate following an increasing gradient of chemokines secreted by cells 
at the site of infection.  (Figure from Muller, 2002) Gillian R Milne, 2008    Chapter 1, 22 
(Carlos and Harlan, 1994).  In response to mediators such as histamine (Geng et al., 1990), 
P-selectin  is  rapidly  translocated  from  intracellular  Weibel-Palade  bodies  to  the  cell 
membrane while stimuli such as lipopolysaccahride (LPS), IL-1 and TNF-a subsequently 
induce the expression of E-selectin with maximal effect after 3-4 hours (Bevilacqua et al., 
1987).    Selectins  interact  with  sulphated  sialyl-Lewis
x  moieties  of  certain  leukocyte 
glycoproteins,  the  major  ligand  for  P-  and  L-selectin  being  P-selectin  glycoprotein-1 
(PSGL-1;  McEver,  2001).    This  interaction  is  weak  and  reversible  and  so  leukocytes 
appear to roll along the endothelium, pulled by the shearing  force of the blood.  This 
increases their probability of coming into contact with chemokines immobilised on the 
endothelial cell surface (Jung et al., 1998).  Leukocytes express b-integrins, for example, 
leukocyte  function  associated  antigen  (LFA-1)  and  Mac-1,  which  in  response  to 
chemokines  such  as  IL-8  and  macrophage  chemotactic  protein-1  (MCP-1),  undergo  a 
conformational  change  which  increases  their  affinity  for  receptors  such  as  intercellular 
adhesion  molecule-1  (ICAM-1)  on  the  endothelium  (Harris  et  al.,  2000).    Rolling  is 
arrested and leukocytes are able to transmigrate out of the blood vessel between or through 
endothelial cells with the help of other molecules such as platelet endothelial cell adhesion 
molecule-1  (PECAM-1)  and  CD99  (Muller,  2003).    In  order  to  cross  the  basement 
membrane, leukocytes secrete matrix metalloproteinase enzymes and migrate following an 
increasing gradient of chemokines secreted by cells at the site of infection (McIntyre et al., 
2003). 
1.2 The vascular endothelium and disease 
Under normal conditions, the endothelium exhibits an anti-inflammatory, anti-coagulatory, 
anti-thrombotic  state  (Hurairah  and  Ferro,  2004;  Michiels,  2003).    This  ensures  that 
inflammatory  responses  are  short-lived,  resulting  in  the  containment  of  infection  and 
elimination  of  pathogens  followed  by  reversion  of  the  endothelium  back  to  its  resting 
phenotype.  However, in certain circumstances, the endothelium becomes dysfunctional 
and the balance between the potentially damaging effects of the inflammatory response and 
the protective mechanisms exhibited by the endothelium is lost.  In this way, endothelial 
inflammation contributes to the progression of numerous diseases including atherosclerosis 
(Anderson  et  al.,  1995),  sepsis  (Zimmerman  et  al.,  1999)  and  systemic  lupus 
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1.2.1 Vascular dysfunction 
The normal, healthy endothelium regulates vascular homeostasis through maintenance of 
vascular tone and control of humoral coagulation, platelet function, smooth muscle growth 
and leukocyte invasion (Trepels et al., 2006).  Maintenance of vascular tone is achieved 
through synthesis and release of a balance of vasodilatory substances, such as nitric oxide 
(NO) and  prostacyclin, and vasoconstrictory substances such as endothelin-1 (ET-1) and 
angiotensin II (ATII; Hurairah and Ferro, 2004).  In addition to their roles in controlling 
vascular  tone,  many  of  the  vasodilators  produced  also  play  protective  roles  while  the 
vasoconstrictors often promote inflammatory and atherogenic responses.  Therefore, any 
damage to the endothelium which alters the balance of these mediators results in vascular 
dysfunction.  Vascular  dysfunction is clinically defined as impairment of endothelium-
dependent vasodilation but is also characterised by conversion of the endothelium to an 
“activated” phenotype associated with increased endothelial permeability and leukocyte 
adhesion  and  production  of  pro-inflammatory  cytokines  (Davignon  and  Ganz,  2004; 
Anderson, 1999).  Many of these effects are due to the loss of NO activity.  NO is the 
major vasodilatory substance in the endothelium.  However, it also has other protective 
roles in inhibiting inflammatory responses.  For example, NO opposes the actions of ATII 
to suppress adhesion molecule expression and inhibit leukocyte adhesion (Nabah et al., 
2005).    In  addition,  NO  works  synergistically  with  prostacyclin  to  inhibit  platelet 
aggregation (de Graaf et al., 1992) and suppresses proliferation of smooth muscle cells 
(Garg  and  Hassid,  1989).    Vascular  dysfunction  leads  to  the  development  of  a  pro-
inflammatory, pro-thrombotic environment within the vascular system.  Therefore, it is 
perhaps not surprising that vascular dysfunction is strongly implicated in the development 
of  vascular  diseases  and  in  particular,  atherosclerosis  (Davignon  and  Ganz,  2004; 
Landemesser et al., 2004; Anderson, 1999). 
1.2.2 Atherosclerosis 
Atherosclerosis can be considered to be a chronic inflammatory disease, characterised by 
the accumulation of macrophages, smooth muscle cells and lymphocytes in the arterial 
wall in response to pro-inflammatory stimuli.  This process leads to the development of 
lipid-rich lesions known as atherosclerotic plaques.  Over time, these plaques may evolve 
to occlude the artery lumen or alternatively they may rupture, triggering thrombosis which 
is often followed by myocardial infarction or stroke (Langheinrich and Bohle, 2005; Glass 
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Vascular  dysfunction  is  generally  accepted  as  the  main  predisposing  factor  towards 
atherosclerosis and is detected prior to the appearance of clinical symptoms (Anderson, 
1999).  Numerous different stimuli may activate the endothelium during the early stages of 
vascular  dysfunction  including  modified  low-density  lipoproteins  (mLDL),  viruses, 
bacterial  pathogens  and  free  radicals.    Initiation  of  atherosclerotic  plaque  formation  is 
characterised by the infiltration of LDL into the artery wall and its modification through 
oxidation or enzymatic attack (Stoll and Bendszus, 2006).  Macrophages recruited to the 
activated  endothelium  take  up  mLDL  via  toll-like  receptors  (TLRs)  and  scavenger 
receptors (Stoll and Bendszus, 2006).  This initially serves a protective role.  However, 
with continued accumulation of LDL, macrophages develop into lipid-lain foam cells and 
contribute  to  the  formation  of  fatty  streaks  in  the  vessel  wall  which  precede  the 
development of atherosclerotic plaques (Stary et al., 1994).  The progression to a mature 
plaque occurs as a result of the immigration of smooth muscle cells into the subendothelial 
space.  Here, smooth muscle cells may proliferate and take up modified lipoproteins to 
contribute  to  foam  cell  formation  while  they  also  secrete  extracellular  matrix  proteins 
which leads to the production of a fibrous cap over the lesion (Hansson, 2005; Glass and 
Witzum, 2001). 
Inflammatory  processes  are  intricately  involved  at  every  stage  of  plaque  development.  
This  is  perhaps  not  surprising  as,  of  the  numerous  stimuli  which  may  activate  the 
endothelium in the early stages of vascular dysfunction, many have the capacity to activate 
the nuclear factor kB (NFkB) pathway which is the major signalling pathway involved in 
transcriptional control of inflammatory genes (de Winther et al., 2005).  In addition, the 
activated endothelium produces pro-inflammatory cytokines such as TNFa, IL-1 and IL-6.  
These are all NFkB-regulated gene products while TNFa and IL-1 also activate the NFkB 
pathway, thereby amplifying the inflammatory response.  Another example of an NFkB-
regulated gene is vascular cell adhesion molecule-1 (VCAM-1) which is believed to be the 
major adhesion molecule responsible for adhesion of monocytes to the endothelium during 
the  early  stages  of  lesion  formation.    In  mouse  models  of  atherosclerosis,  VCAM-1 
expression is upregulated specifically in areas prone to lesion formation (Cybulsky and 
Gimbrone,  1991).    Furthermore,  atherosclerosis-prone  mice  deficient  in  VCAM-1 
expression  have  been  found  to  display  reduced  lesion  formation  compared  to  mice 
expressing normal levels of VCAM-1 (Cybulsky et al., 2001).  Similarly, the adhesion 
molecules P-selectin and ICAM-1 have been shown to be important in mouse models of 
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al., 2001).  Following attachment to the endothelium, monocytes exit the vessel lumen by 
diapedesis, attracted by chemokines such as MCP-1, which is detected at elevated levels in 
both  human  and  animal  atherosclerotic  lesions  (Yla-Herttuala  et  al.,  1991).    This  is  a 
crucial  step  in  the  development  of  atherosclerosis.    Once  resident  in  the  vessel  wall, 
monocytes are induced to differentiate to macrophages by macrophage colony-stimulating 
factor  (MCSF)  and  granulocyte  macrophage  colony-stimulating  factor  (GMCSF).    The 
roles of these cytokines in atherosclerosis progression is complex as demonstrated by the 
fact that administration and deficiency have been found to have similar effects in different 
studies (Hamilton, 2008).  This is perhaps due to the nature of the macrophage-mediated 
response in that clearance of lipids by activated macrophages is initially protective but at 
the same time leads to foam cell formation, thereby promoting lesion formation.  Activated 
macrophages also release pro-inflammatory cytokines that amplify local inflammation in 
the lesion.  In addition to macrophages, other immune cells such as mast cells, dendritic 
cells and T cells are involved in the development of the mature plaque and interactions 
between all of these cell types contribute to the development of a chronic inflammatory 
state (Hansson, 2005; Glass and Witzum, 2001).  T cells found in atherosclerotic plaques 
are generally CD4
+ T cells which are activated by antigens including mLDL presented by 
antigen presenting cells such as macrophages and dendritic cells.   Cytokines expressed 
within the lesion, for example IL-12, promote differentiation into Th1 cells which produce 
the macrophage-activating cytokine IFNg (Hansson, 2005). 
As discussed above, many of the inflammatory mediators and adhesion molecules involved 
in development of atherosclerosis are regulated by signalling through the NFkB pathway 
which is activated either by exogenous stimuli or by the pro-inflammatory cytokines IL-1 
and TNFa.  However, many are also targets of the Janus kinase/signal transducer and 
activator of transcription (JAK/STAT) pathway.  The majority of cytokines signal through 
the JAK/STAT pathway to mediate effects on gene transcription that can be either pro- or 
anti-inflammatory.  In the context of atherosclerosis, the pro-inflammatory role of IL-6 has 
been most extensively studied due to substantial evidence indicating its involvement in the 
disease process.  For example, elevated levels of IL-6 and one of its target gene products, 
C-reactive protein (CRP), are associated with the increased risk of cardiovascular disease 
and events such as myocardial infarction (Tzoulaki et al., 2005; Ridker et al., 2000).  In 
addition, both IL-6 and CRP have been detected in atherosclerotic lesions in humans and in 
animal models (Torzewski et al., 2000; Sukovich et al., 1998; Ikeda et al., 1992).  IL-6 is 
released by macrophages in the first steps of acute inflammation (Naka et al., 2002) and at 
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cells  (Hansson,  2005).    The  endothelium  is  largely  unresponsive  to  IL-6  in  normal 
circumstances  because  it  only  expresses  the  gp130  subunit  of  the  IL-6  receptor  whilst 
initiation  of  IL-6  signalling  requires  the  presence  of  both  gp130  and  an  additional 
component termed the IL-6 a receptor (IL-6Ra; Kallen, 2002).  However, a soluble form 
of the IL-6Ra, shed by neighbouring monocytes or macrophages, can bind IL-6 and form a 
complex with gp130 on endothelial cells to allow them to respond (Marin et al., 2001).  By 
similar means, cultured endothelial cells have been found to respond to a combination of 
IL-6 and sIL-6Ra resulting in the upregulation of VCAM-1, ICAM-1 and E-selectin and 
release  of  the  chemokines  MCP-1  and  IL-8,  indicating  a  potential  role  for  IL-6  in 
promoting leukocyte recruitment during atherogenesis (Modur et al., 1997; Romano et al., 
1997).  IL-6 also has effects on monocytes and macrophages, which express both gp130 
and  the  IL-6Ra,  including  stimulating  their  differentiation  from  monocytes  to 
macrophages (Chomarat et al., 2000).  In addition, IL-6 stimulates smooth muscle cells 
both  directly  and  by  upregulating  gp130  expression,  thereby  increasing  their 
responsiveness  to  IL-6  (Klouche  et  al.,  1999).    This  induces  smooth  muscle  cell 
proliferation,  upregulates  expression  of  ICAM-1  and  MCP-1  and  promotes  foam  cell 
formation  (Klouche  et  al.,  1999),  providing  further  evidence  of  the  pro-atherogenic 
properties of IL-6. 
1.3 Pro-inflammatory signalling 
The process of atherogenesis is a complex multi-step process involving many different cell 
types  which,  directed  by  numerous  pro-inflammatory  mediators,  contribute  to  the 
progression  of  disease.    Traditionally,  therapies  for  atherosclerosis  have  targeted 
hypercholesterolaemia owing to the central role of mLDL in initiating lesion formation.  
However,  the  recognition  of  atherosclerosis  as  an  inflammatory  disease  indicates  that 
modulation  of  inflammatory  processes  may  provide  a  more  useful  means  of  limiting 
disease progression.  As described above, many key molecules involved in the critical 
steps  of  lesion  formation  are  regulated  by  two  major  pro-inflammatory  signalling 
pathways: the NFkB pathway  and the JAK/STAT pathway.  Therefore, studying these 
signalling pathways and the mechanisms which regulate them will provide insights into the 
specific effector mechanisms which contribute to the development of atherosclerosis and 
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1.3.1 The NFk k k kB pathway 
NFkB is the collective name for a family of inducible, dimeric transcription factors found 
in the cytoplasm of most cell types.  In resting cells, NFkB is retained in an inactive state 
through association with a family of inhibitory proteins known as IkBs which prevent its 
translocation to the nucleus (figure 1.2).  NFkB activation occurs in response to a wide 
variety of stimuli including pro-inflammatory cytokines such as TNFa and IL-1, bacterial 
antigens  such  as  LPS,  viral  proteins,  double-stranded  RNA  and  physical  and  chemical 
stresses  (Karin  and  Ben-Neriah,  2000).    These  stimuli  ligate  a  variety  of  receptors  to 
initiate  signalling  pathways  which  converge  on  the  IkB  kinase  complex  (IKK).    On 
activation, IKK phosphorylates IkB on two specific serine residues.  Phosphorylated IkB is 
then recognised and ubiquitinated by members of the Skp1-Cullin-F-box (SCF) family of 
E3 ubiquitin ligases and targeted for degradation by the proteasome.  This frees NFkB to 
enter the nucleus and bind to the promoter or enhancer regions of specific target genes 
(Hayden and Ghosh, 2004; Karin and Ben-Neriah, 2000). 
1.3.1.1  NFk k k kB 
NFkB represents a family of structurally-related proteins which exist in resting cells as 
homo- or heterodimers bound to the inhibitory protein IkB.  There are five members of this 
family in mammals: RelA (p65), RelB, NFkB1 (p50 and its precursor p105), NFkB2 (p52 
and its precursor p100) and c-Rel.  All of these proteins share an N-terminal 300 amino 
acid conserved region known as the Rel homology domain (RHD) which mediates their 
DNA-binding,  dimerisation  and  interaction  with  IkB.    A  nuclear  localisation  sequence 
(NLS)  is  also  contained  within  the  RHD  (Ghosh  et  al.,  1998;  Verma  et  al.,  1995).  
Dimerisation is required for DNA binding and numerous combinations of Rel proteins 
have  been  described.    These  exert  different  effects  on  transcription  of  target  genes  by 
binding to kB sites with the consensus sequence GGGRNNYYCC (where R is purine and 
Y  is  pyrimidine)  with  different  affinities  (Ghosh  et  al.,  1998;  Verma  et  al.,  1995).  
p65/RelA,  RelB  and  c-Rel  have  transcriptional  activation  domains  (TAD)  which  are 
required for transcriptional activity (Blair et al., 1994; Rysek et al., 1992; Schmitz et al., 
1994).    However,  dimers  consisting  only  of  Rel  proteins  that  lack  TADs  may  act  to 
suppress transcription.   For example, p50/p50 homodimers have been found to suppress 
expression of NFkB-regulated genes in unstimulated cells by binding histone deacetylase 
complexes which silence transcription (Zhong et al., 2002).  The most abundant and the  Gillian R Milne, 2008    Chapter 1, 28 
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Figure 1.2 Schematic model of NFk k k kB activation 
In  resting  cells,  NFkB  is  retained  in  an  inactive  state  through  association  with  IkBa.   
NFkB  activation  occurs  in  response  to  a  wide  variety  of  stimuli  including  pro-
inflammatory cytokines such as TNFa and IL-1 which initiate signalling pathways that 
converge on the IkB kinase complex (IKK).  On activation, IKK phosphorylates IkB on 
two specific serine residues (Ser32 and Ser36).  Phosphorylated IkB is then recognised and 
ubiquitinated by members of the Skp1-Cullin-F-box (SCF) family of E3 ubiquitin ligases.  
Ubiquitinated IkBa is recognised by the 26S proteasome and degraded.  This frees NFkB 
to enter the nucleus and bind to the promoter or enhancer regions of specific target genes.
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best well characterised NFkB dimer is p65/p50.  The term NFkB is therefore often used 
synonymously with p65/p50 and so far, mechanisms of regulation appear to be common to 
different  complexes.    However,  dimers  may  show  distinct  preferences  for  binding 
particular IkBs (Karin and Ben-Neria, 2000; Ghosh et al., 1998). 
1.3.1.2  Regulation of NFk k k kB by Ik k k kB 
NFkB activity is regulated by its inhibitory protein IkB, which binds to NFkB and masks 
its nuclear localisation sequence (NLS) thereby inhibiting its translocation to the nucleus. 
The IkB family includes IkBa, IkBb, IkBg, IkBe, Bcl-3 and IkBz in higher vertebrates 
and  the  Drosophila  protein  Cactus  (Yamazaki  et  al.,  2001;  Ghosh  et  al.,  1998).    Two 
additional members are formed from the processing of the NFkB precursor proteins p105 
and  p100  (Rothwarf  and  Karin,  1999).    IkB  family  members  are  characterised  by  the 
presence of either six or seven ankyrin repeats within their sequences.  These are stretches 
of a 30-34 amino acids which form stacked helix-loop-helix structures, representing one of 
the most common protein-protein interaction domains in nature (Li et al., 2006).  Specific 
interactions occur between the ankyrin repeats of IkB proteins and the RHDs in NFkB, 
resulting in the masking of the NLS in NFkB. 
Only IkBa, IkBb and IkBe have N-term regulatory regions which are required for stimuli-
induced  degradation  (Karin  and  Ben-Neriah,  2000).    IkBa  has  been  most  well 
characterised.  It shares a common domain structure with IkBb consisting of an N-terminal 
regulatory region, which is phosphorylated in response to stimuli, a central ankyrin repeat 
domain  and  a  C-terminal  PEST  sequence  which  is  involved  in  regulation  of  protein 
turnover (Ghosh et al., 1998; Verma et al., 1995).  In addition, IkBa also contains leucine-
rich nuclear export sequences (NES) which interact with the nuclear export receptor CRM1 
(Huang et al., 2000; Johnson et al., 1999).  Originally, masking of the NFkB NLS by IkBa 
was  thought  to  be  solely  responsible  for  its  cytoplasmic  localisation.    However, 
crystallographic structures of NFkB in complex with IkBa show that IkBa only masks the 
NLS of p65 while the p50 NLS remains exposed (Malek et al., 2003; Huxford et al., 
1998).  A role for an NES was revealed by the finding that NFkB/IkBa complexes are 
almost completely redistributed to the nucleus following inhibition of CRM1 (Huang et al., 
2000) or deletion of an N-terminal NES in IkBa (Johnson et al., 1999).  The presence of 
both the NLS on p50 and the NES on IkBa results in constant shuttling of the complex 
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cytoplasmic localisation (Huang et al., 2000; Johnson et al., 1999).  The ability of IkBa to 
shuttle  between  the  cytoplasm  and  the  nucleus  allows  it  to  play  a  critical  role  in 
terminating NFkB activity.  Unlike other members of the IkB family, IkBa expression is 
induced by NFkB as part of an autoregulatory feedback loop (de Martin et al., 1993; Le 
Bail et al., 1993).  Newly synthesised IkBa enters the nucleus, removes NFkB from DNA 
and transports it back into the cytoplasm thereby terminating its activity (Rodriguez et al., 
1999; Arenzana-Seisdedos et al., 1997). 
1.3.1.2.1 Stimulus-induced degradation of Ik k k kB 
The defining event in NFkB activation is stimulus-induced degradation of IkB.  This is a 
multi-step process requiring the phosphorylation, polyubiquitination and 26S proteasome-
mediated degradation of IkBa (Hayden and Ghosh, 2004; Karin and Ben-Neriah, 2000).  
Protein  modification  by  ubiquitination  involves  the  formation  of  an  isopeptide  linkage 
between the C-terminal Gly76 of ubiquitin and e-amino groups on lysine residues in the 
substrate protein.  Similar linkages between lysine residues in ubiquitin molecules can 
allow formation of polyubiquitin chains which have different effects on the fate of the 
substrate protein depending on the particular lysine residue utilised.  For example, Lys48-
linked chains target proteins for degradation by the 26S proteasome while Lys63-linked 
chains mediate protein-protein interactions and have been shown to have various effects 
including activation of protein kinases such as the transforming growth factor b activated 
kinase-1 (TAK1) complex which phosphorylates and activates IKK (Fang and Weissman, 
2004).  The process of ubiquitination requires the sequential action of three enzymes: E1, a 
ubiquitin  activating  enzyme,  E2,  a  ubiquitin-conjugating  enzyme  and  E3,  a  ubiquitin 
ligase.  The E3 component confers specificity on the system as it interacts directly and 
specifically with the substrate protein to bring it together with ubiquitin-loaded E2 (Liu, 
2004).  The E3 for IkBa belongs to the Skp1-Cullin-F-box (SCF) family of E3 ubiquitin 
ligases which generally recognise phosphorylated target proteins (Karin and Ben-Neriah, 
2000; Hatakeyama et al., 1999; Yaron et al., 1998).   
In response to NFkB-inducing stimuli, IkBa is phosphorylated by IKK on the N-terminal 
residues Ser32 and Ser36 which triggers its ubiquitination and degradation (Chen et al., 
1995, Brockman et al., 1995; Brown et al., 1995).  The bTrCP receptor subunit of the SCF 
family  binds  specifically  to  the  phosphorylated  form  of  IkB  via  the  E3  recognition 
sequence (DpSGXXpS) which incorporates Ser32 and Ser36 in IkBa (Yaron et al., 1998; Gillian R Milne, 2008    Chapter 1, 31 
Yaron et al., 1997).  This leads to its polyubiquitination on Lys21 and Lys22 and targets 
IkBa for degradation by the 26S proteasome (Di Donato et al., 1996; Chen et al., 1995; 
Scherer et al., 1995). 
1.3.1.3   Ik k k kB kinases 
The IKK complex comprises three subunits: IKKa, IKKb and IKKg (also known as NFkB 
essential modifier (NEMO)).  IKKa and IKKb are highly homologous proteins sharing 50 
% amino acid identity (Karin and Ben-Neriah, 2000).  These are the catalytic subunits of 
the  complex  and  have  similar  functional  domains  including  an  N-terminal  catalytic 
domain,  a  central  leucine  zipper  motif  and  a  C-terminal  helix-loop-helix  domain 
(Yamamoto and Gaynor, 2004).  IKKg has no catalytic activity but is essential for IKK 
activity as demonstrated by the fact that TNFa, IL-1 or LPS fail to induce NFkB activation 
in IKKg-deficient fibroblasts (Rudolph et al., 2000).  IKKg has two coiled coli domains, a 
leucine zipper domain and a zinc finger motif which are known to mediate protein-protein 
interactions.  The leucine zipper domain and a novel ubiquitin-binding domain have been 
found to be important for mediating interactions between the IKK complex and upstream 
signalling proteins that are essential for its activation (Ea et al., 2006; Devin et al., 2001).  
1.3.1.3.1 Activation by TNFa a a a 
TNFa activates NFkB signalling through ligation of the TNF receptor, TNFR1 (figure 
1.3).  TNFa exists as a trimer and binding of the cytokine to its receptor results in receptor 
aggregation which also induces dissociation of the endogenous TNFR inhibitory protein, 
silencer of death domain (SODD).  This exposes an intracellular domain of the receptor 
called the death domain (DD) which is recognised by the adaptor protein TNFR-associated 
death  domain  (TRADD).    TRADD  then  recruits  additional  adaptor  proteins  such  as 
members of the TNFR-associated factor (TRAF) family and the serine/threonine kinase 
receptor interacting protein (RIP1; Hayden and Ghosh, 2004; Chen and Goeddel, 2002).  
TRAF2 and TRAF5 are RING domain proteins and are thought to act as ubiquitin ligases, 
mediating the Lys63-polyubiquitination of RIP1 (Ea et al., 2006).  The IKK complex has 
been reported to be recruited to the receptor complex by two different mechanisms.  One 
study  showed  that  IKK  recruitment  is  dependent  on  an  interaction  between  the  RING 
domain of TRAF2 and the leucine zipper motif in either IKKa or IKKb (Devin et al., 
2001).    However,  another  group  identified  an  interaction  between  IKKg  and  Lys63-
polyubiquitin chains on RIP1 as being necessary for IKK recruitment and NFkB activation  Gillian R Milne, 2008    Chapter 1, 32 
Figure 1.3 TNFR1 and TLR4 signalling to IKK 
Activation of the TNFR1 induces association with the adaptor protein TNFR-associated 
death  domain  (TRADD).    TRADD  then  recruits  additional  adaptor  proteins  such  as 
members of the TNFR-associated factor (TRAF) family and the serine/threonine kinase 
receptor  interacting  protein,  RIP1.    TRAF2  and  TRAF5  are  ubiquitin  ligases  which 
mediate Lys63-polyubiquitination of RIP1.  IKK and the TAK1 complex are recruited to 
the signalling complex via interactions with Lys63 polyubiquitin chains on RIP1.  TAK1 is 
thus activated and phosphorylates IKK either directly or via MEKK.  Activation of TLR4 
by LPS results in recruitment of TIR domain-containing adaptor proteins such as myeloid 
differentiation  gene  88  (MyD88),  TIR-containing  adaptor  inducing  IFNb  (TRIF)  and 
TRIF-related adaptor molecule (TRAM).  MyD88 interacts with members of the IL-1R-
associated  kinase  (IRAK)  family.    Following  interaction  with  MyD88,  IRAKs  are 
phosphorylated which leads to the dissociation of IRAK-1 from MyD88 and its interaction 
with  TRAF6.    TRAF6  Lys63-linked  polyubiquitinates  several  target  proteins  including 
TRAF6 itself and the IKK complex. The TAK1 complex binds to TRAF6 via its Lys63 
polyubiquitin  chains  and  is  activated  which  allows  it  to  phosphorylate  IKKb.  
Deubiquitinating enzymes such as A20 and CYLD regulate NFkB pathway activation by 
removing  Lys63  polyubiquitin  chains  from  TRAFs,  RIP1  and  IKK.    (Figure  from 
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Figure 1.3 TNFR1 and TLR4 signalling to IKK Gillian R Milne, 2008    Chapter 1, 34 
in response to TNFa (Ea et al., 2006).  RIP1 has also been found to interact with a protein 
complex involving TAK1, which is a member of the MAP3K family, and its regulatory 
subunits TAB2 and TAB3.  This depends on an interaction between a highly conserved 
zinc finger domain in TAB2 and TAB3 and the polyubiquitin chains of RIP1 (Kanayama et 
al., 2004; Ea et al., 2006).  This results in activation of TAK1 which then phosphorylates 
and activates IKK either directly or via another MAP3K, MEKK (Kovalenko and Wallach, 
2006). 
1.3.1.3.2 Activation by LPS/IL-1 
Pathogen-associated molecules such as bacterial LPS are recognised by TLRs which are 
expressed on various immune cells such as macrophages, dendritic cells and neutrophils as 
well as non-immune cells such as fibroblasts and epithelial cells (Kawai and Akira, 2007). 
TLRs and IL-1Rs share many of the same signalling components owing to the presence of 
a  conserved  Toll/IL-1R  (TIR)  motif  within  their  intracellular  domains  which  mediates 
oligomerisation with downstream signalling molecules which also express TIR domains 
(Martin and Wesche, 2002).  Activation of TLR4 by LPS results in recruitment of TIR 
domain-containing  adaptor  proteins  such  as  myeloid  differentiation  gene  88  (MyD88), 
TIR-containing adaptor protein (TIRAP), TIR-containing adaptor inducing IFNb (TRIF) 
and  TRIF-related  adaptor  molecule  (TRAM;  figure  1.3).    MyD88  was  the  first  TIR 
domain-containing protein to be characterised and has been shown to be necessary for 
normal activation of NFkB by IL-1 and LPS (Kawai et al., 1999).  MyD88 contains an N-
terminal DD which allows it to interact with the DDs of members of the IL-1R-associated 
kinase  (IRAK)  family  including  IRAK-1,  IRAK-2,  IRAK-4  and  IRAK-M.    Following 
interaction  with  MyD88,  IRAK-4  and  IRAK-1  are  sequentially  phosphorylated  which 
leads to the dissociation of IRAK-1 from MyD88 and its interaction with TRAF6 (Kawai 
and Akira, 2007).  TRAF6 is a RING domain ubiquitin ligase which facilitates Lys63-
linked polyubiquitination of target proteins including TRAF6 itself and the IKKg subunit 
of the  IKK complex (Chen et al., 2006).  TAB2 or TAB3 can then recruit the TAK1 
complex to TRAF6 by interacting with its Lys63 polyubiquitin chains (Kanayama et al., 
2004).  Activated TAK1 has been reported to phosphorylate and activate IKKb (Wang et 
al., 2001; Deng et al. 2000). Gillian R Milne, 2008    Chapter 1, 35 
1.3.1.4  Downregulation of NFk k k kB signalling 
IKK activation represents a crucial step in the pathway leading to activation of NFkB by 
practically all stimuli and therefore represents a key point for regulation.  IKK is activated 
following a complex series of protein-protein interactions and activation steps, many of 
which  depend  upon  Lys63-linked  polyubiquitination  of  NFkB  signalling  proteins  as 
described above (Kawai and Akira, 2007; Hayden and Ghosh, 2004).  As ubiquitin ligases, 
TRAFs are key mediators of this process and their substrates include TRAFs themselves, 
IKKg and the TAB2 and TAB3 components of the TAK1 complex (Adhikari and Chen, 
2007).  Therefore, regulation of the ubiquitination status of these proteins represents an 
important  means  of  controlling  NFkB  activity.    This  is  mediated  by  specific 
deubiquitinating enzymes (DUBs).  Two of the best studied DUBs involved in regulating 
NFkB activity are A20 and CYLD.  These proteins are encoded by NFkB-regulated genes 
and  so  induction  of  A20  and  CYLD  expression  provides  a  negative  feedback  loop  to 
suppress NFkB activity (Sun, 2008). 
CYLD is a member of the ubiquitin-specific protease (USP) family of deubiquitinating 
enzymes (Sun, 2008).  It is proposed that CYLD suppresses NFkB activity by binding to 
signalling components upstream of IKK and de-conjugating Lys63 ubiquitin chains via a 
ubiquitin-carboxy-terminal-hydrolase  domain  (UCH)  present  in  its  C-terminal  region 
(Adhikari and Chen, 2007).  In support of this, CYLD has been found to bind to several 
upstream  mediators  of  IKK  activation  including  NEMO,  TRAF2  and  TRAF6 
(Brummelkamp et al., 2003; Kovalenko et al., 2003 Trompouki et al., 2003).  Furthermore, 
while  polyubiquitination  of  IKKg,  TRAF2  and  TRAF6  has  been  observed  when  these 
proteins are overexpressed in conjunction with HA-ubiquitin, co-transfection with CYLD 
prevented  detection  of  the  polyubiquitinated  forms.      In  contrast,  co-transfection  with 
catalytically  inactive  CYLD  had  no  effect  on  the  ubiquitin  status  of  these  proteins 
indicating  that  wild-type  CYLD  actively  deubiquitinates  IKKg,  TRAF2  and  TRAF6 
(Brummelkamp et al., 2003).  The role of CYLD in regulating NFkB activity has been 
demonstrated in several ways.  For example, suppression of CYLD expression using short 
hairpin RNAs has been shown to lead to increased activation of IKK in response to TNFa 
treatment (Brummelkamp et al., 2003).  A similar effect was achieved by transfecting cells 
with  a  catalytically  inactive  CYLD  mutant  lacking  the  active  site  cysteine  residue 
indicating  that  this  was  due  to  the  loss  of  the  deubiquitinating  activity  of  CYLD 
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been found to inhibit activation of NFkB in response to a wide variety of stimuli indicating 
that it may represent a general mechanism for regulating the NFkB pathway (Kovalenko et 
al., 2003). 
A20 is another DUB which has been shown to potently inhibit NFkB activity (Wertz et al., 
2004; Boone et al., 2004).  The critical nature of A20 in regulating NFkB activation is 
clear from studies using A20 knock-out mice (Lee et al., 2000).  These mice suffered 
severe inflammation and increased sensitivity to TNFa  and  LPS.  Examination of this 
effect in A20-deficient fibroblasts revealed that this was due to persistent activation of the 
NFkB  pathway  as  demonstrated  by  rapid  degradation  of  IkBa  and  a  failure  to 
reaccumulate newly synthesised IkBa following stimulation with TNFa (Lee et al., 2000).  
A20 contains an N-terminal ovarian tumour (OTU) - type domain which has DUB activity 
and seven C-terminal zinc finger domains which are reported to have E3 ligase activity 
(Wertz et al., 2006; Evans et al. 2004).  Therefore, A20 has the unique ability to act as 
both a DUB and an E3 ligase.  A20 has been found to act as a DUB, removing Lys63-
linked ubiquitin chains from several NFkB signalling proteins including TRAF6, RIP1 and 
IKKg (Boone et al., 2004, Wertz et al., 2004; Mauro et al., 2006).  In addition, A20 has 
been  reported  to  mediate  a  second  level  of  regulation  by  catalysing  the  Lys48-linked 
ubiquitination of RIP1 and targeting it for degradation (Wertz et al., 2004). 
1.3.2 The JAK/STAT Pathway 
In  general,  cytokines  mediate  their  effects  through  the  Janus  kinase  (JAK)/signal 
transducer and activator of transcription (STAT) signalling pathway (figure 1.4).  This 
pathway is initiated on binding of a cytokine to its receptor, which results in either receptor 
multimerisation or stabilisation of preformed dimers.  Activation of the receptor induces a 
conformational  change  which  allows  auto-  and  trans-phosphorylation  of  constitutively 
associated JAKs.  The active JAKs are then able to phosphorylate key tyrosine residues on 
the receptor, which then act as docking sites for the Src homology 2 (SH2) domains of 
STATs and other signalling proteins.  STATs are then themselves phosphorylated which 
enables them to dimerise and translocate to the nucleus where they modulate transcription 
of specific STAT-responsive genes (Rawlings et al., 2004; O’Shea et al., 2002, Kisseleva 
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Figure 1.4 Activation of the JAK/STAT pathway by IL-6 
The IL-6 receptor is composed of two different subunits, an 80 kDa IL-6-binding protein 
(IL-6Ra) and a 130 kDa signal-transducing subunit (gp130)  Binding of IL-6 to IL-6Ra 
induces  dimerisation  of  the  gp130  subunit  and  the  receptor  undergoes  a  conformational 
change which allows auto- and trans-phosphoryhlation of constitutively associated Janus 
kinases (JAK1, JAK2 and Tyk2).  JAKs phosphorylate gp130 on specific tyrosine residues 
which then act as docking sites for the SH2 domain-containing proteins, signal transducer 
and  activator  of  transcription  1  (STAT1)  and  STAT3.    STAT1  and  STAT3  are  then 
themselves  phosphorylated,  following  which  they  form  homo-  or  heterodimers  and  are 
translocated  to  the  nucleus  where  they  can  modulate  transcription  of  specific  STAT-
responsive  genes.    Activation  of  the  IL-6  receptor  also  leads  to  activation  of  the  ERK 
pathway via the SH2 domain-containing tyrosine phosphatase, SHP2 which binds to pTyr
759 
on gp130 and is activated by phosphorylation by JAK1.  Activated SHP2 interacts with the 
growth-factor-receptor-bound protein 2 (Grb2) which is constitutively associated with the 
Ras-GTP-exchange factor, Son of Sevenless (SOS). 
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1.3.2.1  JAKs 
In mammals, four different members of the JAK family have been identified: JAK1, JAK2, 
JAK3 and Tyk2.  JAK1, JAK2 and Tyk2 are ubiquitously expressed while JAK3 is present 
only in myeloid and lymphoid cells (Kisseleva et al., 2002).  JAKs associate with the 
membrane-proximal region of cytokine receptors.  In the case of many cytokine receptors, 
this region contains two conserved sequence elements termed box 1 and box 2.  Box 1 is 
proline-rich and has been found to be required for the binding of JAKs to receptors for IL-
2 (Howard et al., 1995) and the IL-6 family of cytokines (Radtke et al., 2002; Murakami et 
al., 1991).  Box 2 is rich in hydrophobic amino acids and is important for JAK association 
with  only  certain  receptors  (Heinrich  et  al.,  1998).    Receptor  ligation  triggers  a 
conformational change in receptor dimers that brings associated JAKs into close proximity, 
permitting autophosphorylation (Remy et al., 1999). 
JAKs are composed of seven conserved JAK homology domains (JH1-7; Kisseleva et al, 
2002).  JH1 at the carboxyl terminus is the kinase domain and has considerable homology 
to  other  kinases,  displaying  features  such  as  an  activation  loop  identified  as  being 
important  in  regulating  activity  (Hubbard  and  Till,  2000).    Mutational  analysis  has 
identified tyrosine residues in JAK2, JAK3 and Tyk2 which are critical components of this 
activation loop; Y1007/Y1008 in JAK2 (Feng et al., 1997), Y980/Y981 in JAK3 (Zhou et 
al., 1997) and Y1054/Y1055 in Tyk2 (Gauzzi et al., 1996).  JAK1 also has two conserved 
tyrosine residues, Y1022/Y1023, which are important for activation (Leonard and O’Shea, 
1998).  JH2 is termed the kinase-like domain, which although catalytically inactive, has a 
regulatory function.  Natural mutations in this region of JAK3 result in an inactive enzyme 
and  severe  combined  immunodeficiency  (SCID;  Chen  et  al.,  2000).    Conversely, 
experimentally-induced  mutations  in  the  kinase-like  domain  of  the  Drosophila  JAK 
homologue,  hopscotch,  results  in  a  constitutively  active  enzyme  and  causes  leukaemia 
(Luo et al., 1997).  The JAK carboxyl terminus (JH3-JH7) contains an SH2-like domain 
and  a  Band-4.1  ezrin,  radixin,  moesin  (FERM)  homology  domain  that  is  involved  in 
receptor association.  For example, binding of JAK2 to IFNg receptor 2 which has no box 
1/box 2 motif is mediated by the JH6 and JH7 domains (Kohlhuber et al., 1997).  These 
regions are also important for binding of JAK3 to the g chain of the IL-2 receptor (Chen et 
al., 1997).  The FERM domain has also been found to associate with the kinase domain to 
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1.3.2.2  STATs 
There are seven mammalian STAT family members designated STAT1, 2, 3, 4, 5a, 5b and 
6 (Kisseleva et al., 2002).  They are ubiquitously expressed with the exception of STAT4 
which is mainly found in the testis, thymus and spleen (Zhong et al., 1994).  STATs are 
composed of several structurally and functionally conserved domains including an amino-
terminal oligomerisation domain, a coiled-coil domain, a DNA binding domain, a linker 
region,  an  SH2  domain  and  a  carboxyl-terminal  transactivation  domain  (Becker  et  al., 
1998; Chen et al., 1998; Vinkemeier et al., 1998). 
1.3.2.2.1 The SH2 domain 
The  SH2  domain  is  highly  conserved  and  is  involved  in  the  recruitment  of  STATs  to 
activated cytokine receptors (Heim et al., 1995; Stahl et al., 1995; Greenlund et al., 1994) 
and the formation of STAT dimers (Shuai et al., 1994) through recognition of specific 
phosphorylated tyrosine motifs.  Different receptor motifs determine which STATs are 
recruited, for example, STAT3 will bind to phospho (p)YXXQ (Stahl et al., 1995) while 
STAT1 will only bind to pYXPQ (Gerhartz et al., 1996).  This difference has been shown 
to  be  due  to  the  SH2  domain  through  the  creation  of  a  chimaeric  STAT3  molecule.  
Hemmann and co-workers (1996) found that substituting the SH2 domain of STAT3 with a 
STAT1  SH2  domain  resulted  in  a  molecule  that  showed  the  receptor  motif  binding 
preference  of  STAT1.    On  recruitment  to  an  activated  cytokine  receptor,  STATs  are 
phosphorylated  by  JAKs  on  a  single  tyrosine  residue  at  the  carboxyl  end  of  the  SH2 
domain (Tyr
701 in STAT1 (Shuai et al., 1994) and Tyr
705 in STAT3 (Kaptein et al., 1996)).  
This enables them to form dimers through an interaction of the phosphorylated tyrosine on 
one STAT with the SH2 domain of another. 
1.3.2.2.2 Gene Regulation 
STAT dimers translocate to the nucleus and bind DNA motifs known as GAS (g activated 
sequence)  elements  (TTN5-6AA)  except  in  the  case  of  the  IFNa/b  response,  where 
complexes formed between STAT1, STAT2 and IRF9 (interferon regulatory factor 9) bind 
to the IFNa/b-response element (ISRE), AGTTN3TTTC (O’Shea et al., 2002).  The STAT 
transcriptional  activation  domain  (TAD)  is  proposed  to  participate  in  modulation  of 
transcription  through  interaction  with  additional  transcription  factors  and  co-activators 
such as c-Jun, BRCA1 and the cAMP-response-element-binding (CREB)-binding protein 
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conserved  serine  residue  within  the  TAD  (Ser
727  in  STAT1,  STAT3  and  STAT4)  is 
believed  to  regulate  these  interactions  to  provide  full  transcriptional  activity  (Horvath, 
2000). 
1.3.2.3  IL-6 signalling 
The IL-6 receptor is composed of two different subunits, an 80 kDa IL-6-binding protein 
(IL-6Ra) and a 130 kDa signal-transducing subunit (gp130), which is shared by all IL-6-
type cytokines (Heinrich et al., 2003).  The gp130 subunit is ubiquitously expressed while 
IL-6Ra expression is restricted to hepatocytes, monocytes, neutrophils and some B and T 
cells (Kallen, 2002).  However, IL-6 can also bind to a soluble form of the receptor (sIL-
6Ra)  which  is  either  shed  from  cell  membranes  (Mullberg  et  al.,  1993)  or  created  by 
alternative splicing of mRNA (Lust et al., 1992).  This complex can associate with gp130 
on cells that do not express the membrane-bound IL-6R thereby widening the spectrum of 
IL-6-responsive  cells.    For  example,  vascular  endothelial  cells  which  express  only  the 
gp130 subunit of the IL-6 receptor become responsive to IL-6 in the presence of sIL-6Ra 
shed from the membranes of activated neutrophils (Marin et al., 2001). 
Binding of IL-6 to IL-6Ra induces dimerisation of the gp130 subunit and formation of a 
fully functional receptor complex (Murakami et al., 1993; figure 1.4).  JAK1, JAK2 and 
Tyk2 are activated upon receptor stimulation (Stahl et al., 1994; Narazaki et al., 1994) and 
phosphorylate gp130 on tyrosine residues 683, 759, 767, 814, 905 and 915 (Stahl et al., 
1994; Hirano et al., 1997).   Studies using mutant cell lines lacking JAK1, JAK2 or Tyk2 
have revealed that signalling absolutely depends on the presence of JAK1 whereas JAK2 
and Tyk2 may be interchangeable (Guschin et al., 1995).  Phosphorylation of gp130 was 
greatly reduced in the absence of JAK1 but was unimpaired in the absence of JAK2 or 
Tyk2. 
STAT1 and STAT3 are recruited to the phosphorylated receptor through recognition of 
consensus  sequences  pY
905LPQ  and  pY
915MPQ.    In  addition,  STAT3  also  recognises 
pY
767RHQ and pY
814FKQ, (Stahl et al., 1995; Gerhartz et al., 1996).  These sites are not 
equivalent,  as  has  been  demonstrated  by  Schmitz  et  al.  (2000a)  using  mutant  gp130 
constructs lacking each of the cytoplasmic tyrosine residues present in wild-type gp130.  
Tyr
905 and Tyr
915 were found to be more potent than Y
767 and Y
814 in terms of their ability 
to  activate  STATs  and  STAT-mediated  transcription.    Upon  binding  to  the  receptor, Gillian R Milne, 2008    Chapter 1, 41 
STAT1 and STAT3 are phosphorylated, following which they form homo- or heterodimers 
and are translocated to the nucleus to modulate transcription.   
STATs are not the only proteins that are recruited to the activated IL-6 receptor.  The SH2-
domain-containing  tyrosine  phosphatase,  SHP2  binds  to  pTyr
759  on  gp130  and  is 
phosphorylated by JAK1 (Schaper et al., 1998).  Activated SHP2 can then activate the 
extracellular signal-regulated kinase (ERK) pathway through interaction with the growth 
factor receptor-bound protein 2 (Grb2) which is constitutively associated with the Ras-
GTP-exchange factor, Son of Sevenless (SOS) (Li et al., 1994). 
1.3.2.4  IFNg g g g signalling 
The functional IFNg receptor (IFNGR) comprises two 90 kDa IFNGR1 and two 62 kDa 
IFNGR2  chains.   IFNGR1 is involved in ligand binding and signal transduction while 
IFNGR2 plays only a small role in ligand binding but is essential for signalling (Stark et 
al., 1998).  Originally, these subunits were not thought to interact in unstimulated cells 
(Bach et al., 1996) but advances in spectroscopic techniques using intact cells have shown 
that the receptor is preassembled and ligand binding results in a conformational change to 
allow signalling to occur (Krause et al., 2002).  IFNGR1 and IFNGR2 have binding motifs 
for JAK1 and JAK2 respectively.  JAK1 binds to a membrane proximal sequence, LPKS at 
residues 266-269 on IFNGR1 (Kaplan et al., 1996) while JAK2 binds a proline-rich non-
contiguous motif, 
263PPSIP
267 followed by 
270IEEYL
274 on IFNGR2 (Bach et al., 1996).  
On activation of the receptor, JAK2 autophosphorylates and is then able to phosphorylate 
JAK1 (Briscoe et al., 1996).  The activated JAKs phosphorylate each IFNGR1 chain on 
tyrosine residue 440 in the sequence 
440YDKPH
444 and this creates a pair of docking sites 
for STAT1 molecules.  STAT1 is thus phosphorylated and dissociates from the receptor, 
forms homodimers and is translocated to the nucleus. 
Activation of the phosphatidylinositol 3-kinase (PI3K) pathway also appears to play a role 
in IFNg-induced STAT1-mediated transcriptional regulation.  Inhibition of PI3K or one of 
its downstream effectors, protein kinase C d (PKCd), blocks phosphorylation of STAT1 on 
Ser727 and reduces its transcriptional activity.  IFNg has been shown to activate PKCd in a 
PI3K dependent manner and so it is proposed that PKCd is a serine kinase for STAT1 
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1.3.2.5  Regulation of the JAK/STAT pathway 
JAK/STAT  signalling  is  central  to  many  biological  processes  and  so  numerous 
mechanisms exist to modulate the pathway at different stages. 
1.3.2.5.1 Protein tyrosine phosphatases 
Tyrosine  phosphorylation  by  kinases  is  a  key  event  in  the  JAK/STAT  pathway.    For 
controlled signalling, it is clear that this rapid, reversible process must be balanced by the 
action of protein tyrosine phosphatases (PTPs).  Several PTPs have been implicated in the 
regulation of JAK/STAT signalling, for example, SHP1, SHP2, and PTPe (Shuai and Lui, 
2003).  SHP1 is a non-transmembrane phosphatase expressed mainly in haematopoietic 
cells.  Its role in regulation of JAK/STAT signalling is apparent on consideration of the 
naturally  occurring  motheaten  mouse  strain  which  lacks  SHP1  activity.    Bone-marrow 
derived macrophages from these mice show dramatically increased levels of JAK1 and 
STAT1 phosphorylation following stimulation with IFNa (David et al., 1995).  SHP1 has 
been shown to bind to receptors for erythropoietin (Epo; Klingmuller et al., 1995) and IL-3 
(Wheadon et al., 2002) to suppress phosphorylation of JAKs and receptors respectively. 
SHP2 is highly homologous to SHP1 but is ubiquitously expressed. It is involved in both 
positive and negative regulation of signalling for a variety of cytokines including IL-6 and 
IFNg (Qu, 2002).  SHP2 is rapidly recruited to Tyr
759 in gp130 following IL-6 stimulation 
(Stahl et al., 1995).  It has a positive role in activating the ERK pathway but an inhibitory 
effect on JAK/STAT signalling.  Mutation of Tyr
759 in gp130 impairs SHP-2 recruitment 
and phosphorylation (Stahl et al., 1995) and leads to enhanced JAK/STAT signalling but 
reduced  ERK  activation  (Schaper  et  al.,  1998).    In  addition,  it  has  been  found  that 
overexpression of dominant negative SHP-2 mutants leads to increased phosphorylation of 
receptors, JAKs and STATs in murine fibroblasts stimulated with IL-6 (Lehmann et al., 
2003).  SHP2 is constitutively associated with the IFNa/b and IFNg receptors (David et al., 
1996).  The relevance of this is apparent in SHP2
-/- mouse fibroblasts.  These cells show 
increased STAT1 and STAT2 activity as measured by DNA binding in response to IFNa 
and IFNg which is diminished on reintroduction of SHP2 (You et al., 1999).  Furthermore, 
SHP2 has been described as a dual-specificity phosphatase that dephosphorylates STAT1 
at both Tyr
701 and Ser
727 (Wu et al., 2002). 
A cytoplasmic form of transmembrane PTPe (PTPe C) is involved in regulation of IL-6 
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phosphorylation of gp130, JAK1, Tyk2, and STAT3 while overexpression of a dominant 
negative form potentiated the IL-6 response.  This inhibitory effect is thought to be specific 
to  certain  cytokines  as  PTPe  C  does  not  affect  IFNg-induced  STAT1  phosphorylation 
(Tanuma et al., 2001).  A phosphatase that does appear to regulate STAT1 activation in 
response to IFNg is a nuclear form of the T cell PTP, PTP TC45 (ten Hoeve et al., 2002).  
Murine embryonic fibroblasts and primary thymocytes expressing defective PTP TC45 fail 
to dephosphorylate STAT1 in the nucleus following IFNg stimulation. 
1.3.2.5.2 Protein inhibitors activated STATs 
The protein inhibitors of activated STATs (PIAS) are a family of constitutively expressed 
transcriptional regulators (Chen et al., 2004).  PIAS1 was identified as a STAT-interacting 
protein in a yeast two-hybrid screen and subsequently, four other members of the family, 
PIAS3,  PIASy,  PIASxa  and  PIASxb  were  recognised  based  on  their  high  sequence 
homology  to  PIAS1  (Liu  et  al.,  1998).    Following  IFNg  stimulation,  PIAS1  binds  to 
activated STAT1, inhibiting DNA binding and therefore gene activation (Liu et al., 1998).  
PIAS3 on the other hand, shows specificity for STAT3 and suppresses IL-6 induced gene 
expression (Chung et al., 1997). 
The  effect  of  PIAS  on  STAT-mediated  transcription  cannot  be  fully  explained  by 
suppression  of  STAT  DNA-binding  activity  as  PIASy,  which  also  inhibits  STAT1-
dependent gene induction, does not prevent STAT-DNA interactions (Liu et al., 2001).  An 
alternative method of regulation that has been suggested is PIAS-directed sumoylation of 
STATs.  SUMO is a small ubiquitin-like protein modifier which has roles in the regulation 
of protein-protein interactions and protein stability, localisation and activation (Schmidt 
and Muller, 2002; Kotaja et al., 2002).  PIAS family members all have SUMO ligase 
activity (Wormald and Hilton, 2004) and both PIAS1 and PIASxa have been found to 
promote sumoylation of STAT1 on lysine residue 703 following stimulation of fibroblasts 
with IFNg (Rogers et al., 2003).  However, the functional relevance of this is unclear as 
there have been conflicting reports on the effect of mutating Lys
703 on the expression of 
IFNg-induced genes (Rogers et al., 2003; Ungureanu et al., 2003).  Ungureanu et al. (2003) 
found that this potentiated transcription of a GAS-luciferase reporter gene while Rogers et 
al. (2003) reported no effect.  More recent studies indicate that sumoylation has a selective 
inhibitory effect on STAT1-mediated transcription.  Using quantitative PCR, Ungureanu et 
al. (2005) showed that mutation of alternative STAT1 residues that are also required for 
sumoylation (Ile
702 and Glu
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target genes tested.  How sumoylation inhibits STAT1 activity is unclear but it has been 
suggested  that  it  may  act  as  a  targeting  signal  (Wormald  and  Hilton,  2004),  a  theory 
supported by the fact that  STAT1 mutants which cannot be sumoylated show prolonged 
nuclear localisation (Ungureanu et al., 2005). 
1.3.2.5.3 Suppressors of cytokine signalling 
SOCS (suppressors of cytokine signalling) are a family of inducible inhibitors of cytokine 
signalling (Starr et al., 1997).  The expression of several SOCS proteins is induced by 
activation of the JAK/STAT pathway by cytokines such as IL-6, IFNg, granulocyte colony-
stimulating  factor  and  IL-11.    They  act  as  classical  negative  feedback  inhibitors  by 
inhibiting the phosphorylation of JAKs, which in turn prevents STAT activation (Chen et 
al., 2004).  There are eight SOCS family members (CIS (cytokine-inducible SH2 protein) 
and SOCS1-7).  Genetic studies have revealed that SOCS1 is particularly important in 
IFNg signalling while SOCS3 has specificity for IL-6 signalling.  Generation of mice with 
a  conditional  deletion  of  SOCS3  in  hepatocytes  or  macrophages  has  revealed  the 
importance of SOCS3 in the IL-6 response.  These mice exhibit hyperresponsiveness to IL-
6 as shown by sustained activation of STAT1 and STAT3 and an increase in the number of 
IL-6-responsive genes while IFNg responses are normal (Croker et al., 2003; Lang et al., 
2003).    SOCS1-deficient  mice  in  contrast,  show  prolonged  IFNg-induced  STAT1 
activation but normal STAT activation in response to IL-6 (Croker et al., 2003).  
SOCS proteins are characterised by a central SH2 domain and a carboxyl-terminal motif 
termed  the  SOCS  box  (Starr  et  al.,  1997)  but  their  inhibitory  effects  are  mediated  by 
several  different  mechanisms.    SOCS1  has  been  found  to  bind  directly  to  the  kinase 
domain of JAK2 via its SH2 domain (Endo  et  al., 1997).   Inhibition is thought to be 
mediated by a second SOCS1 domain, the kinase inhibitory region (KIR), which binds to 
and blocks the substrate-binding site of the JAK kinase domain (Yasukawa et al., 1999).  
However, this model is further complicated by the recent finding that in the case of IFNg 
signalling, SOCS1 appears to interact directly with a phosphorylated Tyr
441 in subunit 1 of 
the  IFNg  receptor  before  binding  to  JAK2  (Qing  et  al.,  2005).      Inhibition  of  IL-6 
signalling  by  SOCS3,  like  SHP-2,  is  dependent  upon  interaction  with  phosphorylated 
Tyr
759  on  activated  gp130  (Schmitz  et  al.,  2000b;  Nicholson  et  al.,  2000).    However, 
SOCS3 can also bind to JAKs and has a KIR motif which may contribute to inhibition 
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Another aspect of negative regulation by SOCS may involve the SOCS box motif.  Zhang 
and co-workers (1999) found that the SOCS box binds to elongins B and C which are 
known to participate in the targeting of proteins to the proteasome for degradation.  By this 
means,  excess  SOCS  proteins  and  their  binding  partners  could  be  removed  from  the 
signalling system. 
1.3.2.5.4 Targeted degradation of STATs 
Ubiquitin-proteasome-dependent degradation has also been suggested to regulate cellular 
levels of STATs.  Kim and Maniatis (1996) found that inhibition of the proteasome led to 
accumulation of ubiquitinated STAT1 molecules in HeLa cells stimulated with IFNg and 
that  this  effect  was  dependent  on  STAT  phosphorylation.    Haspel  et  al.  (1996)  also 
observed sustained levels of STAT1 in response to IFNg when Bud-8 fibroblasts were pre-
incubated with proteasome inhibitors.  However, this was determined to be due to reduced 
receptor turnover and preservation of the signal rather than STAT levels as the effect was 
lost in the presence of a kinase inhibitor.  It is possible that more than one mechanism of 
STAT regulation exists.  In a later study, it was found that proteasome inhibitors prevented 
downregulation of phosphorylated STAT4, STAT5 and STAT6 but not phosphorylated 
STAT1, STAT2 or STAT3 in several cell lines (Wang et al., 2000).   This effect was 
maintained in the presence of a kinase inhibitor.  This group also identified the carboxyl-
terminal transcriptional activation domain of STAT5 as the region involved in regulation 
by the proteasome. 
Certain  viruses  evade  the  antiviral  activities  of  interferons  by  targeting  STATs  for 
degradation  through  the  ubiquitin-proteasome  pathway.    Paramyoxaviruses  of  the 
Rubulavirus  genus  express  “V”  proteins  which  co-ordinate  the  assembly  of  STAT-
ubiquitinating  enzyme  complexes.    Viral  V  proteins  are  E3  ligases  with  high  species-
dependent specificity for different STATs, for example, simian virus 5 targets STAT1 for 
degradation (Didcock et al., 1999) while type II human parainfluenza virus targets STAT2 
(Parisien et al., 2001) and mumps virus targets STAT1 and STAT3 (Ulane et al., 2003). 
New evidence for the role of STAT degradation in regulation of cytokine signalling comes 
from the identification of a mammalian STAT-specific E3 ligase.  STAT-interacting LIM 
protein (SLIM) was identified in a yeast two-hybrid screen and subsequently was found to 
bind phosphorylated STAT1 and STAT4 in the nucleus and to inhibit their transcriptional 
activity (Tanaka et al., 2005).  SLIM has a LIM domain which forms a Zn finger structure 
that resembles RING and PHD structures found in E3 ligases (Capili et al., 2001; Liu, Gillian R Milne, 2008    Chapter 1, 46 
2004).    This  suggested  a  role  for  SLIM  in  ubiquitination  which  was  confirmed  using 
transfection studies where the presence of SLIM promoted ubiquitination and degradation 
of STAT1 and STAT4 (Tanaka et al., 2005). 
1.4 Adenosine 
The  production  of  adenosine  represents  a  means  of  limiting  inflammation  and  tissue 
damage that is in addition to the many specific mechanisms that have evolved to control 
cytokine signalling.  Adenosine is a ubiquitous purine nucleoside that accumulates in many 
tissues in response to metabolic stress such as hypoxia during inflammation (Sitkovsky et 
al., 2004). 
1.4.1 Production 
Under  normal  conditions,  adenosine  is  continuously  produced  by  cells  through  the 
dephosphorylation  of  AMP  by  cytosolic  5’-nucleotidases  or  through  hydrolysis  of  S-
adenosyl-homocysteine.    In  hypoxic  conditions,  ATP  synthesis  is  inhibited  and  AMP 
levels rise which causes a large increase in adenosine production.  Substantial amounts of 
adenosine are also produced by the hydrolysis of adenine nucleotides released from the 
granules of neutrophils, mast cells and endothelial cells as  a result of  cellular damage 
(Sitkovsky et al., 2004; Ramkumar et al., 2001; Linden, 2001).  Ecto-apyrases such as 
CD39  hydrolyse  ATP  or  ADP  to  AMP  which  is  then  converted  to  adenosine  by  the 
extracellular 5’-ectonucleotidase CD73 (Zimmermann, 2000).  Both of these enzymes are 
induced during hypoxia to enhance adenosine production.  In addition, CD73 expression 
on endothelial cells can be upregulated by IFNa (Niemela et al., 2004) and adenosine itself 
(Narravula  et  al.,  2000).    Extracellular  accumulation  of  adenosine  is  further  enhanced 
during  hypoxia  by  inhibition  of  the  enzyme  adenosine  kinase  which  converts  excess 
adenosine back into AMP (Sitkovsky et al., 2004). 
1.4.2 Anti-inflammatory effects of the A2A adenosine receptor 
Adenosine exerts its effects through four different G-protein coupled receptor subtypes 
termed A1, A2A, A2B and A3 (Fredholm et al., 2007).  These differ in their distribution 
patterns and the type of G-protein with which they associate but all have been ascribed 
roles in tissue protection (Linden, 2001).  The A2A adenosine receptor (A2AAR) is coupled 
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A2AAR stimulation also results in activation of the ERK pathway and in addition, some G 
protein-independent effects have been reported (Fredholm et al., 2007).  The A2AAR is 
expressed on many lymphoid cells including neutrophils, monocytes, macrophages, T cells 
and natural killer (NK) cells and its activation by adenosine or adenosine analogues results 
in  a  wide  range  of  anti-inflammatory  responses  (Haskó  et  al.,  2008;  Palmer  and 
Trevethick; 2008).  Activation of the A2AAR on neutrophils has long been know to have 
suppressive effects on their cytotoxic functions by inhibiting phagocytosis (Salmon and 
Cronstein, 1990) and production of reactive oxygen metabolites (Cronstein et al., 1992).  
In addition, A2AAR activation results in reduced neutrophil recruitment to inflammatory 
sites by downregulating expression of the neutrophil adhesion molecule, very late antigen 
4 (VLA–4) which is required for adherence to the endothelium (Sullivan et al., 2004; Zhao 
et  al.,  1996).    The  A2AAR  plays  a  more  general  role  in  suppressing  inflammation  by 
regulating cytokine production by macrophages.  For example, adenosine inhibits release 
of  TNFa  and  IL-12  from  macrophages  predominantly  through  activation  of  A2AARs 
(Kreckler et al., 2006; Haskó et al., 2000).  In addition to suppressing pro-inflammatory 
cytokine  production,  adenosine  and  the  A2AAR-selective  agonist  CGS21680  have  been 
found  to  potentiate  production  of  the  anti-inflammatory  cytokine,  IL-10  (Haskó  et  al., 
2000).  This effect has been confirmed using macrophages from A2AAR-deficient mice 
which fail to produce IL-10 in response to treatment with E. coli and adenosine while the 
same treatment induces a dramatic increase in IL-10 production by wild-type macrophages 
(Csóka et al., 2007).  A2AAR-selective agonists have also been found to produce effects 
which may limit the course of inflammation through ligation of A2AARs expressed by the 
endothelium.  For example, ATL-146E inhibits neutrophil and macrophage adhesion to the 
endothelium  through  down-regulation  of  VCAM-1,  ICAM-1  and  P-selectin  on  the 
activated endothelium (McPherson et al., 2001).  The anti-inflammatory effects of A2AAR 
stimulation on endothelial cells are discussed further in chapter 3. 
In addition to these effects on cells of the innate immune system, the A2AAR also plays key 
roles  in  regulating  T  lymphocyte  function.    For  example,  the  A2AAR-selective  agonist 
ATL313 has been shown to suppress proliferation of naïve CD4
+ T cells by inhibiting 
production of IL-2 and expression of the IL-2 receptor, CD25 (Sevigny et al., 2007).  In 
this  study,  ATL313  also  reduced  expression  of  the  co-stimulatory  molecule  CD40L 
(Sevigny et al., 2007) which binds to CD40 on macrophages and in conjunction with IFNg, 
induces their activation (Stout et al., 1996).  In addition, stimulation of the A2AAR in 
activated CD4
+ T cells inhibits IL-4 and IFNg production (Naganuma et al., 2006; Lappas 
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the A2AAR is formed by the invariant NK (iNKT) cells, so called because they express an 
invariant form of the T cell receptor alongside NK cell markers such as NK1.1 (Haskó et 
al., 2008, Kronenberg, 2005).  Unlike conventional T cells, iNKT cells can be rapidly 
activated  early  in  inflammatory  responses  and  produce  copious  amounts  of  cytokines 
shortly after TCR engagement.  iNKT cells function in innate immunity by recognising self 
or foreign lipid antigens presented by APCs via an MHC1-related molecule called CD1d 
(Kronenberg, 2005).    iNKT cells also express the A2AAR and activation has been shown 
to  suppress  iNKT  production  of  IFNg  induced  by  the  marine  sponge  glycolipid  a-
galactoceramide (Lappas et al., 2006). 
The role of the A2AAR in regulating inflammatory responses has been demonstrated in 
several in vivo models of inflammation and tissue injury and has been particularly well 
studied in ischaemia reperfusion injury (IRI).  For example, in rats subjected to IRI, the 
A2AAR agonist DWH-146e causes a dramatic reduction in tissue injury that is associated 
with reduced neutrophil accumulation and adhesion molecule expression (Okusa et al., 
2000).    Similarly,  Day  et  al.  (2004)  found  that  ischaemic  liver  injury  and  chemokine 
production were suppressed in mice treated with ATL-146E.  Meanwhile, A2AAR-deficient 
mice failed to respond to ATL-146E and liver injury was exacerbated compared with wild-
type mice indicating that endogenously produced adenosine had a protective role (Day et 
al., 2004).  More recently, A2AAR activation has been shown to be beneficial in protecting 
against hepatic IRI due to effects on iNKT cells.  Lappas et al. (2006) found that treatment 
with  ATL146e  immediately  after  reperfusion  resulted  in  reduced  injury  compared  to 
untreated mice.  A similar reduced response was observed in RAG-1-deficient mice which 
lack  mature  lymphocytes  and  in  mice  treated  with  antibodies  against  either  NK1.1  to 
deplete NK cells or CD1d to block iNKT cell activation.  Meanwhile, liver injury in RAG-
1-deficient  mice  following  IRI  could  be  reconstituted  to  wild-type  levels  by  adoptive 
transfer of NK1.1
+ cells from wild-type mice.  These findings suggested that iNKT cells 
play a critical role in mediating IRI.  Adoptive transfer of NK cells from A2A-deficient 
mice was also able to reconstitute liver injury in RAG-1-deficient mice but IRI could not 
be  attenuated  by  ATL146e  indicating  that  ATL146e  exerts  its  effects  by  activating 
receptors  on  NKT  cells.    Similarly,  NK1.1
+  cells  from  IFNg-deficient  mice  could  not 
reconstitute the response showing that injury was dependent on production of IFNg by 
NKT cells.  Taken together, these finding indicate that hepatic IRI is initiated by activation 
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1.5 G protein-coupled receptors 
G  protein-coupled  receptors  (GPCRs)  constitute  the  largest  single  family  of  signalling 
receptors, estimated to represent 1 % of the human genome (Takeda et al., 2002; Bockaert 
and Pin, 1999).  GPCRs are extremely diverse in their functions, transducing signals from 
a vast array of extracellular stimuli including photons of light, ions, odorants, amino acids, 
nucleotides, peptides and phospholipids (Kristiansen, 2004).  GPCRs signal predominantly 
via interaction with and activation of heterotrimeric G-proteins which in turn modulate the 
activity of numerous effector proteins resulting in a wide range of physiological responses.  
The significance of GPCRs is further demonstrated by the fact that GPCRs represent over 
25 % of current drug targets (Overington et al., 2006).   
Phylogenetic analysis has revealed that GPCRs can be divided into five main families, 
termed Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2 and Secretin (Fredriksson et al., 
2003).  The Rhodopsin family is by far the largest family comprising approximately 670 
receptors which bind a  vast array of ligands including odorants and small endogenous 
agonists like adenosine, histamine and adrenaline (Fredriksson et al., 2003; Kristiansen, 
2004).  While overall sequence homology is low between members of this family, they do 
share  several  conserved  sequence  motifs.    The  Secretin  family  is  a  small  family  (15 
members) that in contrast to the Rhodopsin family, has significant sequence identity (21 – 
67%)  between  members.    These  receptors  bind  peptide  hormones  such  as  secretin, 
glucagon and vasoactive intestinal peptide.  With 33 members, the Adhesion family is the 
second largest family of GPCRs.   These share some sequence similarities with Secretin 
receptors but bind extracellular matrix molecules such as glycosaminoglycan chondroitin 
sulphate  via  their  long,  diverse  N-terminal  regions  (Lagerström  and  Schiöth,  2008; 
Fredriksson  et  al.,  2003).    The  Glutamate  family  consists  of  22  members  made  up  of 
metabotropic glutamate receptors, g-aminobutyric acid receptors, calcium-sensing and taste 
receptors (Fredriksson et al., 2003).  Meanwhile, the Frizzled/Taste2 family comprises 10 
frizzled receptors, one smoothened receptor and 25 taste2 receptors.  There is not much 
overall  similarity  between  the  frizzled/smooth  receptors  and  the  taste2  receptors.  
However, they do share certain sequence motifs that are not found in other GPCR families.  
Frizzled/smoothened receptors bind Wnt glycoproteins and so participate in regulation of 
cell  fate  and  proliferation  during  development  while  taste2  receptors  are  less  well 
characterised but appear to act as bitter taste receptors (Lagerström and Schiöth, 2008; 
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1.5.1 Structure 
There is no overall sequence similarity between GPCRs from different families.  However, 
they do all share one common feature which is the presence of seven stretches of 25-35 
amino acids that are mostly hydrophobic in nature.  These regions are predicted to form 
alpha  helices  in  the  plasma  membrane  to  give  GPCRs  their  characteristic  seven-
transmembrane configuration (Ulloa-Aguirre et al., 1999).  Of the five families described 
above, GPCRs of the Rhodopsin family have been most well studied.  Until recently, the 
only crystal structure information available for any GPCR came from studies on rhodopsin 
and this was used to predict a general structural model for other GPCRs (Gether, 2000; 
Baldwin, 1993).  However, rhodopsin is unique among GPCRs in that it constitutively 
binds its ligand, 11-cis-retinal, via a covalent interaction which maintains the receptor in a 
stable conformation (Filipek et al., 2003).  All other GPCRs bind diffusible ligands and 
exist in much more flexible conformations.  Therefore, the recent solving of structures for 
the b2 adrenergic receptor (b2AR) has been an important step in allowing more detailed 
analysis of structural features that may be conserved amongst GPCRs in general (Cherezov 
et al., 2007; Rosenbaum et al., 2007; Rasmussen et al., 2007). 
All  GPCR  structures  obtained  so  far  conform  to  a  general  model  where  the  seven 
hydrophobic regions identified by sequence analysis form seven a-helical transmembrane 
domains  (TM  I-VII;  figure  1.5).    These  are  linked  by  alternating  intracellular  and 
extracellular  loops  of  varying  lengths  which  extend  on  either  side  of  the  membrane 
(Bockaert and Pin, 1999).  The transmembrane domains form a barrel shape orientated 
perpendicular to the membrane with the helices tightly packed on the intracellular side but 
more openly arranged on the extracellular side to form a binding pocket (Unger et al., 
1997).    The  barrel  conformation  is  stabilised  by  numerous  hydrogen  bonds  and 
hydrophobic interactions, mostly between residues which are highly conserved between 
GPCRs.    The  majority  of  Rhodopsin  family  receptors  (72  %)  have  an  E/DRY  triplet 
sequence within TM III (Kobilka and Deupi, 2007).  In rhodopsin, Glu134 and Arg135 on 
TM III interact via a salt bridge while Arg135 also interacts with Thr251 and Glu247 on 
TM VI.  This is thought to stabilise rhodopsin in an inactive conformation and prevent 
constitutive activity in the absence of light, which is essential for vision (Palczewski et al., 
2000).  In the b2AR, although the corresponding residues (Asp130-Arg131-Tyr132) are 
present, they do not form the same electrostatic interactions in the crystal structure and the 
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Figure  1.5  Schematic  representation  of  a  family  A  G  protein-coupled 
receptor 
Seven  transmembrane  domains  form  a  barrel  shape  in  the  plasma  membrane.    These 
domains are linked by alternating intracellular and extracellular loops.  The N-terminus is 
on  the  extracellular  side  of  the  membrane  and  typically  contains  sites  for  N-linked 
glycosylation.   Meanwhile the C-terminus is intracellular and usually  contains several 
serine and threonine residues representing sites for phosphorylation by kinases involved in 
desensitisation.    This  region  is  also  the  site  of  interactions  between  GPCRs  and  an 
increasing  number  of  proteins  reported  to  modulate  GPCR  signalling.    (Figure  from 
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Rasmussen et al., 2007; Cherezov et al., 2007).  This is proposed to reflect the ability of 
the b2AR to isomerise between active and inactive conformations leading to constitutive 
activity in the absence of agonist (Audet and Bouvier, 2008; Rosenbaum et al., 2007).  
Another difference between the crystal structures of rhodopsin and the b2AR lies in the 
second extracellular loop.  In rhodopsin, this loop folds deep into the rhodopsin molecule 
in  contact  with  11-cis-retinal  and  restricts  access  to  the  binding  pocket  from  the 
extracellular side (Filipek et al., 2003).  However, in the b2AR, the loop forms an a-helix 
on  the  periphery  of  the  receptor  which  appears  to  be  stabilised  by  disulphide  bonds 
therefore  leaving  the  binding  pocket  exposed  and  accessible  to  diffusible  ligands 
(Cherezov et al., 2007).  The N- and C- terminal domains of GPCRs vary considerably in 
size and sequence.  Most GPCRs contain consensus sites for N-linked glycosylation (N-X-
S/T) in their extracellular N-terminal regions.  The role of glycosylation is unclear but may 
be important for correct folding and trafficking as prevention of glycosylation has been 
found to reduce cell-surface expression of some GPCRs (Ulloa-Aguirre et al., 1999).  The 
C-terminus  is  intracellular  and  alongside  the  other  intracellular  portions  of  GPCRs  is 
important for G protein recognition and activation.  The C-terminal tails of most GPCRs 
contain several Ser/Thr residues representing potential sites for phosphorylation by kinases 
involved in desensitisation but this region is also the site of interactions between GPCRs 
and an increasing number of proteins reported to modulate GPCR signalling (Kristiansen, 
2004; Hall and Lefkowitz, 2002). 
1.5.2 Receptor activation 
Activation  of  GPCRs  is  a  dynamic  process.    In  a  simplified  model,  receptors  exist  in 
equilibrium  between  an  inactive  state  and  an  active  state  that  differ  in  their  ability  to 
activate  G  proteins  (Samama  et  al.,  1993).    In  the  absence  of  agonist,  the  receptor  is 
maintained  mostly  in  the  inactive  state  by  intramolecular  interactions  between  the 
transmembrane domains.  Agonist binding stabilises the active state in which the receptor 
is able to interact with G proteins and initiate downstream signalling (Maudsley et al., 
2005).  However, it is now known that GPCRs can exist in multiple conformations and 
distinct states of activation that are influenced by the binding of ligands with different 
efficacies (Kobilka and Deupi, 2007). 
Activation of the receptor initiates a change in conformation resulting from disruption of 
interhelical interactions including those mediated by the E/DRY motif.  This causes TM III 
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receptor to interact with G proteins (Wess, 1997; Ulloa-Aguirre et al., 1999; Bhattacharya 
et al., 2008).  The activated receptor acts as a guanine nucleotide exchange factor for the 
associated  G  protein,  catalysing  the  exchange  of  GDP  for  GTP.    The  activated 
heterotrimeric G protein dissociates into an a subunit and a bg dimer which independently 
activate downstream effector proteins (Ulloa-Aguirre et al., 1999; figure 1.6). 
1.5.3 G proteins 
G-proteins are composed of three subunits termed a, b and g.  The alpha subunit contains 
two domains, a GTPase domain which binds and hydrolyses GTP to GDP, and a helical 
domain that buries GTP within the core of the protein (Noel et al., 1993).  The bg subunits 
form a single functional unit which associates with a hydrophobic pocket in the GDP-
bound form of the a subunit.  On GTP binding, the hydrophobic pocket is lost and bg 
dissociates (Lambright et al., 1996). 
G proteins can be divided into four groups based on sequence similarities between their a 
subunits and the distinct sets of downstream effector proteins with which they interact 
(Cabrera-Vera et al., 2003, Neves et al., 2002).  Active Gas subunits classically stimulate, 
while Gai/o subunits inhibit, adenylyl cyclase (AC) activity, thereby altering intracellular 
levels  of  cAMP.    Elevation  of  intracellular  levels  of  cAMP  results  in  activation  of 
downstream effector proteins such as PKA, exchange proteins directly activated by cAMP 
(Epacs) and cyclic nucleotide-gated ion channels (Beavo and Brunton, 2002; figure 1.6).  
Gaq/11 subunits activate different PLCb isoforms leading to the generation of the second 
messengers inositol-1,4,5-trisphosphate (IP3) and sn1,2-diacylglycerol (DAG; Neves et al., 
2002; Wess, 1998).  The Ga12/13 subunits have been found to interact with a number of 
effector proteins, the most well-characterised being guanine nucleotide exchange factors 
for the RhoA family of monomeric small G proteins (Kelly et al., 2007). 
Free bg subunits generated on dissociation of the active a subunit also have important roles 
in  downstream  signalling  with  the  ability  to  interact  with  a  large  number  of  effectors 
including PLCb, AC, G protein-coupled receptor kinase (GRK) 2, components of MAPK 
pathways and Ca
2+ and K
+ channels (Cabrera-Vera et al., 2003).  Some of these targets are 
shared  by  a  subunits  and  bg  subunits  can  have  effects  that  are  either  synergistic  or 
opposing to the activity of the a subunit (Wess, 1998).  Free a subunits also have the 
ability to modulate bg activity.  This is because the structure of the bg subunit is not altered  Gillian R Milne, 2008    Chapter 1, 54 
Figure 1.6 Classical G-protein-dependent signalling 
Agonist binding to the receptor initiates a conformational change that allows the receptor 
to interact with G proteins.  The activated receptor acts as a guanine nucleotide exchange 
factor  for  the  associated  G  protein,  catalysing  the  exchange  of  GDP  for  GTP.    The 
activated heterotrimeric G protein dissociates into an a subunit and a bg dimer which 
independently activate downstream effector proteins.  Gas activates adenylyl cyclase (AC) 
resulting  in  an  elevation  in  the  intracellular  levels  of  cAMP  which  then  activates 
downstream effectors PKA, exchange proteins directly activated by cAMP (Epacs) and 
cyclic  nucleotide-gated  ion  channels.    Meanwhile,  free bg  subunits  have  the  ability  to 
interact with a large number of effectors including PLCb, AC and components of MAPK 
pathways.  (Adapted from Pierce et al., 2002) 
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on dissociation from active GTP-bound a meaning that following GTP hydrolysis, free 
GDP-bound  a  subunits  can  bind  and  reform  the  original  inactive  trimeric  G  protein 
(Cabrera-Vera et al., 2003; Wess, 1998).  Hydrolysis of GTP to GDP by the a subunit 
marks termination of the GPCR activation cycle and is regulated by regulator of G-protein 
signalling (RGS) proteins.  These proteins act as GTPase activating proteins for the  a 
subunit promoting the hydrolysis of GTP and accelerating the deactivation of the pathway 
(De Vries et al., 2000). 
1.5.4 Regulation 
Many mechanisms have evolved to regulate GPCR signalling.  One of the best-studied is 
the phenomenon of receptor desensitisation which is crucial in protecting the cell from 
over-stimulation.    The  process  of  desensitisation  results  in  the  dampening  of  receptor 
responsiveness despite the continued presence of agonist.  Desensitisation is mediated by 
several  different  mechanisms  including  phosphorylation  of  receptors  resulting  in 
uncoupling  from  G  proteins,  sequestration  of  receptors  by  internalisation,  receptor 
degradation and downregulation of receptor gene expression (Kristiansen, 2004; Ferguson, 
2001).  The importance of this process is demonstrated in diseases involving mutations in 
genes  encoding  proteins  which  regulate  desensitisation.    For  example,  patients  with 
Oguchi’s  disease  suffer  night  blindness  and  retinal  degeneration  as  a  result  of  over-
stimulation  of  rhodopsin  (Métayé  et  al.,  2005).    Desensitisation  may  be  described  as 
homologous  or  heterologous.    Homologous  desensitisation  is  initiated  on  binding  of 
agonist  to  a  receptor  and  results  in  dampening  of  signalling  from  the  same  receptor.  
Meanwhile during heterologous desensitisation, agonist activation of one receptor leads to 
dampening of signalling from other unrelated receptors even if they are not occupied by 
agonist (Kelly et al., 2008; Pierce et al., 2002). 
1.5.4.1  Phosphorylation 
Typically, agonist stimulation leads to rapid desensitisation (seconds to minutes) as a result 
of  receptor  phosphorylation.    This  is  mediated  by  both  second  messenger-dependent 
kinases, such as PKC and PKA, and a distinct family of seven G protein-coupled receptor 
kinases  (GRKs).    Phosphorylation  mediated  by  PKC  or  PKA  results  in  the  direct 
uncoupling  of  receptors  from  their  respective  G  protein.    Meanwhile,  GRK 
phosphorylation  promotes  the  binding  of  cytosolic  inhibitory  proteins  called  arrestins, 
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therefore  terminate  downstream  signalling  (Kristiansen,  2004;  Krupnick  and  Benovic, 
1998; figure 1.7). 
1.5.4.1.1 G protein-coupled receptor kinases (GRKs) 
GRKs mediate a very general mechanism of desensitisation that is homologous in nature 
owing to the fact that GRKs selectively phosphorylate agonist-occupied receptors.  There 
are seven GRK family members, termed GRK1-7.  GRK1 and 7 are primarily expressed in 
the retina where they regulate the opsin light receptors while GRK4 is mainly found in the 
testis.  GRKs 2, 3, 5 and 6 however, are widely expressed and phosphorylate a wide range 
of receptors with overlapping preferences (Premont and Gainetdinov, 2007).  GRK family 
members  share  a  common  functional  domain  structure  with  an  N-terminal  substrate 
recognition domain, a central catalytic domain, and a C-terminal domain that is involved in 
membrane targeting (Ferguson, 2001).  Following receptor stimulation, GRKs 1, 2 and 3 
are translocated to the plasma membrane while GRKs 4, 5 and 6 are found primarily at the 
membrane  even  in  the  absence  of  agonist.    GRKs  bind  to  activated  receptors  and 
phosphorylate specific serine and threonine residues in their cytoplasmic regions (Premont 
et al., 1995).  In the case of the b2AR, GRK1, GRK2 and GRK5 phosphorylate sites in the 
C-terminal tail of the receptor (Premont et al., 1994) while the M2 muscarinic receptor, 
which has a short C-terminal tail, is phosphorylated on residues in its third intracellular 
loop (Nakata et al., 1994).  A specific consensus sequence for phosphorylation by GRKs 
has not been defined.  However, in studies using synthetic peptides, GRK1, GRK2 and by 
extension  GRK3  have  been  found  to  preferentially  phosphorylate  serine  and  threonine 
residues present in an acidic environment (Onorato et al., 1991; Benovic et al., 1990). 
GRK-mediated phosphorylation in itself has little effect on receptor function but it triggers 
the desensitisation process by increasing the affinity of the receptor for arrestin proteins.  
There  are  four  arrestin  family  members.    Visual  and  cone  arrestin  are  expressed 
exclusively in the retina while b-arrestin 1 and b-arrestin 2 are ubiquitously expressed 
(Luttrell  and  Lefokowitz,  2002).    Arrestins  bind  to  regions  of  GRK-phosphorylated 
receptors involved in G-protein coupling thereby mediating desensitisation by sterically 
blocking interactions with G proteins.  In addition, the b-arrestins further contribute to 
desensitisation by facilitating agonist-induced internalisation as described below (Luttrell 
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Figure  1.7  The  role  of  GRKs  and  b b b b-arrestin  in  desensitisation  and 
internalisation 
Following agonist-stimulation, GPCRs undergo a conformational change which allows 
them to act as a guanine nucleotide exchange factor for G proteins.  The activated GPCR 
is recognised by members of the G protein-coupled receptor kinase (GRK) family which 
phosphorylate the receptor at specific sites on the intracellular loops and C-terminal tail.  
GRK  phosphorylation  promotes  the  binding  of  cytosolic  inhibitory  proteins  called 
arrestins,  which  sterically  inhibit  further  interactions  between  the  receptor  and  the  G 
protein  and  therefore  terminate  downstream  signalling.    b-arrestins  also  mediate 
internalisation of the receptor by interacting with components of the endocytic machinery 
required for formation of clathrin-coated pits, including the heavy chain of clathrin itself 
and the clathrin adapter protein AP-2.  Newly formed vesicles are pinched off from the 
plasma  membrane  by  the  GTPase  dynamin  to  form  endosomes.    Receptors  may  be 
dephosphorylated by phosphatases present in endosomes and recycled back to the cell 
surface or they may be targeted to lysosomes for degradation.  (Figure from Pierce et al., 
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1.5.4.1.2 2
nd messenger dependent kinases 
GPCR  stimulation  results  in  elevation  of  cellular  levels  of  second  messengers  such  as 
cAMP and DAG which activate the second messenger-dependent kinases PKA and PKC 
respectively.    PKA  and  PKC  have  the  potential  to  phosphorylate  a  multitude  of 
downstream targets but they can also feedback and phosphorylate GPCRs to regulate their 
activity  in  either  a  homologous  or  heterologous  manner.    For  example,  in  response  to 
agonist  treatment,  the  b2AR  is  phosphorylated  by  PKA  on  serine262  within  the  PKA 
consensus sequence RRSSK
263 (Yuan et al., 1994; Clark et al., 1989).  This sequence is in 
the third intracellular loop of the receptor adjacent to sites required for coupling to Gs 
(O’Dowd et al., 1988; Strader et al., 1987) and so it is likely that desensitisation occurs as 
a result of phosphorylation inhibiting the receptor/G protein interaction.  Phosphorylation 
of the b2AR by PKA appears to occur independently of GRK-mediated phosphorylation 
(Vaughan et al., 2006) and is believed to be an important mechanism of desensitisation at 
low agonist concentrations when GRK activity is low.  Phosphorylation at the PKA site 
occurs at low agonist concentrations (EC50 = 20-40 pM epinephrine) because only small 
changes in cAMP are required to activate PKA while phosphorylation by GRKs requires 
higher concentrations (EC50 = 200 nM epinephrine) as receptors must be occupied (Tran et 
al., 2004).  Interestingly, phosphorylation by PKA not only results in desensitisation by 
uncoupling  the  receptor  from  Gs,  it  also  increases  receptor  affinity  for  Gi,  thereby 
converting the stimulatory effect on AC to an inhibitory one.  In addition, coupling to Gi 
allows activation of the ERK pathway that does not occur through Gs, indicating a role for 
receptor phosphorylation in initiating new signalling events (Daaka et al., 1997).  Several 
other  receptors  have  been  reported  to  undergo  desensitisation  in  response  to 
phosphorylation  by  PKC.    For  example,  desensitisation  of  the  a2AAR  is  regulated  by 
phosphorylation by PKC on serine 360 in the third intracellular loop of the receptor (Liang 
et  al.,  2002)  while  in  the  case  of  the  a1BAR  (Diviani  et  al.,  1997)  and  the  type  1A 
angiotensin II receptor (Tang et al., 1998), phosphorylation of serine residues in the C-
terminal tail is required for PKC-mediated desensitisation. 
Other serine/threonine kinases implicated in the regulation of GPCR activity are casein 
kinase 1a (CK1a) and casein kinase 2 (CK2).  Agonist mediated phosphorylation of the 
third intracellular loop of the Gq coupled muscarinic M3 acetylcholine receptor is at least in 
part  mediated  by  CK1a  (Budd  et  al.,  2001,  Tobin  et  al.,  1997).    The  functional 
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demonstrated.  M3 activation of the ERK pathway is compromised in CHO cells expressing 
either a mutant M3 receptor lacking the third intracellular loop or a dominant negative 
mutant  of  CK1a  (Budd  et  al.,  2001).    CK1a  phosphorylates  serine  residues  within 
consensus  sequences  commonly  found  in  GPCRs  indicating  potential  for  regulating 
phosphorylation  of  GPCRs  in  general  (Tobin,  2002).    CK2  has  also  been  shown  to 
phosphorylate the M3 receptor.  This has no effect on internalisation of the receptor or 
agonist-mediated  ERK  activation  but  does  affect  Jun  kinase  MAPK  activation 
demonstrating that phosphorylation by different kinases can modulate receptor signalling 
in different cell types (Torrecilla et al., 2007). 
1.5.4.2  Internalisation 
Following  agonist-stimulation,  many  receptors  undergo  internalisation  into  endocytic 
vesicles.  This contributes to desensitisation by sequestering receptors away from the cell 
surface but also promotes receptor resensitisation through dephosphorylation and recycling 
to the plasma membrane (Ferguson, 2001).  The best well characterised mechanism of 
internalisation involves b-arrestin-mediated targeting of receptors to clathrin-coated pits 
(Luttrell and Lefkowitz, 2002, Ferguson, 2001; figure 1.7).  This is facilitated by the ability 
of  b-arrestins  to  interact  with  components  of  the  endocytic  machinery  required  for 
formation  of  clathrin-coated  pits,  including  the  heavy  chain  of  clathrin  itself  and  the 
clathrin adapter protein AP-2 (Luttrell and Lefkowitz, 2002; Claing et al., 2002).   Newly 
formed vesicles are pinched off from the plasma membrane by the GTPase dynamin to 
form  endosomes.    Receptors  may  be  dephosphorylated  by  phosphatases  present  in 
endosomes and recycled back to the cell surface or they may be targeted to lysosomes and 
degraded (Luttrell and Lefkowitz, 2002; Claing et al., 2002). 
An alternative mechanism for receptor internalisation appears to involve cholesterol-rich 
plasma membrane structures called caveolae (Claing et al. 2002).  It is not entirely clear 
how receptors are targeted for internalisation by caveolae but numerous GPCRs, probably 
due to their palmitoylated nature, have been found to be localised to caveolae including the 
M2 muscarinic receptor  (Feron et al., 1997), the b2-adrenergic  receptor  (Dupree et al., 
1993) and the endothelin ETB receptor (Teixeira et al., 1999).  Furthermore, agents which 
disrupt the structure of caveolae have been shown to inhibit internalisation of receptors 
such as the ETB endothelin receptor (Okamoto et al., 2000). Gillian R Milne, 2008    Chapter 1, 60 
1.5.5 GPCR-interacting proteins 
Classically, signalling by GPCRs relies on their ability to interact with heterotrimeric G 
proteins.  However, this is a very simplistic model as GPCRs are able to interact with a 
large number of proteins other than G proteins and the kinases and arrestins which mediate 
desensitisation and internalisation (Bockaert et al., 2004; Heuss and Gerber, 2000).  Many 
GPCRs have specific sequence motifs in their C-terminal tails or in their third intracellular 
loop  which  enable  interactions  with  proteins  which  have  particular  protein-protein 
interaction domains within their structures (Kristiansen, 2004; Heuss and Gerber, 2000).  
For example, PDZ domains (named after their discovery in postsynaptic density protein 
(PSD)  95,  the  Drosophila  septate  junction  protein  Discs-large,  and  the  epithelial  tight 
junction protein ZO-1) which bind specifically to short sequences at the very C-terminus of 
target proteins (Sheng and Sala, 2001).  Other proteins interact via Src homology 2 (SH2), 
SH3 or enabled Vasp homology domains (EVD) or are recruited by arrestins.  Proteins 
recruited to the GPCR in this manner may directly initiate alternative signalling pathways 
independently of G proteins and/or may act as adaptor or scaffold proteins which allow 
recruitment and spatial organisation of additional signalling components to improve the 
specificity  and  efficiency  of  downstream  signalling  (Bockaert  et  al.,  2004;  Hall  and 
Lefkowitz, 2002; Heuss and Gerber, 2000). 
1.5.5.1  PDZ 
A clear example of a GPCR-binding protein which promotes efficient signalling through 
scaffolding  interactions  is  the  large  cytoplasmic  protein  INAD  which  interacts  with 
Drosophila rhodopsin (Xu et al., 1998; Chevesich et al., 1997).    INAD has five PDZ 
domains, two of which mediate binding to rhodopsin while the other three are involved in 
interactions with a number of proteins required for visual signalling in Drosphila (Xu et 
al.,  1998).    Light  activation  of  rhodopsin  results  in  Gq-mediated  stimulation  of  PLCb 
which results in elevation of intracellular calcium levels, activation of PKC and opening of 
calcium-regulated transient receptor potential (TRP) channels (Tsunoda and Zuker, 1999).  
INAD has been found to interact with most of the components of this signalling pathway 
including PLCb, PKC and TRP thereby creating a highly organised “transducisome” to 
allow  extremely  rapid  signalling  (Tsunoda  et  al.,  1997).    The  importance  of  these 
interactions has been demonstrated using Drosophila mutants lacking functional INAD.  In 
INAD-null cells, TRP, PLCb and PKC are mislocalised and photoreceptors have profound 
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In  addition  to  scaffolding  roles,  the  association  of  some  PDZ-containing  proteins  with 
GPCRs  has  been  shown  to  regulate  the  nature  of  downstream  signalling  events.    For 
example, agonist-induced association of the b2AR with the Na
+/H
+ exchanger regulatory 
factor  (NHERF)  1  confers  the  ability  to  positively  regulate  renal  Na
+/H
+  exchange  by 
Na
+/H
+ exchanger 3 (NHE3; Hall et al., 1998).  Normally,  activation  of a Gs coupled 
receptor such as the b2AR would not be expected to have this effect as increasing cAMP 
usually  leads  to  PKA-mediated  association  of  NHERF1  with  NHE3  which  inhibits  its 
activity (Weinman and Shenolikar, 1993).  The stimulatory effect of the b2AR on NHE3 
function can be blocked by mutating the final residue in the receptor so that it cannot bind 
NHERF1.  Therefore, it is proposed that the agonist-induced association of NHERF1 with 
b2AR  displaces  NHERF1  from  NHE3  and  removes  its  inhibitory  effect  leading  to  an 
increase in NHE3 activity (Hall et al., 1998). 
The closely-related NHERF2 has been found to modulate downstream signalling from the 
parathyroid  hormone  (PTH1)  receptor.    NHERF2  interacts  simultaneously  with  the 
parathyroid hormone 1 (PTH1) receptor and PLCb through two separate PDZ domains 
(Mahon et al., 2002).  The PTH1 receptor can couple to Gs, Gq and Gi although in most 
cells, signalling occurs predominantly through activation of AC (Abou-Samra et al., 1992).  
When the PTH1 receptor is expressed in cells lacking NHERF, signalling occurs almost 
exclusively  through  AC  (Mahon  et  al.,  2002).    However,  when  wild-type  PTH1  and 
NHERF are coexpressed, only small increases in cAMP are observed following receptor 
stimulation and signalling occurs predominantly through activation of PLC.  This response 
can  be  reversed  and  AC  signalling  partially  restored  by  treatment  with  pertussis  toxin 
indicating that NHERF binding acts like a molecular switch to promote PTH1 receptor 
signalling through Gi rather than Gs (Mahon et al., 2002; Weinman et al., 2006).  NHERF2 
also plays a scaffolding role not dissimilar to INAD by bringing the PTH1 receptor and 
PLCb into close proximity thereby promoting more efficient signalling through Gi (Mahon 
et al., 2002). 
1.5.5.2  Non-PDZ 
While  PDZ-containing  proteins  bind  predominantly  to  the  sequences  at  the  very  C-
terminus of GPCRs, other proteins bind to sequences in other regions of the receptor tail.  
Certain proteins have been found to bind via their SH2 domains to phosphorylated tyrosine 
residues in the tail of GPCRs to enable organisation of signalling complexes in a manner 
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the underlying mechanism by which stimulation of the angiotensin II AT1A receptor results 
in  activation  of  the  JAK/STAT  pathway  which  is  otherwise  generally  regarded  as  a 
cytokine/growth  factor-regulated  pathway  (Godeny  et  al.,  2007;  Marrero  et  al.,  1998).  
JAK2 associates with the AT1A receptor via a specific phosphorylated YIPP motif in the C-
terminal tail of the receptor (Ali et al., 1997) but since JAK2 does not contain an SH2 
domain, it was not clear initially how this was achieved.   It is now apparent that this 
association depends upon the SH2 domain-containing protein SHP2 which appears to act 
as an adaptor for JAK2 (Godeny et al. 2007, Marrero et al., 1998).  JAK2 then recruits and 
phosphorylates STAT1 leading to activation of the JAK/STAT pathway (Ali et al., 2000). 
Another class of proteins which interacts with phosphorylated motifs in target proteins is 
the 14-3-3 family which comprises seven isoforms termed b, e, g, h, s, t and z (Fu et al., 
2000).  Numerous biological activities have been attributed to 14-3-3 proteins including 
cell  signalling,  regulation  of  cell  cycle  progression,  intracellular  trafficking  and 
transcription  (Aitken,  2006).    Many  of  these  functions  involve  the  regulation  of 
interactions  between  proteins  with  14-3-3  proteins  often  acting  as  scaffold  or  adapter 
proteins (Tzivion et al., 2001).  This is facilitated by the fact that 14-3-3 proteins exist as 
dimers and so can bind to two interaction partners simultaneously (Jones et al., 1995).  14-
3-3 proteins bind to proteins containing phosphorylated serine residues within either R-S-
X-pS-X-P or R-X-f-X-pS-X-P motifs (Yaffe et al., 1997; Muslin et al., 1996) although 
some interacting proteins do not contain these sequences indicating that other modes of 
binding  do  occur  (Aitken  et  al.,  2006).    There  are  several  reports  of  14-3-3  proteins 
interacting  with  GPCRs  with  varying  functional  consequences.    For  example,  14-3-3e 
interacts with the b1AR with effects on regulation of cardiac repolarisation by the voltage-
gated potassium channel Kv11.1 (Tutor et al., 2006).  This was found to occur in a PKA-
dependent manner and required the presence of two PKA phosphorylation motifs in the 
third intracellular loop and tail of the receptor, suggesting that 14-3-3e binds at these sites.  
The functional effects of this interaction were demonstrated by co-transfecting Kv11.1 and 
14-3-3e in the presence or absence of the b1AR.  It was found that in cells lacking the 
b1AR, Kv11.1 bound to 14-3-3e, an interaction which enhances Kv11.1 activity (Kagan et 
al., 2002), while coexpression of the b1AR disrupted this interaction.  It was therefore 
proposed  that  b1AR  competing  for  14-3-3e  binding  represents  a  novel  mechanism  by 
which the b1AR regulates the Kv11.1 channel (Tutor et al., 2006).  In further examples of 
14-3-3 proteins interacting with GPCRs, 14-3-3z is reported to bind to the a2A, a2B and 
a2C ARs (Prezeau et al., 1999) and to the thromboxane TPa and TPb receptors (Yan et al., Gillian R Milne, 2008    Chapter 1, 63 
2006).  This is proposed to facilitate Ras-mediated activation of the ERK pathway owing 
to the ability of 14-3-3 proteins to bind and aid in the activation of Raf (Tzivion et al., 
1998; Luo et al., 1996).  This is discussed further in Section 3.3. 
1.5.5.3  Arrestins 
More generalised scaffold formation is mediated by arrestins which do not require specific 
motifs in order to interact with GPCRs.  Following agonist activation, most GPCRs are 
phosphorylated  by  GRKs  which  leads  to  receptor  association  with  b  arrestins  and 
uncoupling from G proteins (Ferguson, 2001).  In addition to interactions with proteins 
involved in receptor endocytosis during desensitisation, b arrestins also bind a variety of 
other proteins such as Src family tyrosine kinases and components of MAPK pathways and 
recruit them to agonist-occupied receptors (Luttrell and Lefkowitz, 2002).  For example, 
agonist stimulation of the b2AR promotes its association with Src via b-arrestin 1.  As a 
consequence of binding to b-arrestin 1, Src is activated resulting in Ras-dependent ERK 
signalling  (Luttrell  et  al.,  1999).    b-arrestins  further  influence  MAPK  signalling  by 
scaffolding together the appropriate kinases of  the ERK  and JNK MAPK pathways to 
allow specificity in signalling (Reiter and Lefkowitz, 2006). 
b-arrestins  have  also  been  found  to  bind  to  members  of  the  phosphodiesterase  (PDE) 
family which degrade cAMP (Perry et al., 2002).  Following agonist stimulation of the 
b2AR, the PDE isoform PDE4D5 is translocated to the receptor concomitantly with b-
arrestin 1 or b-arrestin 2.  By this means, arrestins not only dampen signalling from the 
receptor  to  AC,  they  also  increase  the  rate  of  cAMP  degradation,  thereby  reducing 
activation of PKA at the plasma membrane (Perry et al., 2002).  Phosphorylation of the 
b2AR by membrane-localised PKA switches G protein coupling of the receptor from Gs to 
Gi leading to activation of the ERK pathway (Daaka et al., 1997).  The importance of b-
arrestin-mediated recruitment of PDE4D5 to the receptor in regulating this switch has been 
demonstrated using a dominant negative form of PDE4D5 which cannot bind b-arrestins.  
Overexpression of this construct in HEK 293 cells resulted in enhanced agonist-induced 
phosphorylation of the b2AR and a marked potentiation in ERK activation (Baillie et al., 
2003). 
Other  important  binding  partners  of  arrestins  are  the  ubiquitin  E3  ligases  Mdm2  and 
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of the b2AR.  b-arrestin 2 is ubiquitinated by Mdm2 and this modification is required for 
rapid  agonist-induced  internalisation  of  the  b2AR  (Shenoy  et  al.,  2001).    Meanwhile, 
recruitment of Nedd4 to the b2AR via b-arrestin 2 facilitates ubiquitination of the receptor 
and is required for targeting receptors to lysosomes for degradation following long-term 
stimulation (Shenoy et al., 2008). 
1.6 The A2AAR 
In common with the other AR subtypes, the A2AAR assumes a protein structure typical of 
GPCRs with TM5, 6 and 7 forming a hydrophobic pocket where adenosine binds (Kim et 
al., 1995).  The recent solving of the crystal structure of the A2AAR in complex with high 
affinity anatagonist ZM241385 has revealed that the extracellular loops of the receptor are 
arranged in a different manner to those of the previously characterised b1AR, b2AR and 
rhodopsin (Jaakola et al., 2008).  In particular, a network of disulphide bridges contributes 
to the formation of a rigid open structure that exposes the ligand-binding cavity to solvent.  
ZM241385 binds within this cavity in an extendend conformation perpendicular to the 
membrane in quite a different manner to ligands of the bARs and rhodopsin (Jaakola et al., 
2008).  Another finding from this study was that an eighth helical segment known as helix 
8 which is found in the cytoplasmic tail of the receptor is stabilised by interactions with 
helix  1.    Many  GPCRs  are  palmitoylated  in  this  region  (Kristiansen,  2004)  and  in 
rhodopsin, helix 8 is stabilised via interactions with the plasma membrane (Moench et al., 
1994).  However, this cannot occur in the case of the A2AAR as it does not contain sites for 
palmitoylation (Palmer and Stiles, 1995). 
In common with other GPCRs, the A2AAR has the conserved DRY sequence which is 
believed to be important for G protein activation present in its second intracellular loop 
(Palmer and Stiles, 1995).  Two N-linked glycosylation consensus sequences are present in 
the second extracellular loop of all adenosine receptors (Palmer and Stiles, 1995).  In the 
case of the A2AAR, immunoblotting analysis suggests that only one of these sites is used 
(Palmer et al., 1992).  The significance of this modification is unclear but it does not 
appear to be important for ligand binding as inhibition of N-linked glycosylation has been 
shown to have no effect on the agonist binding characteristics of the A2AAR (Piersen et al., 
1994).  Structurally, the A2AAR differs most noticeably from other adenosine receptors in 
its size.  While the genes for human A1, A2B and A3 receptors encode proteins of 326 
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al., 1993), the A2AAR is 412 amino acids long, the additional 84-94 amino acids of its 
sequence constituting an extended C-terminal tail (Furlong et al., 1992; figure 1.8, figure 
1.9). 
The A2AAR, like many GPCRs can form dimeric or possibly oligomeric complexes and 
studies using cell-surface biotinylation and of proteins and fluorescence resonance energy 
transfer (FRET) have indicated that homodimers may be the predominant form on the cell 
surface  (Canals  et  al.,  2004).    In  addition,  the  A2AAR  has  also  been  found  to  form 
heterodimers with the A1AR and the dopamine D2 receptor in striatal tissues (Fredholm et 
al., 2007).  The interaction of the A2AAR with the A1AR is thought to allow different 
signalling  responses  depending  on  the  concentration  of  adenosine  present.    At  low 
concentrations, the high-affinity A1AR is activated preferentially leading to decreases in 
levels of cAMP while at higher concentrations, the A2AAR is activated and levels of cAMP 
rise  (Schiffmann  et  al.,  2007).    Meanwhile,  the  interaction  of  the  A2AAR  with  the 
dopamine D2 receptor is antagonistic with A2AAR agonists such as CGS21680 reducing the 
affinity of the D2 receptor binding site (Fuxe et al., 2005). 
1.6.1.1  G protein coupling 
The region of the A2AAR responsible for G protein coupling has not been fully described.  
Studies  in  other  GPCRs  indicate  that  several  different  regions  may  be  important  for 
interactions with G proteins, particularly regions in intracellular loops 2 and 3 and the 
membrane  proximal  portion  of  the  C-terminal  tail  (Wess,  1997;  Ulloa-Aguirre  et  al., 
1999).  The importance of the third intracellular loop of the A2AAR in mediating coupling 
to Gs has been shown in a study using a series of chimaeric A1/A2A receptors.  Olah (1997) 
found  that  replacement  of  the  third  intracellular  loop  of  the  canine  A2AAR  with 
corresponding  sequences  from  the  human  A1AR  drastically  reduced  agonist-stimulated 
activation of AC.  Through the use of more restricted chimaeras, a stretch of 15 amino 
acids in the N-terminal portion of intracellular loop 3 and in particular Lys219 and Glu212 
were identified as being important for coupling to Gs (Figure 1.8).  Similar examination of 
the second intracellular loop revealed that Gly118 and Thr119 at the junction of this loop 
and  TMIV  were  required  for  Gs  coupling.    However,  since  individual  substitutions  or 
substitution with alanine residues had no effect on AC activation, it was suggested that 
these residues play a role in directing protein conformation to allow interaction with G 
proteins  rather  than  directly  activating  Gs.        Importantly,  none  of  the  more  restricted 
chimaeras or individual mutations used in this study fully mimicked the effect of  Gillian R Milne, 2008    Chapter 1, 66 
 
Figure  1.8  Schematic  representation  of  the  membrane  topology  of  the 
canine A2AAR 
The A2AAR has an extended C-terminal tail.  Serine and threonine residues representing 
potential phosphorylation sites are marked by asterisks.  The last ~100 amino acids of the 
receptor appear to be dispensable for agonist binding, G protein coupling and agonist-
induced  desensitisation.    However,  several  proteins  are  reported  to  interact  with  the 
A2AAR in this region.  (Figure adapted from Palmer and Stiles, 1997) 
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                                                  ICL1 
A2AAR_HUMAN     MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAA 50 
A2AR_CAN        MSTMGSWVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAA 50 
                *. *** ******************************************* 
 
A2AR_HUMAN      ADIAVGVLAIPFAITISTGFCAACHGCLFIACFVLVLTQSSIFSLLAIAI 100 
A2AR_CAN        ADIAVGVLAIPFAITISTGFCAACHNCLFFACFVLVLTQSSIFSLLAIAI 100 
                *************************.***:******************** 
 
                           ICL2 
A2AR_HUMAN      DRYIAIRIPLRYNGLVTGTRAKGIIAICWVLSFAIGLTPMLGWNNCGQPK 150 
A2AR_CAN        DRYIAIRIPLRYNGLVTGTRAKGIIAVCWVLSFAIGLTPMLGWNNCSQPK 150 
                **************************:*******************.*** 
 
A2AR_HUMAN      EGKNHSQGCGEGQVACLFEDVVPMNYMVYFNFFACVLVPLLLMLGVYLRI 200 
A2AR_CAN        EGRNYSQGCGEGQVACLFEDVVPMNYMVYYNFFAFVLVPLLLMLGVYLRI 200 
                **:*:************************:**** *************** 
 
                            ICL3 
A2AR_HUMAN      FLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVGLFALCWLPLH 250 
A2AR_CAN        FLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVGLFALCWLPLH 250 
                ************************************************** 
 
A2AR_HUMAN      IINCFTFFCPDCSHAPLWLMYLAIVLSHTNSVVNPFIYAYRIREFRQTFR 300 
A2AR_CAN        IINCFTFFCPECSHAPLWLMYLTIVLSHTNSVVNPFIYAYRIREFRQTFR 300 
                **********:***********:*************************** 
 
A2AR_HUMAN      KIIRSHVLRQQEPFKAAGTSARVLAAHGSDGEQVSLRLNGHPPGVWANGS 350 
A2AR_CAN        KIIRSHVLRRREPFKAGGTSARALAAHGSDGEQISLRLNGHPPGVWANGS 350 
                *********::*****.*****.**********:**************** 
 
A2AR_HUMAN      APHPERRPNGYALGLVSGGSAQESQGNTGLPDVELLSHELKGVCPEPPGL 400 
A2AR_CAN        APHPERRPNGYTLGLVSGGIAPESHGDMGLPDVELLSHELKGACPESPGL 400 
                ***********:******* * **:*: **************.***.*** 
 
A2AR_HUMAN      DDPLAQDGAGVS 412 
A2AR_CAN        EGPLAQDGAGVS 412 
                :.********** 
Figure 1.9 Sequence alignment of human and canine A2AARs 
Sequences defining intracellular loop 1 (ICL1; Leu33-Val40), ICL2 (Ile108-Gly118) 
and ICL3 (Leu208-Ala221) as identified in the crystal structure of the human A2AAR 
(Jaakola et al., 2008) are shown in blue.  The C-terminal tail of the receptor is shown in 
green.  Identical residues are marked with an asterisk while (:) denotes a conserved 
substitution and (.) denotes a semi-conserved substitution.  Residues with no similarity 
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substituting larger portions of the receptor suggesting that multiple amino acids are likely 
to be involved in selective coupling of the A2AAR to Gs (Olah, 1997). 
1.6.1.2  A2AAR signalling 
Classically, signalling through the A2AAR relies on its coupling to Gs and stimulation of 
AC (Linden, 2001).  This results in elevation of intracellular levels of cAMP which then 
activate downstream effectors including PKA, cyclic nucleotide-gated ion channels and 
exchange  proteins  directly  activated  by  cAMP  (Epacs;  Beavo  and  Brunton,  2002).  
Stimulation of the A2AAR also results in activation of the ERK signalling cascade.  This 
can occur via Gs-dependent or Gs-independent mechanisms.  For example, in CHO cells 
heterologously expressing the A2AAR and in PC12 cells, Gs stimulation of AC has been 
shown to result in PKA-mediated activation of ERK via Src kinases (Klinger et al., 2002a).  
Meanwhile, in endothelial cells, ERK can be activated independently of cAMP elevation 
and requires Ras (Sexl et al., 1997). 
1.6.1.3  Regulation of the A2AAR 
1.6.1.3.1 Desensitisation 
The A2AAR has been shown to undergo rapid functional desensitisation after short-term 
agonist treatment in a variety of cell types which express endogenous receptors including 
rat  aortic  vascular  smooth  muscle  cells  (Anand-Srivastava  et  al.,  1989),  NG108-15 
neuroblastoma ´ glioma hybrid cells (Mundell and Kelly, 1998), hamster smooth muscle 
DDT1  MF-2  cells  (Ramkumar  et  al.,  1991)  and  the  PC12  rat  adrenal  tumour  cell  line 
(Chern et al., 1993). 
This effect and the various mechanisms responsible have been further characterised using 
CHO cells stably expressing the canine A2AAR.  In these cells, short-term exposure to 
agonist  (30  minutes)  resulted  in  a  rapid  reduction  in  subsequent  agonist-induced  AC 
activation (Palmer et al., 1994).  This was associated with receptor phosphorylation and 
reduced coupling to Gs.  However, this effect could not be mimicked by treatment with 
forskolin or PMA indicating that phosphorylation by PKA or PKC was not responsible.  
Long-term agonist treatment (24 hours) produced a comparable reduction in AC activity 
but much slower recovery and this was associated with receptor downregulation (Palmer et 
al.,  1994).    The  structural  requirements  for  desensitisation  of  the  A2AAR  have  been 
examined using mutated forms of the canine A2AAR expressed in CHO cells (Palmer and Gillian R Milne, 2008    Chapter 1, 69 
Stiles, 1997).  Palmer and Stiles (1997) found that truncation of the receptor removing 95 
amino acids from the C-terminal tail did not inhibit desensitisation.  In fact the mutant 
receptor desensitised faster than the wild-type form (T. Palmer; personal communication).  
This was surprising as numerous serine and threonine residues are present in this region 
representing potential sites for phosphorylation by regulatory kinases.  Truncation of other 
GPCRs such as the a1BAR (Lattion et al., 1994) and the b2AR (Bouvier et al., 1988) which 
have relatively long C-terminal tails rich in serine and threonine residues abolishes agonist-
induced  receptor  phosphorylation  and  desensitisation.    However,  an  A2AAR  mutant  in 
which two residues in the membrane proximal region of the C-terminal tail (Thr298 and 
Ser305) were replaced with alanine residues failed to exhibit any significant desensitisation 
response  (Palmer  and  Stiles,  1997,  figure  1.8).    Generation  of  receptors  with  single 
mutations at these residues revealed that short-term desensitisation of the A2AAR relies on 
the presence of the threonine residue at position 298.  The mutant receptor lacking Thr298 
also failed to undergo agonist-induced phosphorylation suggesting that phosphorylation of 
this single residue may be required for short-term desensitisation of the A2AAR (Palmer et 
al., 1997). 
Because elevation of cAMP through stimulation of AC with forskolin does not induce 
desensitisation of the A2AAR (Palmer et al., 1994), it is unlikely that PKA is responsible 
for agonist-induced phosphorylation and desensitisation of the receptor.  This indicates the 
involvement of a GRK, a theory which has been investigated further using NG108-15 cells 
which express endogenous A2AARs and GRK2 (Mundell et al., 1997).  Following short-
term agonist treatment, the A2AAR desensitised in these cells in a similar manner to that 
observed in CHO cells.  However, on introduction of a mutant GRK2 (Lys220Arg) which 
lacks  kinase  activity,  this  response  was  significantly  reduced.    In  a  subsequent  study, 
suppression of GRK2 expression using anti-sense cDNA revealed that this effect was due 
specifically to loss of GRK2 activity rather than effects on other GRKs present in these 
cells,  indicating  that  GRK2  is  at  least  partly  responsible  for  mediating  short-term 
desensitisation of natively expressed A2AARs (Mundell et al., 1999). 
1.6.1.3.2 Role of the C-terminal tail 
In comparison to other adenosine receptors and to GPCRs in general, the A2AAR has an 
unusually long C-terminal tail (Zezula and Freissmuth, 2008).  However, the functional 
significance of this is not clear.  As discussed above, truncation of the tail has no effect on 
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found that the agonist-binding properties of a mutant canine A2AAR in which the last 102 
residues have been replaced with a hexahistidine sequence are comparable to those of the 
wild-type  receptor  (Piersen  et  al.,  1994).    The  C-terminal  tail  also  appears  to  be 
dispensable  for  G  protein  coupling  and  stimulation  of  AC  (Palmer  and  Stiles,  1997).  
However, it does appear to be important for constitutive receptor signalling as truncated 
forms exhibit a reduced ability to activate AC in the absence of agonist (Klinger et al., 
2002b).  The difference in AC activation between wild-type and truncated receptors only 
occurred in intact cells and so it was proposed that the higher levels of constitutive activity 
observed for the wild-type receptor were dependent on an additional as yet unidentified 
factor which bound to the receptor tail (Klinger et al., 2002b). 
The presence of 12 serine and threonine residues within the C-terminal tail of the A2AAR 
suggests that phosphorylation in this region may be important for regulation of receptor 
activity (figure 1.8).  Agonist-induced phosphorylation of the A2AAR is associated with its 
desensitisation (Palmer et al., 1994).  However, the canine A2AAR has also been shown to 
undergo  PKC-mediated  phosphorylation  in  response  to  PMA  treatment  or  following 
stimulation of endogenous receptors which activate PKC (Palmer and Stiles, 1999).  The 
canine A2AAR contains  three consensus PKC phosphorylation sequences within the C-
terminal tail (Thr298, Ser320 and Ser335, figure 1.8).  However, a mutant receptor in 
which  these  sites  were  disrupted  displayed  levels  of  basal  and  PMA-induced 
phosphorylation  comparable  with  the  wild-type  receptor,  indicating  that  although  PKC 
regulates phosphorylation of the A2AAR, it does not occur at these PKC consensus sites.  
Furthermore,  PKC-mediated  phosphorylation  did  not  induce  desensitisation  as  no 
significant changes in the signalling capacity or cell surface expression of the receptor 
were observed following PMA treatment (Palmer and Stiles, 1999).  Thus, the role of 
PKC-mediated phosphorylation of the C-terminal tail of the A2AAR remains undetermined.  
One  possibility  is  that  phosphorylation  regulates  the  ability  of  the  receptor  to  bind  C-
terminal interacting proteins.  Several proteins have been reported to bind to the C-terminal 
tail of the A2AAR as listed in Table 1.  These interactions are discussed further in Chapter 
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Interacting protein  Interaction site on A2AAR  Reference 
ARNO  291-312  Gsandtner et al., 2005 
a-actinin  293-321  Burgueño et al., 2003 
Ubiquitin-specific protease 4 
(USP4) 
385-412  Milojević et al., 2006 
TRAX  Not determined  Sun et al., 2006 
14-3-3t  Not determined  M. Freissmuth, personal 
communication 
D2-dopamine receptor  Not determined  Fuxe et al., 2005 
 
 
 
 
 
  
Table 1: C-terminal interaction partners of the A2AAR 
ARNO, a-actinin, USP4 and TRAX have been identified as C-terminal interaction partners 
of  the  A2AAR  based  on  evidence  from  yeast  two-hybrid  screens  and  from  co-
immunoprecipitation and GST pull-down assays.  The A2AAR has been found to interact 
with  the  D2-dopamine  receptor  through  the  use  of  co-immunoprecipitation  and  FRET 
analysis, confirming an association that has long been predicted to exist on the basis of 
physiological evidence. Gillian R Milne, 2008    Chapter 1, 72 
Aims 
The finding that levels of inflammatory cytokines and components of the NFkB signalling 
pathway  are  upregulated  in  A2AAR-deficient  mice  suggest  that  one  way  in  which  the 
A2AAR  may  limit  inflammation  is  through  suppression  of  pro-inflammatory  signalling 
pathways.  One of the aims of this study was to determine whether modulation of the 
NFkB  and  JAK/STAT  pro-inflammatory  signalling  pathways  by  the  A2AAR  plays  a 
significant role in suppressing endothelial inflammation in vivo by examining the levels 
and activation status of components of these pathways in the aortae of A2AAR-deficient 
mice. 
A second aim of this study was to determine whether the human A2AAR is regulated by 
phosphorylation as has been shown previously for the canine receptor.  This was to be 
achieved by identifying stimuli which induce phosphorylation of the A2AAR and the kinase 
responsible.    In  addition,  it  was  of  interest  to  determine  whether  stimuli-induced 
phosphorylation  of  the  A2AAR  could  have  consequences  for  regulating  interactions 
between the A2AAR and 14-3-3t and TRAX, two proteins which have been identified as 
interaction partners of the C-terminal tail of the receptor. 73 
2  Materials and methods 
2.1 Materials 
American Radiolabeled Chemicals, St Louis, MO, USA 
3H-ZM241385 (20 Ci/mmol) 
Bio-rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK 
Precision Plus Protein Kaleidoscope Standards 
Brandel Inc, Gaithersberg, MD, USA 
Glass fibre filters 
Cambridge Bioscience Ltd, Cambridge, UK 
Cell Biolabs Inc QuickTitre Addenovirus Immunoassay Kit 
GE Healthcare Life Sciences, Amersham, Buckinghamshire, UK 
Glutathione-Sepharose, protein G-Sepharose,
 [
32P] orthophosphate (8500-9120 Ci/mmol) 
Inverclyde Biologicals, Bellshill, Lanarkshire, UK 
Whatman Protran nitrocellulose membrane 
Invitrogen, Paisley, UK 
BioSource Mouse Inflammatory Four-Plex kit, Opti-mem, Lipofectamine, Oligofectamine, 
Gibco low-phosphate Dulbecco’s modified Eagle’s medium (DMEM) with GlutaMax 
Lonza, Cambridge, UK 
Endothelial basal medium (EBM) plus supplements, DMEM, Ham’s F-12 medium 
May and Baker Ltd, London, UK 
Sagatal Gillian R Milne, 2008    Chapter 2, 74 
Merck Chemicals Ltd, Nottingham, UK 
Novagen GeneJuice 
Perkin-Elmer Life Sciences, Waltham, MA, USA 
Western Lightning Plus Enhanced chemiluminescence (ECL) substrate 
Promega UK Ltd, Southampton, UK 
XbaI and HindIII restriction enzymes, 1 kb DNA markers 
Promocell, Heidelberg, Germany 
Human umbilical vein endothelial cells (HUVECs) 
Qiagen, Crawley, West Sussex, UK 
Proteinase K, Taq DNA polymerase, dNTPs, PCR buffer, Q-solution, Plasmid Maxi Kit 
Santa Cruz Biotechnology Inc, Santa cruz, CA, USA 
Horseradish  peroxidise  (HRP)-conjugated  bovine  anti-goat  IgG,  short  interfering  RNA 
(siRNA) 
Sigma-Aldrich, Poole, Dorset, UK 
Lipopolysaccharide  (LPS)  from  Escherichia  coli  O111:B4,  endotoxin-free  phosphate-
buffered  saline  (PBS),  fetal  bovine  serum  (FBS),  L-glutamine,  penicillin/streptomycin 
solution,  trypsin-EDTA  solution,  trypsin-EDTA  for  endothelial  cells,  IgG-free  bovine 
serum  albumin  (BSA),  30%  acrylamide/bis-acrylamide  solution,  HRP-conjugated  goat 
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2.2 Methods 
2.2.1 Characterisation of A2AAR-deficient mice 
2.2.1.1  Breeding of A2AAR-deficient mice 
All animal experiments, genotyping and cytokine assays were carried out by Dr Claire 
Rutherford (IBLS, University of Glasgow, UK) under the Home Office project license PPL 
60/3119. 
CD-1 mice heterozygous for an inactive allele of the A2AAR were produced as described 
by Ledent et al. (1997) and were supplied alongside wild-type CD-1 mice by Charles River 
Laboratories, Margate, Kent, UK.  Briefly, the wild-type murine A2AAR was cloned and 
the coding sequence interrupted by insertion of the neomycin gene under control of the 
phosphoglycerine kinase promoter in the first exon, thereby replacing the first 102 codons 
of the A2AAR gene which encode transmembrane segments 1 to 3.  The resulting construct 
was introduced into R1 embryonic stem (ES) cells to allow homologous recombination.  
Clones  carrying  the  recombinant  A2AAR  were  selected  for  by  resistance  to  G418  and 
screened by Southern blotting after digestion with DraI using a 2 800-bp EcoRI fragment 
complementary to a region spanning the site of insertion.  Clumps of recombinant ES cells 
were allowed to aggregate with single CD-1 eight-cell stage embryos from which the zona 
pellucida had been removed and the resulting embryos were transferred into the uteri of 
pseudopregnant recipients to generate chimaeric mice.  Chimaeras, when mated with wild-
type CD-1 mice, produced animals heterozygous for the inactive A2AAR gene (A2AAR
-/+).  
On  arrival,  A2AAR
-/+  mice  were  bred  for  several  generations  to  generate  homozygous 
animals  which  were  then  selected  for  further  breeding  to  create  a  colony  of  A2AAR-
deficient (A2AAR 
-/-) mice. 
2.2.1.2  Genotyping of A2AAR-deficient mice 
2.2.1.2.1 Extraction of DNA from tail-snips 
Mice were confirmed as carriers of the mutant allele of the A2AAR using polymerase chain 
reaction (PCR) analysis of DNA extracted from tail-snips.  A 0.3 cm tail-snip was removed 
from each animal at the time of death and stored at – 80 °C for future processing.  Each 
tail-snip was digested by incubation with 300 ml TNES buffer (100 mM Tris, pH 7.5, 200 Gillian R Milne, 2008    Chapter 2, 76 
mM  NaCl,  5mM  EDTA,  0.2  %  (w/v)  sodium  dodecyl  sulphate  (SDS))  and  40  mg 
proteinase  K  at  55  °C  overnight.    Once  all  tissue  was  digested,  100  ml  saturated 
(approximately  6  M)  NaCl  was  added  and  the  mixture  was  vortexed  for  15  seconds.  
Insoluble debris was pelleted by centrifugation (16 000 g, 5 mins, room temperature (RT)) 
and the supernatant removed to a fresh microfuge tube.  DNA was precipitated by addition 
of 300 ml room temperature isopropanol.  The mixture was centrifuged again (16 000 g, 5 
mins, RT) and the isopropanol supernatant removed.  The DNA pellet was washed with 
300 ml room temperature 70 % (v/v) ethanol and centrifuged once more.  The ethanol was 
decanted and the pellet allowed to dry at room temperature before resuspension in 60 ml 
TE buffer (10 mM Tris, pH 7.5, 1 mM EDTA). 
2.2.1.2.2 Polymerase chain reaction (PCR) 
DNA from tail-snips was screened for the presence of the wild-type and mutant alleles of 
the A2AAR in a single PCR assay using the following primers: 
A2R3:  5’ – CTC CAC CAT GAT GTA CAC CG – 3’ 
Neo R3:  5’ – AGG GAA GGG TGA GAA CAG AG – 3’ 
A2D3:  5’ – CAT GGT TTC GGG AGA TGC AG – 3’ 
Primers  were  designed  by  Catherine  Ledent  (Institut  de  Recherche  Interdisciplinaire, 
Universite  de  Bruxelles,  Brussels,  Belgium)  and  synthesised  by  Thermo  Electron 
Corporation, Ulm, Germany.  A2R3 and A2D3 amplified a 229 bp sequence from the wild-
type A2AAR while Neo R3 and A2D3 amplified a 570 bp sequence from the mutant allele.  
Reactions  were  carried  out  using  the  Qiagen  Taq  DNA  polymerase  system  in  a  total 
volume of 26 ml containing 1 mg of DNA extracted from tail-snips, 5 pmol of each primer, 
0.2 mM each of dATP, dCTP, dGTP and dTTP, 1 mM MgCl2, 1.5 U Taq DNA polymerase 
plus Qiagen PCR buffer and Q-solution as recommended by the manufacturer.  PCR was 
performed  using  a  Progene  Techne  thermal  cycler  programmed  to  give  an  initial 
denaturation step of 94 °C for 2 minutes followed by 30 cycles of denaturation at 94 °C for 
30 seconds, annealing at 56 °C for 1 minute and elongation at 72°C for 30 seconds and 
finishing with a final elongation at 72 °C for 10 minutes. 
PCR products were viewed using agarose gel electrophoresis (1.2 % (w/v) agarose) as 
described in Section 2.2.6.7. Gillian R Milne, 2008    Chapter 2, 77 
2.2.1.3  Bacterial endotoxin-induced septic shock 
Endotoxic shock was induced in equal numbers of male and female wild-type and A2AAR
-/- 
mice by intraperitoneal injection of 400 ml (200 mg) lipopolysaccharide (LPS) in order to 
produce an acute vascular inflammatory response.  A similar group of mice were injected 
with  an  equal  volume  (400  ml)  of  phosphate-buffered  saline  (PBS)  to  give  four 
experimental groups in total: (i) Wild-type mice + PBS, (ii) Wild-type mice + LPS, (iii) 
A2AAR
-/- mice + PBS, (iv) A2AAR
-/- mice + LPS.  Animals were then returned to their 
cages and observed closely.  After 4 hours, mice were euthanised by anaesthetic overdose 
via intraperitoneal injection of 0.3 ml Sagatal.  Following confirmation of death, a small 
blood sample (approximately 0.5 ml) was taken for measurement of cytokine levels and 
animals were then perfused with PBS through a needle inserted into the left ventricle.  
Aortas were dissected out, snap-frozen by immersion in liquid nitrogen and stored at – 80 
°C until required for preparation of protein samples. 
2.2.1.4  Measurement of proinflammatory cytokines in serum 
Blood collected at time of death was allowed to clot around a cocktail stick by incubating 
at room temperature for 1 hour and then at 4° C overnight.  The following day, the clot was 
discarded and the remaining serum was transferred to a microfuge tube.  Samples were 
centrifuged  (16  000  g,  13  mins,  4°C)  and  the  clear  supernatant  was  collected  for 
measurement of cytokine levels. 
Levels  of  the  proinflammatory  cytokines  TNFa,  IL-6,  IL-1b  and  GMCSF  in  serum 
samples were measured using the BioSource Mouse Inflammatory Four-Plex fluorescent 
immunoassay  kit  according  to  the  manufacturer’s  instructions.    This  assay  relies  on 
specific interactions between antibodies conjugated to polystyrene beads and a particular 
cytokine in the serum sample.  Four different cytokines can be measured simultaneously by 
mixing four populations of beads, each displaying different antibodies.  Each population of 
beads is internally dyed with fluorophores to give individual spectral properties allowing 
them to be distinguished from one another during the detection process. 
Serum  samples  and  standards  of  known  concentration  were  incubated  with  beads  in  a 
filter-bottom microplate for 2 hours at room temperature to allow TNFa, IL-6, IL-1b and 
GMCSF to bind to the antibodies on the beads.  The beads are light sensitive and so all 
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which recognise epitopes on the bound cytokines were added and incubated for a further 
hour at room temperature.  Excess biotinylated antibody was washed away and streptavidin 
conjugated to the fluorescent protein, R-phycoerythrin (streptavidin-RPE) was added to the 
beads and incubated at room temperature for 30 minutes.  Streptavidin-RPE binds to the 
biotinylated antibody which is associated with the cytokine-antibody complex on the bead.  
After  washing,  the  beads  were  loaded  into  a  BioSource  Luminex  100  instrument  for 
analysis.  The Luminex 100 monitors both the spectral properties of the beads and the level 
of fluorescence associated with RPE to generate a standard curve allowing calculation of 
the concentration of each cytokine in the sample. 
2.2.2 Cell culture and transfections 
2.2.2.1  Cell maintenance 
Human umbilical vein endothelial cells (HUVECs) were cultured in 150 cm
2 flasks in 
endothelial basal media (EBM) supplemented with 2 % (w/v) fetal bovine serum, 0.04 % 
(v/v)  hydrocortisone,  0.1  %  (v/v)  ascorbate  and  recombinant  growth  factors  as 
recommended by the supplier.  Cells were passaged on reaching 70 to 80 % confluence 
(approximately once a week).  Because HUVECs are particularly sensitive to trypsin, a 
non-standard method of subculturing was employed.  Cell monolayers were washed twice 
with  5  ml  warm  PBS  before  addition  of  endothelial  grade  trypsin-EDTA  solution  (5 
units/ml  porcine  trypsin,  1.8  %  (w/v)  EDTA).    Cells  were  then  incubated  at  room 
temperature  for  5  minutes  and  adherent  cells  dislodged  from  flasks  by  gentle  tapping.  
Trypsin  was  neutralised  by  addition  of  fresh  media  and  cells  were  pelleted  by 
centrifugation (200 g, 5 mins, RT).  Cell pellets were resuspended in a volume of media 
determined to give a suitable cell density for counting using a cytometer (typically 5 ml per 
150 cm
2 flask). 
HUVECs  were  used  for  experiments  between  passages  2  and  5.    Beyond  passage  5, 
HUVECs have been found to express altered levels of cell adhesion molecules in response 
to proinflammatory stimuli such as TNFa and LPS (Muller et al., 2002).  This suggests 
that  in  later  passages  HUVECs  may  begin  to  lose  their  suitability  as  a  model  for  the 
endothelium in vivo.  Cells were therefore discarded at this stage. 
Human embryonic kidney 293 (HEK 293) cells were maintained in Dulbecco’s modified 
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were maintained in Ham’s F-12 medium, each supplemented with 10 % (v/v) FBS, 1 % 
(v/v)  L-glutamine,  100  units/ml  penicillin  and  100  mg/ml  streptomycin.    Cells  were 
passaged when approximately 80 % confluent using buffered trypsin (0.5% (w/v) porcine 
trypsin, 0.2 % (w/v) EDTA). 
All cells were grown at 37°C in a humidified atmosphere containing 5 % (v/v) CO2. 
2.2.2.2  Transient transfection of HEK 293 and CHO cells 
HEK 293 or CHO cells were plated in 10 cm dishes at a density of 8 ´ 10
5 cells dish and 
cultured overnight in complete DMEM or Ham’s F-12, respectively.  The following day, 
cells were transfected with plasmids encoding either wild-type or truncated forms of the 
human A2AAR.  For each dish, 12 mg DNA and 400 ml Opti-mem serum-free medium were 
mixed in a sterile microfuge tube.  In a separate tube, 18 ml of the transfection reagent 
Lipofectamine  were  added  directly  to  400  ml  Opti-mem  and  mixed  thoroughly.    The 
Lipofectamine/Opti-mem mix was then transferred to the tube containing the DNA, mixed 
thoroughly and incubated at room temperature in the dark for 20 minutes.  During the 
incubation, cells were washed once with 5 ml Opti-mem which was then replaced with 5.2 
ml  fresh  Opti-mem.    The  Lipofectamine/DNA  mix  was  then  added  dropwise  over  the 
surface of the cells and the plate was rocked gently to ensure even distribution.  Cells were 
incubated for 3 hours at 37 °C.  The transfection medium was then replaced with normal 
complete medium.  Transfection efficiency was assessed by examining cells transfected in 
tandem  with  a  plasmid  encoding  GFP.    First,  the  total  number  of  cells  per  field  was 
estimated by counting 5 fields in bright-field using a 10 ´ objective lens and calculating 
the  mean.    Fluorescent  GFP-expressing  cells  were  then  counted  using  fluorescent 
microscopy  and  the  numbers  compared  to  estimate  the  percentage  of  transfected  cells.  
Transfection was deemed to be successful if the percentage of fluorescing cells exceeded 
50 %. 
2.2.2.3  Transient transfection of C6 cells 
C6  cells  were  plated  in  6-well  dishes  at  a  density  of  3´10
5  cells/well  and  cultured 
overnight in complete Ham’s F-12 medium.  The following day, cells were fed with fresh 
medium 1 hour prior to transfection using the transfection reagent, GeneJuice.  200 ml/well 
of Opti-mem and 1 mg DNA was placed in a sterile microfuge tube and mixed gently.  
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and  incubated  at  room  temperature  for  20  minutes.    The  appropriate  volume  of 
GeneJuice/DNA mixture was then added dropwise over the surface of cells in complete 
medium and plates were rocked gently to ensure even distribution.  Cells were incubated 
for 24 hours at 37°C.  The transfection mixture was then removed and replaced with fresh 
complete medium. 
2.2.2.4  Transfection of HUVECs with short interfering RNA 
Target-specific  short  interfering  RNAs  (siRNAs)  designed  to  knock  down  PKCa  and 
PKCe  and  non-targeting  control  siRNA  were  introduced  into  HUVECs  using  the 
transfection reagent Oligofectamine.  HUVECs were plated in 6cm dishes and grown until 
70 % confluent.  For each dish, 50 pmol siRNA was mixed with 240 ml Optimem in a 
sterile microfuge tube.  In a separate tube, 4.5 ml Oligofectamine was mixed with 18 ml 
Opti-mem.  Following a 5 minute incubation, the Oligofectamine mixture was added to the 
tube containing the siRNA and incubated for 20 minutes at room temperature.  Meanwhile, 
cells were washed twice with 2 ml Optimem which was then replaced with 1.5 ml fresh 
Optimem.  The siRNA/Oligofectamine mix was added dropwise over the surface of the 
cells and the dishes were agitated gently to ensure even distribution.  Cells were incubated 
for 5 hours at 37 °C and then the serum-free transfection medium was supplemented with 
an equal volume of fresh complete medium.  The transfection was repeated the following 
day and cells were used in experiments one day later.  Efficiency of knock-down by siRNA 
was assessed by immunoblotting as described in Section 2.2.5. 
2.2.3 Generation and maintenance of recombinant adenovirus 
2.2.3.1  Generation of myc-tagged human A2AAR-expressing adenovirus 
Recombinant  adenovirus  encoding  the  myc-tagged  human  A2AAR  (myc-hA2AAR)  was 
generated  by  Dr  William  Sands  (University  of  Glasgow,  Glasgow,  UK)  using  the 
“AdEasy” system (He et al., 1997) and has been described previously (Sands et al., 2004).  
In brief, the myc-humA2AAR was first cloned into the shuttle vector, pAdTrackCMV.  The 
resultant construct was then linearised by digestion with PmeI and co-transformed into E. 
coli  BJ5183  cells  with  the  adenoviral  backbone  plasmid,  pAdEasy1.    Successful 
recombination  of  pAdEasy1/myc-hA2AAR  was  confirmed  by  PmeI  digestion  and  PCR 
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cells  and  linearised  plasmids  were  transfected  into  HEK  293  cells  which  acted  as  a 
packaging cell line to allow viral production. 
The pAdEasy1 plasmid contains an open reading frame encoding GFP which is maintained 
in the recombinant adenovirus and so viral infection of HEK 293 cells can be detected by 
fluorescence  microscopy.    Six  days  post-infection,  HEK  293  cells  were  harvested  and 
disrupted by freeze-thawing to release adenovirus particles.  Cleared lysate was used to 
infect two 150 cm
2 tissue culture flasks of 70 % confluent HEK 293 cells.  Following 
successful infection, cells were harvested and viral particles collected as before in order to 
infect twenty 150 cm
2 flasks for a large scale preparation. 
Recombinant adenovirus encoding GFP  alone was kindly  donated by Professor Robert 
White (Beatson Institute for Cancer Research, Glasgow, UK). 
2.2.3.2  Large scale preparation of recombinant adenoviruses 
Pure  high  titre  stocks  of  recombinant  adenovirus  were  obtained  by  amplification  and 
purification  with  reference  to  the  method  described  by  Nicklin  and  Baker  (1999).  
Confluent 150 cm
2 flasks of low-passage HEK 293 cells were infected with either crude 
viral extract from previously infected HEK 293 cells or with plaque-purified recombinant 
adenovirus at an MOI of 0.1-10 per flask and incubated for 2-6 days at 37 °C, 5 % (v/v) 
CO2.  Once the cytopathic effect of the virus had caused the cells to detach from the flasks, 
cells were harvested and pelleted by centrifugation (250 g, 10 mins, RT).  Pellets were 
stored at - 80° C, ready for viral harvesting and purification. 
Cell pellets from twenty 150 cm
2 flasks were defrosted at room temperature and pooled by 
resuspension in a total volume of 10 ml room temperature PBS followed by centrifugation 
(250 g, 10 mins, RT).  The resultant single pellet was resuspended in 5 ml PBS and cells 
were lysed by 5 cycles of freeze/thawing in a dry ice/methanol bath followed by incubation 
with agitation in a 37 °C water bath.  The cell suspension was vortexed vigorously for 30 
seconds  between  cycles  to  encourage  cell  breakage.    The  lysate  was  cleared  by 
centrifugation (7000 g, 10 mins, 4 °C) and the supernatant containing the adenovirus was 
collected for further purification. 
Adenovirus obtained by the freeze/thawing method is contaminated with cellular protein 
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the supernatant from the previous step  was separated on  a discontinuous CsCl density 
gradient.  The CsCl gradient was created by underlying 3 ml of 1.2 g/ml CsCl solution with 
1.5 ml of 1.4 g/ml CsCl solution in a 14 ´ 95 mm Ultra-Clear centrifuge tube (Beckman).  
The crude adenovirus extract was applied to the top of the gradient and centrifuged (90 000 
g, 1.5 h, 8 °C) with zero deceleration to produce a translucent white band between the two 
layers of CsCl, representing pure adenovirus.  Zero deceleration was selected during the 
centrifugation step to prevent disruption of the delicate band by turbulence during braking.  
The adenovirus band was extracted using a syringe and a 21-gauge needle to puncture the 
side of the centrifuge tube and then transferred to a 3 ml Slide-A-Lyser dialysis cassette 
(Pierce).  The extract was dialysed overnight at 4 °C in 600 ml TE buffer (10 mM Tris, pH 
7.4, 1 mM EDTA, pH 8.0) with three changes.  The following day, the purified adenovirus 
was diluted in an equal volume of sterile storage buffer (10 mM Tris, pH 8.0, 100 mM 
NaCl, 0.1 % (w/v) BSA, 50 % (v/v) glycerol) and stored at – 80 °C in 10 ml aliquots. 
2.2.3.3  Titration of adenoviruses 
Purified  adenovirus  was  titred  using  a  Cell  Biolabs  Inc  QuickTitre  Adenovirus 
Immunoassay  Kit  according  to  the  manufacturer’s  instructions.    HEK  293  cells  were 
seeded in poly-D-lysine-coated 24-well tissue culture plates and incubated for 1 hour at 37 
°C,  5  %  (v/v)  CO2.    A  series  of  10-fold  dilutions  of  the  CsCl-purified  adenovirus 
preparation was prepared and used to infect the HEK 293 cells in duplicate.  Forty-eight 
hours  later,  cells  were  fixed  using  ice-cold  methanol  and  then  immunostained  using  a 
primary antibody directed against the adenoviral capsid protein, hexon (supplied) and a 
secondary horseradish peroxidise (HRP)-conjugated antibody which recognises the anti-
hexon  antibody  (supplied).    Binding  of  the  HRP-conjugated  antibody  was  detected  by 
incubation with a solution of the HRP substrate, diaminobenzidine (DAB; supplied).  DAB 
undergoes  oxidative  polymerisation  in  the  presence  of  HRP  to  produce  a  dark  brown 
precipitate.  Adenovirus-infected cells stained rapidly and were clearly visible under light 
microscopy as discrete brown patches in the cell monolayer.  Positively stained cells were 
counted in ten fields at a virus dilution that gave 5-50 positive cells/field when viewed 
using a 10 ´ objective.  The mean result was determined and used to calculate the number 
of  infected  cells  per  ml  of  the  original  adenovirus  preparation  to  give  a  titre  value  in 
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2.2.3.4  Infection of HUVECs with recombinant adenoviruses 
HUVECs  were  seeded  in  tissue  culture  dishes  at  a  density  that  would  produce  70  % 
confluence on the following day.  This equated to 3 ´ 10
5 cells/well in 6-well plates, 6 ´ 
10
5 cells in 6 cm dishes or 8 ´ 10
5 cells in 10 cm dishes.  The next day, cells were infected 
with adenovirus encoding either the human A2AAR (adA2AAR) or GFP alone (adGFP) at a 
level of 30 ifu/cell or as described in figure legends.  Cells were incubated for 24 hours and 
then  infective  media  was  replaced  with  fresh  media.    Experiments  were  performed  24 
hours later. 
2.2.4 Preparation of protein samples for immunoblotting 
2.2.4.1  Preparation of aortic extracts 
For each snap-frozen aorta to be crushed, 250 ml 2 % SDS sample buffer (2 % (w/v) SDS, 
50  mM  Tris,  pH  7.5,  10  %  (v/v)  glycerol,  0.1  mM  PMSF,  10  mg/ml  soybean  trypsin 
inhibitor, 10 mg/ml benzamidine, 5 mg/ml complete EDTA-free protease inhibitor cocktail 
tablet)  was  crushed  to  a  fine  powder  using  a  liquid  nitrogen-cooled  mortar  and  pestle 
resting on dry ice.  The aorta was added to the mortar and crushed together with the 2 % 
SDS sample buffer to produce a fine frozen powder.  The crushed tissue extract was then 
transferred to a chilled microfuge tube, allowed to thaw and then sonicated to disperse 
aggregated material.  Extracts were  centrifuged (16 000  g, 15 mins, 4 °C) to separate 
soluble protein from  cellular lipids and insoluble debris.   The soluble supernatant  was 
transferred to a fresh tube and the centrifugation process was repeated twice more to obtain 
a homogenous protein sample which was then frozen at – 80 °C for analysis by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). 
2.2.4.2  Preparation of extracts from cultured cells 
Protein extracts for SDS-PAGE and immunoblotting were prepared from confluent cells 
grown in 6-well plates.  Cells were first treated as described in figure legends.  Reactions 
were terminated by placing dishes on ice and washing cells three times in 1 ml ice-cold 
PBS prior to solubilisation in 100 ml RIPA buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 
1 % (v/v) Triton X-100, 0.5 % (w/v) sodium deoxycholate, 0.1 % (w/v) SDS, 10 mM 
sodium fluoride, 5 mM EDTA, 10 mM sodium phosphate, 0.1 mM phenylmethylsulfonyl 
fluoride, 10  mg/ml benzamidine, 10  mg/ml soybean trypsin inhibitor, 5 mg/ml complete Gillian R Milne, 2008    Chapter 2, 84 
EDTA-free protease inhibitor cocktail tablet).  For HUVEC samples, the volume of RIPA 
buffer was reduced to 50 ml per well to compensate for the low protein content of these 
cells.    Samples  were  incubated  on  ice  for  30  minutes  to  aid  solubilisation  before 
centrifugation (10 000 g, 15 mins, 4 °C) to pellet insoluble debris.  Protein concentration of 
supernatants was measured using a bicinchoninic acid (BCA)-based method as described 
below. 
2.2.4.3  Determination of protein concentration using the bicinchoninic acid 
(BCA) assay 
For  each  experiment,  10  ml  aliquots  of  bovine  serum  albumin  (BSA)  of  known 
concentration (ranging from 0 to 2 mg/ml) dissolved in the appropriate lysis buffer, and 10 
ml of each protein sample were added in duplicate to a 96-well plate.  100 ml of BCA 
reagent  (1  %  (w/v)  4,4  dicarboxy-2,2  biquinoline  disodium  salt,  2%  (w/v)  sodium 
carbonate, 0.16 % (w/v) sodium potassium tartrate, 0.4 % (w/v) sodium hydroxide, 0.95 % 
(w/v) sodium hydrogen carbonate, 0.08 % (w/v) copper (II) sulphate) was added to each 
well and the plate was incubated at room temperature for 10 minutes before measuring 
absorbance  at  490  nm  using  a  Dynex  MRX-TC  Revelation  microplate  reader.    Upon 
mixing with protein, Cu2+ ions in the BCA reagent are reduced to Cu
+ which then reacts 
with BCA to produce a colour change from blue to purple which is detectable at 490 nm.   
The extent of the colour change is directly proportional to the amount of protein in  a 
sample.    The  absorbance  measurements  obtained  for  the  BSA  standards  were  used  to 
derive a straight line graph from which the concentrations of the protein samples were 
calculated using Dynex Revelation software. 
2.2.5 SDS-PAGE and immunoblotting 
Equal quantities of protein (30 - 60 mg per sample, diluted to a final volume of 15 ml) were 
denatured in an equal volume of 12 % (w/v) SDS sample buffer (12 % (w/v) SDS, 50 mM 
Tris, pH 6.8, 10 % (v/v) glycerol, 10 mM dithiothreitol (DTT), bromophenol blue).  Of 
this, 25 ml samples were fractionated by SDS-PAGE on 10 % (w/v) acrylamide resolving 
gels (10 % (w/v) acrylamide, 375 mM Tris, pH 8.8, 0.1 % (w/v) SDS) with 4 % (w/v) 
acrylamide stacking gels (4 % (w/v) acrylamide, 125 mM Tris, pH 6.8, 0.1 % (w/v) SDS).  
To  allow  size  estimation  of  immunoreactive  protein  bands,  Biorad  Rainbow  molecular 
weight  markers  were  fractionated  alongside  protein  samples.    Electrophoresis  was 
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Tris, pH 8.3) at a constant voltage of 180 V for approximately 1.5 hours until the dye front 
reached the bottom of the gel. 
Proteins were electrotransferred from the gel on to a Protran nitrocellulose membrane (0.2 
mm pore size) for 45 min at a constant current of 400 mA in a transfer buffer containing 
192 mM glycine, 25 mM Tris, pH 8.3 and 20 % (v/v) methanol.  Membranes were then 
blocked for at least 1 hour at room temperature in immunoblotting buffer (20 mM Tris, pH 
7.4, 140 mM NaCl, 0.1 % (v/v) Tween 20, 5 % (w/v) milk proteins) prior to incubation 
with rotation with primary antibody for either 1 hour at room temperature or overnight at 
4°C.  Antibodies used during this study are listed in Table 1.  Antibodies were diluted in 
either immunoblotting buffer or 5 % (w/v) BSA in Tris-buffered saline/1 % (v/v) Tween 
20 (TBST; 20 mM Tris, pH 7.4, 140 mM NaCl, 1 % (v/v) Tween 20).  After 3 ´ 5 minute 
washes  in  TBST,  membranes  were  exposed  to  the  appropriate  horseradish  peroxidise-
conjugated secondary antibody diluted 1/1000 in immunoblotting buffer for 1 hour at room 
temperature.  Membranes were then washed 5 ´ 5 minutes in TBST.  Immunoreactive 
proteins were visualised using Perkin-Elmer enhanced chemiluminescence (ECL) detection 
reagents, according to the manufacturer’s instructions. Gillian R Milne, 2008    Chapter 2, 86 
 
Antibody reactivity  Supplier  Catalogue 
Number 
Dilution 
Phospho-IkBa (Ser 
32/36) (5A5)  Cell Signalling 
Technology 
9246  1:1000 
IkBa (C-21)  Santa Cruz 
Biotechnology, Inc. 
Sc -371  1:1000 
NFkB p65 (A)  Santa Cruz 
Biotechnology, Inc. 
Sc -109  1:400 
VCAM-1  R & D Systems  AF643  1:1000 
ICAM-1  R & D Systems  AF796  1:500 
Phospho-STAT1 (Tyr
701)  Cell Signalling 
Technology 
9171  1:1000 
STAT1  Cell Signalling 
Technology 
9172  1:1000 
Phospho-STAT3 (Tyr
705) (D3A7)  Cell Signalling 
Technology 
9145  1:1000 
STAT3  Cell Signalling 
Technology 
9132  1:1000 
TAP-1 (M-18)  Santa Cruz 
Biotechnology, Inc. 
Sc-11465  1:500 
Glyceraldehyde-3-phosphate 
dehydrogenase 
abcam  ab9484  1:20 000 
Phospho-p44/42 MAPK 
(Thr
202/Tyr
204) (E10) 
Cell Signalling 
Technology 
9106  1:1000 
c-myc (9E10)  Eurogentec  Ascites fluid  1:1000 
A2A Adenosine Receptor  Cambridge Bioscience  PA1-042  1:1000 
PKC (A-9)  Santa Cruz 
Biotechnology, Inc. 
Sc-17804  1:500 
PKCe (22B10)  Cell Signalling 
Technology 
2683  1:250 
PKCa  Cell Signalling 
Technology 
2056  1:250 
Table 2: Antibodies used for immunoblotting Gillian R Milne, 2008    Chapter 2, 87 
2.2.6 Molecular Biology 
2.2.6.1  Plasmid DNA constructs 
Plasmids encoding the wild-type human A2AAR (pcDNA3.1/mycHis-hum A2AAR) and the 
carboxyl terminus-truncated mutant receptors (pcDNA3.1/mycHis-hum A2AAR 1-311 and 
pcDNA3.1/mycHis-hum A2AAR 1-360) were constructed by Dr Tim Palmer (Institute of 
Biomedical and Life Sciences, University of Glasgow, Glasgow, UK).  Briefly, a myc 
epitope (EQKLISEEDL) and His6 sequences were added to the carboxyl terminus of the 
human  A2AAR  by  PCR  using  pCMV5/human  A2AAR  as  a  template.    Primers  were 
designed to amplify the A2A region while removing the stop codon and introducing an XbaI 
site.    The  resultant  PCR  product  was  digested  with  HindIII  and  XbaI  and  ligated  into 
similarly  digested  pcDNA3.1/mycHisA  in-frame  and  upstream  of  the  myc  and  His 
sequences.  Plasmids encoding truncated human A2AAR mutants were created in the same 
way but using different antisense primers designed to remove either 101 or 52 amino acids 
from  the  carboxyl  terminus  to  generate  pcDNA3.1/mycHis-hum  A2AAR  1-311  and 
pcDNA3.1/mycHis-hum A2AAR 1-360 respectively. 
pGEX-TRAX (Sun et al., 2006) was kindly donated by Dr Yijuang Chern (Institute of 
Biomedical Sciences, Academia Sinica, Taipei, Taiwan). 
pGEX-14-3-3t  (Ward  and Milligan, 2005) was a  gift from Professor  Graeme Milligan 
(Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, UK). 
2.2.6.2  Bacterial Strains and Media 
E. coli XL1 Blue cells were used for the propagation of plasmid vectors while recombinant 
proteins were expressed in E. coli BL21 cells.  E. coli were grown in sterile Luria-Bertani 
broth (LB; 10 g/l bacto-tryptone, 10 g/l NaCl, 5 g/l, pH 7.5) supplemented with ampicillin 
(50 mg/ml) where necessary (LB
Amp).  LB
Amp plates were made by inclusion of 1.5 % (w/v) 
agar and stored at 4 °C until required. 
2.2.6.3  Transformation of competent E. coli 
Aliquots of E. coli XL1 Blue or BL21 competent bacteria were thawed on ice and 40 ml 
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50 ng DNA.  Cells were incubated on ice for 15 minutes before heat shocking at 42 °C for 
45 seconds.  The tubes were immediately returned to ice for 2 minutes.  LB (1 ml) was 
then added and the cells were incubated with shaking at 37 °C for 1 hour.  200 ml of this 
mix was plated out on LB
Amp plates and grown overnight at 37 °C to allow growth of 
bacterial colonies. 
2.2.6.4  Preparation of plasmid DNA 
DNA  was  purified  from  bacterial  cultures  using  the  Qiagen  Plasmid  Maxi  kit  as 
recommended by the manufacturer.  An isolated colony from an agar plate was used to 
inoculate 5 ml LB
Amp and grown for eight hours at 37 °C with shaking at 200 rpm.  This 
culture was used to inoculate 250 ml LB
Amp which was grown for a further 16 hours in the 
same  conditions.    Typically,  5  ml  of  culture  was  reserved  for  preparation  of  glycerol 
stocks.  Bacteria were harvested from the remaining culture by centrifugation (6 000g, 15 
mins, 4°C) and then resuspended in 10 ml Buffer P1 (50 mM Tris, pH 8.0, 10 mM EDTA, 
100 mg/ml RNase A).  Cells were lysed by addition of 10 ml Buffer P2 (200 mM NaOH, 1 
%  (w/v)  SDS)  and  incubation  at  room  temperature  for  5  minutes.    The  lysates  were 
neutralised by addition of Buffer P3 (3 M potassium acetate, pH 5.5), mixed by inversion 
and  incubated  on  ice  to  facilitate  precipitation  of  potassium  dodecyl  sulphate,  SDS-
denatured proteins, genomic DNA and cellular debris.  The lysate was then cleared by 
centrifugation (20 000 g, 10 mins, 4 °C).  The supernatant containing soluble plasmid 
DNA was applied to a Qiagen-tip 500, pre-equilibrated with 10 ml Buffer QBT (750 mM 
NaCl, 50 mM MOPS, pH 7.0, 15 % (v/v) isopropanol, 0.15 % (v/v) Triton X-100) and 
allowed to enter the resin within the tip by gravity flow.  The tip was then washed twice 
with 30 ml Buffer QC (1 M NaCl, 50 mM MOPS, pH 7.0, 15 % (v/v) isopropanol) and 
DNA was eluted using 15 ml Buffer QF (1.25 M NaCl, 50 mM Tris, pH 8.5, 15 % (v/v) 
isopropanol).  DNA was precipitated by addition of 10.5 ml room temperature isopropanol 
and incubation at room temperature for 30 minutes before being pelleted by centrifugation 
(15 000 g, 30 mins, 4 °C).  The DNA pellet was washed with 5 ml room temperature 
ethanol, centrifuged once more and allowed to air-dry for 10 minutes before resuspension 
in 500 ml sterile TE buffer.  DNA concentration was determined by diluting the preparation 
1 in 500 in distilled water and measuring absorbance at 260 nm (A260), assuming that a 50 
mg/ml solution of double-stranded DNA has an A260 of 1 unit.  Absorbance at 280 nm 
(A280) was also measured and used to determine DNA purity assuming that pure DNA has 
an A260/A280 ratio of 1.8. Gillian R Milne, 2008    Chapter 2, 89 
2.2.6.5  Preparation of glycerol stocks 
Glycerol stocks were prepared for long-term storage of plasmid DNA.  For each glycerol 
stock, 0.7 ml overnight culture was added to 0.3 ml sterile 50 % (v/v) glycerol in a sterile 
cryovial.    Vials  were  vortexed  vigorously  to  ensure  even  dispersal  of  glycerol,  frozen 
rapidly on dry ice and stored at – 80 °C. 
2.2.6.6  Restriction digestion of plasmid DNA 
Plasmids encoding wild-type and truncated forms of myc-hA2AAR were digested using 
HindIII and XbaI.  DNA (1mg) was digested in a reaction mixture containing 5 U each of 
HindIII and XbaI, 3 ml of Promega Buffer E (6mM Tris, pH 7.5, 6 mM MgCl2, 100 mM 
NaCl, 1 mM DTT, pH 7.5) and nuclease-free water to a total volume of 10 ml.  Reactions 
were  allowed  to  proceed  for  1.5-3  hours  and  fragments  were  analysed  by  agarose  gel 
electrophoresis using 1 % (w/v) agarose gels as described below. 
2.2.6.7  Agarose gel electrophoresis 
Plasmid DNA and PCR products were analysed by agarose gel electrophoresis using 1 % 
(w/v) and 1.2 % (w/v) gels respectively.  Gels were prepared by dissolving 0.4 or 0.48 g of 
agarose in 40 ml TAE buffer (40 mM Tris, 1 mM EDTA, 40 mM glacial acetic acid) with 
heating.  Gels were cooled to hand-warm and 4 ml of 10 mg/ml ethidium bromide solution 
was added in order to stain DNA bands for visualisation under UV light.  Before loading, 2 
ml DNA loading Buffer (0.25 % (w/v) bromophenol blue, 40 % (w/v) sucrose in TAE 
buffer) was added to samples to be analysed.  Samples were run alongside 1 kb step ladder 
markers at 100 V/ 250 mA in TAE buffer for approximately 1 hour until the dye front 
reached the end of the gel.  Bands were detected by ethidium bromide staining and viewed 
using a UV transilluminator. 
2.2.6.8  Preparation of GST fusion proteins 
A scraping from a glycerol stock of E. coli BL21 cells transformed with pGEX plasmid 
DNA encoding either GST-14-3-3t, GST-TRAX or GST alone was used to inoculate 10 
ml LB
Amp.  Cells were cultured for 8 hours (GST-TRAX) or overnight (GST and GST-14-
3-3t), at 37 °C with shaking at 200 rpm.  This culture was used to inoculate 300 ml LB
Amp 
and cells were then grown for approximately 2 hours until an OD600 of 0.3 was reached, Gillian R Milne, 2008    Chapter 2, 90 
indicating that bacteria were growing exponentially.  Isopropyl b-thiogalalactopyranoside 
(IPTG) (0.2 - 1 mM) was then added to induce expression of recombinant protein and 
bacteria were grown for a further 4 hours at 37°C (GST and GST-14-3-3t) or overnight at 
25 ° C (GST-TRAX).  Bacteria were harvested by centrifugation (6700 g, 15 mins, 4 °C) 
and pellets were stored at – 80 °C for protein purification the following day. 
Pellets  containing  GST-tagged  proteins  were  defrosted  at  room  temperature  and 
resuspended in 20 ml lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 
% (v/v) Triton X-100).  Samples were probe sonicated on ice for 6 ´ 20 seconds with 20 
second intervals to prevent build-up of heat and centrifuged (27 000 g, 30 mins, 4 °C) to 
pellet  insoluble  material.    The  cleared  lysate  was  mixed  with  0.3  ml  of  a  50  %  (v/v) 
glutathione Sepharose bead suspension in lysis buffer and incubated for 1 hour at 4 °C with 
rotation in order to immobilise GST-tagged proteins on the beads.  The beads were pelleted 
by  gentle  centrifugation  (335  g,  1  min,  4  °C),  washed  twice  in  10  ml  PBS  and  then 
transferred to a microfuge tube for a final wash in 1 ml PBS.  PBS was aspirated from 
tubes and beads were resuspended in 0.3 ml 50 % (v/v) glycerol in PBS supplemented with 
protease  inhibitors  (0.1  mM  PMSF,  10  mg/ml  soybean  trypsin  inhibitor,  10  mg/ml 
benzamidine) and stored at – 20 °C. 
Concentration  of  GST-tagged  proteins  was  determined  by  SDS-PAGE  on  10  %  (w/v) 
polyacrylamide resolving gels as described in Section 2.2.5.  Proteins were eluted from 
beads following a brief spin to allow removal of the glycerol/PBS storage solution.  Beads 
were resuspended in 20 ml 12 % (w/v) SDS sample buffer and incubated at 65 °C for 1 
hour with occasional vortexing.  Eluted samples were transferred to fresh microfuge tubes 
using a Hamilton syringe and then run on gels in parallel with known quantities of BSA 
ranging  between  0.2  and  2  mg.    To  view  bands,  gels  were  stained  in  0.25  %  (w/v) 
Coomassie brilliant blue, 10 % (v/v)  acetic  acid, 45 % (v/v) methanol for 1 hour  and 
destained in 10 % (v/v) acetic acid, 10 % (v/v) methanol.  Gels were scanned and the 
densities  of  bands  produced  by  the  BSA  standards  and  the  GST-tagged  proteins  were 
quantitated by densitometry using Non-linear Dynamics TotalLab software.  Results from 
the  BSA  standards  were  then  used  to  generate  a  straight  line  graph  from  which  the 
concentration of the eluted GST-tagged proteins could be calculated. 
To  track  expression  and  recovery  of  fusion  proteins,  100  ml  samples  were  reserved  at 
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volume of 12 % (w/v) SDS sample buffer for analysis by SDS-PAGE and Coomassie 
staining as described above. 
2.2.7 GST pull-down assay 
HUVECs  were  seeded  in  10  cm  dishes  and  infected  with  adA2AAR  at  30  ifu/cell  as 
described  in  Section  2.2.3.4.    Cells  were  treated  as  described  in  figure  legends  and 
reactions were terminated by placing dishes on ice and washing twice with 5 ml ice-cold 
PBS.  Cells were harvested by scraping into 750 ml pull-down lysis buffer (50 mM HEPES, 
pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 % (v/v) Triton X-100) supplemented with protease 
inhibitors (0.1 mM PMSF, 10 mg/ml soybean trypsin inhibitor, 10 mg/ml benzamidine, 5 
mg/ml  complete  EDTA-free  protease  inhibitor  cocktail  tablet,  100  mM  sodium 
orthovanadate)  and  incubated  for  1  hour  with  rotation  at  4  °C  to  aid  solubilisation.  
Samples were then centrifuged (20 000 g, 15 mins, 4 °C) to pellet insoluble material and 
assessed  for  protein  concentration  using  a  BCA  assay  as  described  in  Section  2.2.4.3.  
Extracts containing equivalent amounts of protein in a volume of 680 ml were added to 
microfuge  tubes  containing  the  appropriate  volume  of  GST-fusion  protein  glutathione 
Sepharose beads to give 20 mg of either GST, GST-14-3-3t or GST-TRAX.  Samples were 
then incubated overnight at 4 °C with rotation to allow protein complexes to form.  The 
following  day,  beads  and  any  associated  protein  complexes  were  pelleted  by  gentle 
centrifugation (600 g, 1 min, 4 °C) and then washed 3 times in 1 ml ice-cold pull-down 
lysis buffer.  Bound proteins were eluted by adding 40 ml 12 % (w/v) SDS sample buffer 
and  incubating  at  65  °C  for  30  minutes,  vortexing  every  10  minutes.    Samples  were 
transferred to fresh microfuge tubes using a Hamilton syringe and analysed by SDS-PAGE 
and immunoblotting as described in Section 2.2.5. 
2.2.8 Intact cell receptor phosphorylation assay 
For characterisation of wild-type A2AAR phosphorylation, HUVECs were grown in 6-well 
dishes and infected with 30 ifu/cell adA2AAR or adGFP as described in Section 2.2.3.4.  
Forty-eight hours post-infection, cells were washed twice with 2 ml/well low-phosphate 
DMEM  and  incubated  for  90  min  at  37°  C,  5  %  CO2  in  0.75  ml  of  the  same  media 
supplemented with 0.8 mCi/ml [
32P] orthophosphate in order to label the intracellular pool 
of ATP.  Cells were then treated as described in figure legends.  Reactions were terminated 
by placing dishes on ice and washing twice in ice-cold PBS.  Cells were solubilised by Gillian R Milne, 2008    Chapter 2, 92 
scraping  into  250  ml  RIPA  buffer  supplemented  with  100  mM  sodium  orthovanadate 
followed by rotation at 4 ° C for 1 hour.  Samples were cleared of cellular debris by 
centrifugation (10 000 g, 15 mins, 4 °C) and 10 ml portions of undiluted supernatants were 
assayed for protein content as described in Section 2.2.4.3.  For immunoprecipitation of 
phosphorylated receptors, extracts containing equivalent amounts of protein in a volume of 
180 ml were added to microfuge tubes containing 30 ml of a 50 % suspension of protein G-
sepharose beads, 5 ml 9E10 ascites fluid and 100 ml 0.2 % (w/v) IgG-free BSA.  Extracts 
were incubated with beads on a rotating wheel for 90 minutes at 4° C.  Immune complexes 
conjugated to beads were then recovered by brief centrifugation (10 000 g, 15 secs, 4 °C) 
and washed 3 times in 1 ml ice-cold RIPA buffer.  Pelleted beads were resuspended in 
12% (w/v) SDS sample buffer and complexes were eluted by vortexing and incubation at 
room  temperature  overnight.    The  following  day,  beads  were  pelleted  by  brief 
centrifugation (10 000 g, 15 secs, RT) and supernatants were transferred to fresh microfuge 
tubes using a Hamilton syringe.  Samples were boiled at 95° C for 5 minutes to denature 
antibody heavy and light chains prior to loading on to 10 % (w/v) polyacrylamide gels for 
analysis by SDS-PAGE and autoradiography.  Gels were dried under vacuum with heat for 
2 hours and exposed to film between 2 intensifying screens for 2-7 days at -80 ° C. 
For  analysis  of  phosphorylation  of  truncated  A2A  adenosine  receptors,  HEK  293,  C6 
glioma or CHO cells were plated in 10 cm dishes.  On reaching 70 % confluence, cells 
were transfected with constructs encoding wild-type or truncated forms of the A2AAR as 
described in Sections 2.2.2.2 and 2.2.2.3.  The following day, each 10 cm dish was split 
into 6-well plates in order to minimise variation in transfection efficiency between wells.  
Intact  cell  phosphorylation  assays  were  carried  out  as  described  above  with  minor 
alterations depending on the efficiency of recovery of protein from different cell types.  
HEK 293, CHO and C6 glioma cells were labelled with 0.4 mCi/ml [
32P] orthophosphate 
rather than 0.8 mCi/ml and were solubilised in 500 ml RIPA buffer rather than 250 ml 
allowing 430 ml of each sample to be used in the immunoprecipitation step. 
2.2.9 Saturation binding assay 
2.2.9.1  HUVEC membrane preparation 
HUVECs were seeded in 10 cm dishes and infected with adA2AAR or adGFP as described 
in Section 2.2.3.4.  Forty-eight hours post infection, dishes were placed on ice and washed Gillian R Milne, 2008    Chapter 2, 93 
3 times with 5 ml ice-cold PBS.  Cells were scraped into 5 ml/dish lysis buffer (10 mM 
Hepes, pH 7.5 at RT, 5 mM EDTA) and lysed on ice by 20 up-and-down strokes of a 7 ml 
Dounce homogeniser.  The homogenate was transferred to a chilled centrifuge tube and 
membranes were pelleted by centrifugation (14 000g, 15 mins, 4 °C).  The membrane 
pellet was resuspended in 400 ml binding buffer (50 mM Hepes, pH 6.8 at RT, 10 mM 
MgCl2) and subjected to further homogenisation by 20 up-and-down strokes in a 1 ml 
Dounce  homogeniser.    A  50  ml  sample  was  removed  and  stored  at  –  20  °C  for 
determination of protein concentration at a later date.  The membrane preparation was then 
diluted to a final volume of 4 ml with binding buffer supplemented with 1 U/ml adenosine 
deaminase to degrade endogenous adenosine.  The extract was homogenised once more 
before immediate use in binding assays. 
2.2.9.2 
3H-ZM241385 saturation binding assay 
Binding assays were performed in duplicate in a total volume 250 ml containing 150 ml 
membrane  preparation  and  50  ml 
3H-ZM241385  at  final  concentrations  ranging  from 
approximately 0.25 nM to 8 nM.  Non-specific binding was defined in parallel by inclusion 
of NECA at a final concentration of 50 mM.  Samples were incubated for 1 hour with 
shaking in a 37 °C water bath to allow binding to reach equilibrium.  Bound radioligand 
was  isolated  by  rapid  vacuum  filtration  over  0.3  %  (v/v)  polyethyleneimine  solution-
soaked GF/C glass fibre filters using a Brandel cell harvester.  Filters were then washed 
three times with 3 ml ice-cold wash buffer (50 mM Tris, 10 mM MgCl2, 1 mM EDTA, pH 
7.4 at 4 °C) supplemented with 0.03 % (w/v) CHAPS detergent to minimise non-specific 
binding.  Filter discs for each sample were added to scintillation vials containing 5 ml 
scintillation fluid and incubated at 4 °C overnight to reduce chemiluminescence before 
scintillation  counting.    Non-specific  counts  were  subtracted  from  total  counts  to  give 
values  for  specific  binding  in  dpm  which  were  then  plotted  against 
3H-ZM241385 
concentration (nM) using GraphPad Prism software.  The data was fitted to a hyperbola 
using a non-linear regression equation in order to determine the total number of receptors 
expressed (Bmax) and the equilibrium dissociation constant (Kd).  Samples reserved during 
membrane preparation were assayed for protein content using a BCA protein assay and the 
results used to calculate Bmax in pmol/mg. Gillian R Milne, 2008    Chapter 2, 94 
2.2.10  Statistical analysis 
All  statistical  analyses  were  carried  out  using  a  one-way  ANOVA  with  a  Bonferroni 
comparisons post test using GraphPad Prism software. 95 
3  The role of the A2A adenosine receptor in 
suppressing vascular inflammation 
3.1 Introduction 
Inflammation of the vascular endothelium is central to the development of major diseases 
including  atherosclerosis.    In  the  earliest  stages  of  inflammation,  endothelial  cells  are 
activated by various stimuli to express adhesion molecules such as VCAM-1, ICAM-1 and 
E-selectin which initiate the recruitment of inflammatory cells (Muller, 2002).  This is a 
critical step in the development of atherosclerosis, as macrophage infiltration of the vessel 
wall  and  subsequent  foam-cell  formation  leads  to  the  development  of  atherosclerotic 
plaques (Glass and Witztum, 2001).  Activated endothelial cells also elaborate numerous 
inflammatory mediators such as IL-6 and IL-1 which contribute to disease progression in 
many  ways  including  by  promoting  macrophage  differentiation,  smooth  muscle  cell 
proliferation, and further cytokine expression (von der Thüsen et al., 2003).  It is important 
to study how these events are regulated as this could reveal new targets for therapeutic 
intervention and allow development of better strategies for the treatment of inflammatory 
disease. 
One way that the body naturally deals with the risk of excessive inflammation and tissue 
damage is through accumulation of extracellular adenosine.  Adenosine exerts its effects 
through stimulation of A1, A2A, A2B and A3 receptors, of which the A2AAR appears to be 
most important in mediating anti-inflammatory responses (Linden, 2001).   Endothelial 
cells are key targets for adenosine as they express both A2A and A2BARs.  The A2AAR has 
been reported to be the predominant form in large blood vessels which is significant in 
terms of disease as this is the site of atherosclerotic lesion formation (Feoktistov et al., 
2002).  Endothlelial cells are also significant producers of adenosine both directly and via 
the sequential dephosphorylation of adenine nucleotides released from damaged cells to 
adenosine by the ecto-apyrase CD39 and the ecto-nucleotidase CD73, which they express 
on their cell surface (Lennon et al., 1998).  Gene-targeting studies have shown that a lack 
of functional CD39 (Eltzschig et al., 2003) or CD73 (Thompson et al., 2004) results in 
excessive vascular leakage in response to hypoxia which points to the crucial nature of this 
pathway and suggests that its defective regulation may predispose toward disease.   A2AAR 
activation  therefore  potentially  represents  an  important  endogenous  mechanism  for 
limiting vascular inflammation. Gillian R Milne, 2008    Chapter 3, 96 
Several  in  vitro  studies  have  demonstrated  the  potential  for  adenosine  and  signalling 
through the A2AAR to modulate inflammatory responses in endothelial cells.  For example, 
activation of A2AARs with the A2AAR-selective agonist CGS21680 has been shown to 
inhibit phorbol ester-stimulated adhesion of neutrophils to porcine aortic endothelial cells 
(Felsch  et  al.,  1995).    In  HUVECs  stimulated  with  LPS,  TNFa  or  IL-1b,  adenosine 
inhibited  release  of  the  pro-inflammatory  cytokines  IL-6  and  IL-8  and  also  reduced 
expression of the adhesion molecules VCAM-1 and E-selectin which mediate monocyte 
adhesion (Bouma et al., 1996).  A specific role for the A2AAR in regulating leukocyte 
recruitment has been demonstrated in HUVECs through adenoviral-mediated gene transfer.  
In these cells, increased presence of the A2AAR was sufficient to inhibit TNFa-induced E-
selectin expression and monocyte adhesion to the endothelium (Sands et al., 2004). 
The beneficial effects of signalling through the A2AAR in vivo have been shown using 
animal models of inflammation and disease.  For example, in the murine carotid artery 
ligation model of arterial inflammation, mice treated with the A2AAR agonist ATL-146e 
displayed significantly reduced neutrophil and macrophage recruitment and expression of 
VCAM-1, ICAM-1 and P-selectin and this was associated with markedly reduced lesion 
formation (McPherson et al., 2001).  Furthermore, a physiological role for the A2A receptor 
in  in  vivo  regulation  of  inflammation  has  been  confirmed  through  creation  of  an  A2A-
deficient mouse strain.  When these mice were subjected to experimentally induced models 
of hepatitis and septic shock, it was found that even low doses of inflammatory stimuli 
which had little effect on wild-type mice caused extensive inflammation and tissue damage 
(Ohta and Sitkovsky, 2001).  This was accompanied by elevated levels and a prolonged 
presence of pro-inflammatory cytokines such as TNFa and IFNg and IL-6.   
Despite the wealth of evidence regarding the anti-inflammatory properties of the A2AAR, 
the molecular mechanisms behind these effects have not been well studied.  Signalling 
through the A2AAR produces diverse but consistently anti-inflammatory effects in a wide 
range  of  cell  types  and  disease  models  suggesting  that  there  could  be  a  common 
mechanism.  Despite the complexity of responses to tissue damage and inflammation, the 
majority  are  mediated  through  activation  of  only  a  few  major  signalling  pathways 
including the NFkB and JAK/STAT pathways.  If the A2AAR could influence signalling 
through  these  pathways,  this  would  provide  an  explanation  for  its  wide  range  of  anti-
inflammatory  actions.    This  case  is  strengthened  by  the  fact  that  all  of  the  adhesion 
molecules and inflammatory mediators that have been shown to be affected by adenosine 
or A2AAR stimulation have their expression regulated by NFkB and STAT proteins.  In Gillian R Milne, 2008    Chapter 3, 97 
addition, in vitro studies have shown that signalling through the A2AAR suppresses NFkB 
(Sands et al., 2004) and JAK/STAT (Sands et al., 2006) pathway activation in cultured 
endothelial  cells.    Whether  this  is  a  relevant  physiological  mechanism  for  limiting 
inflammation in vivo is not known. 
A2AAR-deficient mice have been used to demonstrate the protective role of the A2AAR in 
several models of inflammatory disease (Naganuma et al., 2006; Day et al., 2004; Ohta 
and Sitkovsky, 2001).  If the A2AAR mediates this effect through suppression of NFkB and 
JAK/STAT signalling, then it can be hypothesised that these signalling pathways will be 
hyperactivated in A2AAR-deficient mice.  To determine whether this is the case, in this 
study,  A2AAR-deficient  mice  were  subjected  to  LPS-induced  septic  shock  to  induce 
vascular  inflammation  and  then  activation  of  NFkB  and  JAK/STAT  pathways  was 
compared with wild-type mice by detecting levels of activated signalling proteins in the 
aorta. Gillian R Milne, 2008    Chapter 3, 98 
3.2 Results 
The lack of a functional A2AAR has been shown to exacerbate inflammation and tissue 
damage in several animal models of inflammatory disease (Naganuma et al., 2006; Day et 
al.,  2004;  Ohta  and  Sitovsky,  2001).    However,  there  is  little  information  available 
regarding  the  molecular  mechanisms  which  produce  these  effects  in  vivo.    Two  major 
pathways involved in the inflammatory response are the NFkB and JAK/STAT pathways.  
Hyperactivation  of  the  NFkB  and  JAK/STAT  signalling  pathways  is  found  in  several 
inflammatory  diseases  and  so  they  present  important  potential  targets  for  the  anti-
inflammatory actions of the A2AAR (Miagkov et al., 1998; Hajra et al., 2000; Gharavi et 
al.,  2007;  Schreiber  et  al.,  2002).    Specifically,  the  importance  of  NFkB  in  the 
development of atherosclerosis is indicated by studies using LDLR
-/- mice in which the 
NFkB pathway was found to be primed for activation in endothelial cells in atherosclerotic 
lesion-prone regions of the aorta (Hajra et al., 2000).  Stimulation of A2AARs has been 
shown to reduce arterial inflammation and lesion formation in the murine carotid artery 
ligation model (McPherson et al., 2001) but whether this involves suppression of pro-
inflammatory signalling has not been addressed.  In this study, the physiological role of the 
A2AAR  in  regulating  pro-inflammatory  signalling  in  vivo  was  assessed  by  measuring 
activation of NFkB and JAK/STAT signalling in the aortae of A2AAR
-/- mice. 
To examine whether the A2AAR has an effect on pro-inflammatory signalling in vivo, a 
colony of A2AAR-deficient mice was created as described previously (Ledent et al., 1997).  
Carriers of the wild-type and the non-functional mutant A2AAR were identified by PCR 
analysis of DNA extracted from tail-snips using specific primers.  As shown in figure 3.1, 
samples from wild-type mice generated a single 229 bp PCR product while samples from 
mice homozygous for the mutant allele generated a single 570 bp fragment.  These mice 
were selected for use in subsequent studies. 
In  order  to  study  inflammatory  responses  in  the  presence  and  absence  of  a  functional 
A2AAR, mice were subjected to an LPS-induced model of sepsis which has been used 
previously  to  induce  acute  systemic  activation  of  the  aortic  endothelium  (Hajra  et  al., 
2000).  Mice were injected intraperitoneally with either 200 mg LPS or an equal volume of 
PBS and then euthanized 4 hours later.  Serum levels of the pro-inflammatory cytokines 
TNFa, IL-6, IL-1 and GM-CSF were measured (figure 3.2).  Levels of TNFa, IL-6 and 
GM-CSF were significantly elevated in wild-type mice treated with LPS compared to PBS- Gillian R Milne, 2008    Chapter 3, 99 
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Figure 3.1 Genotyping of wild-type and A2AAR-deficient mice 
CD-1 mice heterozygous for an inactive allele of the A2AAR gene were bred to produce a 
colony of A2AAR-deficient (A2AAR
-/-) mice.  Genomic DNA extracted from tail-snips was 
screened  for  the  presence  of  wild-type  and  mutant  alleles  of  the  A2AAR  using  PCR 
analysis with specific primers.  PCR products were separated on a 1.5 % (w/v) agarose 
gel.  Fragments representing the wild-type (229 bp) and the mutant A2AAR (570 bp) are 
indicated. Gillian R Milne, 2008    Chapter 3, 100 
WT+PBS
WT+LPS
+PBS
-/-
AR
2A
A
+LPS
-/-
AR
2A
A
0
1000
2000
3000
4000
5000
6000
p<0.001
p<0.001
[
I
L
-
6
]
 
(
p
g
/
m
l
)
WT+PBS
WT+LPS
+PBS
-/-
AR
2A
A
+LPS
-/-
AR
2A
A
0
5
10
15
20
25
30
35
40
45
50
55
p<0.001
[
I
L
-
1
]
 
(
p
g
/
m
l
)
WT+PBS
WT+LPS
+PBS
-/-
AR
2A
A
+LPS
-/-
AR
2A
A
0
20
40
60
80
100
120
140
p<0.001
p<0.001
p<0.05
[
G
M
-
C
S
F
]
 
(
p
g
/
m
l
)
WT+PBS
WT+LPS
+PBS
-/-
AR
2A
A
+LPS
-/-
AR
2A
A
0
50
100
150
200
250
300
350
400
450
p<0.01
p<0.001
p<0.001
[
T
N
F
-
a
]
 
(
p
g
/
m
l
)
Figure  3.2  Serum  levels  of  proinflammatory  cytokines  are  enhanced  in 
A2AAR-deficient mice treated with LPS 
Wild-type (WT) and A2AAR
-/- mice were subjected to intraperitoneal injection of 200 mg 
LPS or PBS vehicle.  Animals were euthanised after 4 hours and blood was collected for 
preparation of serum samples. Levels of specific proinflammatory cytokines in serum 
were measured using a BioSource four-plex fluorescent immunoassay kit and detected 
using a Luminex instrument as described in Section 2.2.1.4.  Values were obtained for 
40 mice and are represented in the graphs as the mean ± S.E. Gillian R Milne, 2008    Chapter 3, 101 
treated  controls  which  confirmed  the  effectiveness  of  the  LPS  administration.    This 
response was potentiated in A2AAR-deficient mice which also displayed a large increase in 
IL-1  following  LPS  treatment  which  was  not  seen  in  wild-type  mice.    There  were  no 
significant  differences  in  cytokine  levels  between  wild-type  and  A2AAR-deficient  mice 
treated with PBS.  Thus, LPS-induced pro-inflammatory cytokine production is greatly 
enhanced in the absence of the A2AAR. 
In vitro studies have shown that one mechanism by which the A2AAR may exert its anti-
inflammatory  effects  is  through  suppression  of  pro-inflammatory  signalling  pathway 
activation.    For  example,  increasing  expression  of  the  A2AAR  in  C6  glioma  cells  and 
HUVECs has been shown to reduce NFkB binding to target DNA in response to LPS and 
TNFa  via  cell  type-specific  mechanisms  (Sands  et  al.,  2004).    In  C6  cells,  this  was 
associated with almost complete inhibition of IkBa phosphorylation and degradation while 
in HUVECs, IkBa degradation was unaffected but NFkB translocation to the nucleus is 
severely impaired.  A role for the A2AAR in regulating NFkB has also been demonstrated 
using A2AAR
-/- mice (Lukashev et al., 2004).  Following injection with CpG DNA, NFkB 
DNA-binding activity was found to be enhanced in macrophages derived from A2AAR
-/- 
compared to those from wild-type mice.  This appeared to be due to a greater availability 
of active NFkB as levels of IkB phosphorylation and degradation were also increased. 
To see whether the absence of a functional A2AAR potentiates NFkB signalling in the 
aorta, protein samples were analysed by SDS-PAGE and immunoblotting using phospho-
specific and total IkBa antibodies (figure 3.3).  In its inactive state, NFkB is found in the 
cytoplasm in complex with an inhibitory protein such as IkBa.  In response to stimuli such 
as  LPS,  IkBa  is  phosphorylated  by  IKK  on  Ser32  and  Ser36  which  marks  it  for 
ubiquitination and degradation by the proteasome.  Active NFkB is thereby released from 
the inhibitory complex and translocates to the nucleus to modulate transcription (Mercurio 
and Manning, 1999).  Because phosphorylation of IkB and its subsequent degradation are 
critical  regulatory  steps  in  the  NFkB  pathway  (Karin  and  Ben-Neriah,  2000), 
phosphorylated and total levels of IkB can be used to measure NFkB activation.  Low 
levels of phosphorylated IkBa were detected in both LPS and PBS treated wild-type mice 
while samples from A2AAR
-/- mice had greatly elevated levels of IkBa regardless of LPS 
treatment.  Intriguingly, although phosphorylation of IkBa usually leads to its degradation, 
total levels of IkBa remained constant between different groups of mice. Gillian R Milne, 2008    Chapter 3, 102 
Figure 3.3 Ik k k kBa a a a phosphorylation is increased in A2AAR
-/- mice 
A. Wild-type (WT) and A2AAR
-/- mice were subjected to intraperitoneal injection of 200 
mg LPS or PBS vehicle and then euthanised 4 hours later.  Protein extracts were prepared 
from aortic tissue and normalised for protein content before fractionation by SDS-PAGE 
on  10  %  (w/v)  polyacrylamide  gels.    Proteins  were  transferred  to  nitrocellulose  for 
immunoblotting  using  phospho-specific  IkBa  (pIkBa)  and  total  IkBa  antibodies.    B. 
Immunoreactive bands were quantitated by densitometry.  Levels of phosphorylated and 
total IkBa are shown on the graph as a mean percentage of the maximal response ± S.E. 
(n=12). 
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Figure 3.3 Ik k k kBa a a a phosphorylation is increased in A2AAR
-/- mice 
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In addition to activation status, the relative abundance of NFkB subunits could potentially 
have  an  effect  on  NFkB  signalling.    NFkB  constitutes  a  family  of  structurally  related 
proteins which form homo- or heterodimers.  The p50/p65 dimer is the predominant form 
found in endothelial cells (Read et al., 1994) and is of particular interest due to its role in 
regulating expression of VCAM-1 (Shu et al., 1993) and E-selectin (Read et al., 1994) 
which are involved in key steps of leukocyte recruitment during inflammatory responses in 
the  vasculature  (Muller,  2002).    Levels  of  p65  in  aortic  extracts  were  measured  by 
immunoblotting.    However,  no  significant  changes  were  observed  in  p65  levels  in  the 
aortae of wild-type or A2AAR
-/- mice in response to LPS treatment (figure 3.4). 
A2AAR
-/- mice displayed dramatically increased levels of phosphorylated IkBa compared 
wild-type mice even in the absence of LPS stimulation.  However, this did not appear to 
translate into increased degradation of IkBa.  To determine whether the increases in IkBa 
phosphorylation had an effect on downstream targets of NFkB, immunoblots were probed 
for VCAM-1 and ICAM-1, the expression of which is dependent upon NFkB (Schu et al., 
1993; Roebuck and Finnegan, 1999).  VCAM-1 was barely detectable in samples from 
PBS  treated  wild-type  or  A2AAR
-/-  mice  but  was  strongly  induced  in  response  to  LPS 
treatment  (figure  3.5).    There  was  no  notable  difference  in  the  LPS-induced  response 
between wild-type and A2AAR
-/- mice.  Similarly, low levels of ICAM-1 were detected in 
PBS treated wild-type and A2AAR
-/- mice while it was strongly upregulated to a similar 
extent in both wild-type and A2AAR
-/- mice treated with LPS (figure 3.6). 
In addition to its effects on activation of the NFkB pathway, the A2AAR has also been 
found  to  influence  pro-inflammatory  signalling  through  suppression  of  the  JAK/STAT 
pathway.    In  studies  using  HUVECs,  stimulation  of  endogenous  A2AARs  resulted  in 
reduced STAT3 phosphorylation in response to IL-6 treatment which was associated with 
induction of SOCS3 (Sands et al., 2006).  In addition, increasing expression of the A2AAR 
has been shown to inhibit IL-6 and IFNg-induced JAK/STAT signalling via ubiquitination 
and proteasomal degradation of STAT proteins (Safhi et al., submitted for publication).  To 
determine  whether  inhibition  of  JAK/STAT  signalling  by  the  A2AAR  is  a  significant 
mechanism in vivo, aortae dissected from wild-type and A2AAR
-/- mice were used to make 
protein samples which were then analysed for the presence of active JAK-phosphorylated 
STAT proteins using SDS-PAGE and immunoblotting.  Levels of phosphorylated STATs 
were measured as STAT phosphorylation by JAKs represents the key hormone-regulated 
step in activation of the JAK/STAT pathway and because tyrosine phosphorylation of  Gillian R Milne, 2008    Chapter 3, 105 
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Figure 3.4 Total levels of the NFk k k kB subunit p65 remain unchanged in A2AAR
-/- 
mice subjected to LPS-induced septic shock 
A. Wild-type (WT) and A2AAR
-/- mice were subjected to intraperitoneal injection of 200 mg 
LPS or PBS vehicle and then euthanised 4 hours later. Protein extracts were prepared from 
aortic tissue and normalised for protein content before fractionation by SDS-PAGE on 10 
%  (w/v)  polyacrylamide  gels.    Proteins  were  transferred  to  nitrocellulose  for 
immunoblotting using an antibody directed against p65.  B. Immunoreactive bands were 
quantitated by densitometry.  Values are represented on the graph as a mean percentage of 
the maximal response ± S.E. (n=12). 
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Figure 3.5 Induction of VCAM-1 is unaffected by A2AAR gene deletion 
A. Wild-type (WT) and A2AAR
-/- mice were subjected to intraperitoneal injection of 200 mg 
LPS or PBS vehicle and then euthanised 4 hours later. Protein extracts were prepared from 
aortic tissue and bnormalised for protein content before fractionation by SDS-PAGE on 10 
%  (w/v)  polyacrylamide  gels.    Proteins  were  transferred  to  nitrocellulose  for 
immunoblotting using an antibody directed against VCAM-1.  B. Immunoreactive bands 
were  quantitated  by  densitometry.    Values  are  represented  on  the  graph  as  a  mean 
percentage of the maximal response ± S.E. (n=12). Gillian R Milne, 2008    Chapter 3, 107 
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Figure 3.6 Induction of ICAM-1 is unaffected by A2AAR gene deletion 
A. Wild-type (WT) and A2AAR
-/- mice were subjected to intraperitoneal injection of 200 
mg LPS or PBS vehicle and then euthanised 4 hours later. Protein extracts were prepared 
from aortic tissue and normalised for protein content before fractionation by SDS-PAGE 
on  10  %  (w/v)  polyacrylamide  gels.    Proteins  were  transferred  to  nitrocellulose  for 
immunoblotting using an antibody directed against ICAM-1.  B. Immunoreactive bands 
were  quantitated  by  densitometry.    Values  are  represented  on  the  graph  as  a  mean 
percentage of the maximal response ± S.E. (n=12). Gillian R Milne, 2008    Chapter 3, 108 
STATs  is  required  for  STAT  dimerisation  and  translocation  to  the  nucleus  to  allow 
transcriptional activity (Shuai et al., 1993, Kaptein et al., 1996). 
Tyr
701-phosphorylated STAT1 was barely detectable in PBS-treated wild-type or A2AAR
-/- 
mice  but  was  increased  in  LPS-treated  mice  indicating  activation  of  the  JAK/STAT 
pathway  (figure  3.7  A,  top  panel).    Interestingly,  the  observed  increase  in  STAT1 
phosphorylation was significantly greater in A2AAR
-/- mice compared to wild-type mice 
(p<0.001; figure 3.7 B).  This was not due to changes in the abundance of STAT1 protein 
in A2AAR
-/- samples as total STAT1 levels did not vary significantly between groups of 
mice. 
Levels of Tyr
705-phosphorylated STAT3 were also very low in PBS-treated mice but were 
elevated in mice injected with LPS (figure 3.8 A, top panel).  While the increase in STAT3 
phosphorylation did appear to be greater in A2AAR
-/- mice, the difference was not judged to 
be  statistically  significant  (p>0.05;  figure  3.8  B).    Total  levels  of  STAT3  remained 
unchanged between wild-type and A2AAR
-/- samples. 
Since A2AAR
-/- mice had increased levels of phosphorylated STAT1 compared to wild-type 
mice when treated with LPS, it was possible that these mice would express elevated levels 
of STAT1-dependent gene products such as transporter of antigenic peptides 1 (TAP-1).  
TAP-1 is part of the TAP complex which transports antigenic peptides generated by the 
proteasome into the endoplasmic reticulum and facilitates their loading on to class I MHC 
molecules (Owen and Pease, 1999; Neefjes et al., 1993).  TAP-1 expression is induced in 
response to LPS (Marqués et al., 2004) and pro-inflammatory cytokines such as interferons 
and  TNFa  (Epperson  et  al.,  1992)  and  has  been  shown  to  be  dependent  on  STAT1 
activation in several cell types including endothelial cells (Mahboubi and Pober, 2002; 
Cramer  et  al.,  2000;  Min  et  al.,  1996).  To  determine  whether  increased  STAT1 
phosphorylation in A2AAR
-/- mice had effect on TAP-1 expression, aortic protein samples 
were subjected to SDS-PAGE and immunoblotting using an anti-TAP-1 antibody.  TAP-1 
was detected in PBS-treated wild-type and A2AAR
-/- mice representing basal expression.  
However, no significant increases were observed in response to LPS treatment (figure 3.9). Gillian R Milne, 2008    Chapter 3, 109 
Figure  3.7  Effect  of  LPS  treatment  on  STAT1  activation  in  the  aortae  of 
A2AAR-deficient mice 
A. Wild-type (WT) and A2AAR
-/- mice were subjected to intraperitoneal injection of 200 
mg LPS or PBS vehicle and then euthanised 4 hours later.  Protein extracts were prepared 
from aortic tissue and normalised for protein content before fractionation by SDS-PAGE 
on  10  %  (w/v)  polyacrylamide  gels.    Proteins  were  transferred  to  nitrocellulose  for 
immunoblotting  using  antibodies  specific  for  phosphorylated  STAT1  (pSTAT1),  total 
STAT1  and  GAPDH  as  indicated.    B.  Immunoreactive  bands  were  quantitated  by 
densitometry.  Levels of phosphorylated and total STAT1 were normalised to GAPDH to 
account for variations in protein loading and are shown on the graph as a mean percentage 
of the maximal response ± S.E. (n=12). Gillian R Milne, 2008    Chapter 3, 110 
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Figure  3.7  Effect  of  LPS  treatment  on  STAT1  activation  in  the  aortae  of 
A2AAR-deficient mice Gillian R Milne, 2008    Chapter 3, 111 
Figure  3.8  Effect  of  LPS  treatment  on  STAT3  activation  in  the  aortae  of 
A2AAR-deficient mice 
A. Wild-type (WT) and A2AAR
-/- mice were subjected to intraperitoneal injection of 200 
mg LPS or PBS vehicle and then euthanised 4 hours later.  Protein extracts were prepared 
from aortic tissue and normalised for protein content before fractionation by SDS-PAGE 
on  10  %  (w/v)  polyacrylamide  gels.    Proteins  were  transferred  to  nitrocellulose  for 
immunoblotting  using  antibodies  specific  for  phosphorylated  STAT3  (pSTAT3),  total 
STAT3  and  GAPDH  as  indicated.    B.  Immunoreactive  bands  were  quantitated  by 
densitometry.  Levels of phosphorylated and total STAT3 were normalised to GAPDH to 
account for variations in protein loading and are shown on the graph as a mean percentage 
of the maximal response ± S.E. (n=12). Gillian R Milne, 2008    Chapter 3, 112 
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Figure 3.8 Effect of LPS treatment on STAT3 activation in the aortae of 
A2AAR-deficient mice 
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Figure 3.9 Levels of the STAT1-dependent protein TAP-1 are unchanged in 
LPS-challenged A2AAR
-/- mice 
A. Wild-type (WT) and A2AAR
-/- mice were subjected to intraperitoneal injection of 200 
mg LPS or PBS vehicle and then euthanised 4 hours later.  Protein extracts were prepared 
from aortic tissue and normalised for protein content before fractionation by SDS-PAGE 
on  10  %  (w/v)  polyacrylamide  gels.    Proteins  were  transferred  to  nitrocellulose  for 
immunoblotting using an antibody directed against TAP-1 and GAPDH as indicated.  B. 
Immunoreactive  bands  were  quantitated  by  densitometry.    Levels  of  TAP-1  were 
normalised to GAPDH to account for variations in protein loading and are shown on the 
graph as a mean percentage of the maximal response ± S.E. (n=12). 
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3.3 Discussion 
It  is  important  to  understand  mechanisms  by  which  the  body  regulates  inflammatory 
responses  as  excessive  and  inappropriate  inflammation  contribute  to  the  pathology  of 
major  diseases  including  atherosclerosis  (Hansson,  2005;  Libby,  2002).    Studies  using 
A2AAR-deficient  mice  have  shown  that  signalling  through  the  A2AAR  represents  an 
endogenous  means  of  limiting  inflammatory  responses  and  tissue  damage  (Ohta  and 
Sitkovsky, 2001).  However, the mechanisms behind this effect are not well understood.  
Findings from in vitro studies indicate that the A2AAR could mediate some of its effects 
through suppression of the NFkB (Sands et al., 2004) and JAK/STAT (Sands et al., 2006) 
pro-inflammatory signalling pathways but whether this is a significant mechanism in vivo 
is not known.  The aim of this study was to investigate the molecular mechanisms behind 
the anti-inflammatory actions of the A2AAR in vivo using A2AAR-deficient mice.    This 
was achieved through examination of NFkB and JAK/STAT pathway activation in the 
aortae of A2AAR-deficient mice subjected to LPS-induced septic shock. 
Data presented here show that in mice lacking the A2AAR, LPS-induced pro-inflammatory 
cytokine production is markedly enhanced compared to wild-type mice.  Consistent with 
this observation, activation of the JAK/STAT pathway in response to LPS was potentiated 
in  the  aortae  of  these  animals  as  shown  by  elevated  levels  of  phosphorylated  STAT1. 
However, STAT1-dependent gene expression as assessed by detecting levels of TAP-1 was 
unaffected.    NFkB  signalling  was  also  altered  in  A2AAR-deficient  mice  as  shown  by 
elevated levels of IkB phosphorylation even in the absence of LPS stimulation.  However, 
total  levels  of  IkBa  and  RelA/P65  were  unaffected  as  was  expression  of  the  NFkB-
dependent gene products VCAM-1 and ICAM-1. 
Interruption of the A2AAR gene in A2AAR-deficient mice was confirmed by PCR as shown 
by the increased size of the PCR product representing the gene with the neomycin cassette 
inserted compared to the wild-type gene.  Although expression of receptor protein was not 
measured in the current study, the lack of a functional A2AAR in A2AAR-deficient mice 
created  in  the  same  way  has  been  confirmed  previously  (Ledent  et  al.,  1997).    In  the 
original  study  characterising  A2AAR-deficient  mice,  binding  of  [
3H]CGS21680  was 
detected in brain slices and membrane preparations from the striatum of wild-type mice but 
not those in which the A2AAR gene had been interrupted, demonstrating a lack of binding 
sites in A2AAR-deficient mice (Ledent et al., 1997). Gillian R Milne, 2008    Chapter 3, 115 
Although it was found in this study that the presence of a functional A2AAR was important 
for regulation of the NFkB and JAK/STAT signalling pathways, it is possible that other 
adenosine  receptor  subtypes  may  have  been  upregulated  in  A2AAR-deficient  mice  and 
masked some of the effects of the loss of the A2AAR.  For example, the A2BAR is also 
coupled to Gs and so may be able to compensate for the loss of some of the A2AAR’s 
cAMP-mediated effects.  Levels of the different receptor subtypes were not examined in 
this study.  However, in previous studies comparing mRNA expression of A1, A2B or A3 
receptors  in  the  lympoid  organs  of  A2AAR-deficient  mice  and  wild-type  mice,  no 
significant changes were observed (Lukashev et al., 2003).  This indicates that loss of the 
A2AAR  does  not  affect  expression  of  other  adenosine  receptor  subtypes  in  normal 
conditions.  However, there is evidence that adenosine receptors expression is subject to 
regulation by cytokines produced during inflammatory conditions.  For example IL-1b and 
TNFa have been found to increase expression of the A2AAR in lung epithelial A549 cells, 
(Morello et al., 2006), human monocytic THP-1 cells (Khoa et al., 2001) and in rat PC12 
cells  (Trincavelli  et  al.,  2002).    Meanwhile,  in  studies  using  human  microvascular 
endothelial cells, IL-1 and TNFa have been found to increase expression of the A2AAR 
and  the  A2BAR  while  IFNg  also  increased  expression  of  the  A2BAR  but  decreased 
expression of the A2AAR (Khoa et al., 2003).  Expression of the A2BAR is also upregulated 
in macrophages in response to IFNg treatment (Xaus et al., 1999).  These studies indicate 
that proinflammatory cytokines can alter the adenosine receptor profile of various different 
tissues,  potentially  with  different  effects  in  wild-type  and  adenosine  receptor-deficient 
mice.    This  is  likely  to  have  significance  in  the  present  study  where  levels  of  these 
cytokines were increased following LPS treatment. 
In this study, LPS-induced septic shock was used as a model of vascular inflammation.  
LPS activates toll-like receptor 4 (TLR4) on macrophages and neutrophils to induce an 
acute inflammatory response (Bosshart and Heinzelmann, 2007; Han and Ulevitch, 2005).  
Activation of pro-inflammatory signalling pathways in macrophages results in expression 
of cytokines and other inflammatory mediators including TNFa, IL-1, IL-6 and GM-CSF 
(Murphy  et  al.,  2008).    In  this  study,  administration  of  LPS  effectively  induced  an 
inflammatory response as shown by the increased levels of these cytokines detected in 
serum  from  LPS-treated  mice  compared  to  PBS-treated  mice.    In  A2AAR
-/-  mice,  the 
increase was significantly greater than in wild-type mice indicating that the A2AAR had a 
suppressive role in regulating pro-inflammatory cytokine production.  This is in agreement 
with data from previous studies which showed increased serum levels of IL-6 and TNFa in Gillian R Milne, 2008    Chapter 3, 116 
LPS-treated A2AAR
-/- mice compared to wild-type mice (Ohta and Sitkovsky, 2001).  In 
further in vivo studies, the increases in cytokine production observed in A2AAR-deficient 
mice were found to be due to positive transcriptional regulation as mRNA levels of pro-
inflammatory cytokines were increased in LPS-treated A2AAR
-/- mice compared to wild-
type mice (Lukashev et al., 2004).  This effect could be simulated by pharmacological 
inactivation  of  the  A2AAR  in  wild-type  mice  using  the  A2AAR-selective  antagonist 
ZM241385.    In  contrast,  activation  of  the  A2AAR  by  injection  of  the  A2AAR-selective 
agonist CGS21680 resulted in reduced expression of pro-inflammatory cytokine mRNA, 
providing further evidence that signalling through the A2AAR regulates inflammation in 
vivo through suppression of pro-inflammatory cytokine expression (Lukashev et al., 2004). 
To begin to investigate mechanisms potentially responsible for the increased inflammatory 
responses seen in A2AAR-deficient mice, protein samples produced from the aortae of LPS 
and PBS-treated wild-type and A2AAR-deficient mice were examined for the presence of 
components of the NFkB and JAK/STAT signalling pathways. 
In this study, activation of the NFkB pathway as determined by IkB phosphorylation was 
strikingly upregulated in both PBS and LPS-treated A2AAR
-/- mice compared to wild-type 
mice suggesting that the A2AAR plays a role in regulating activation of the pathway even 
in the absence of stimuli.  A negative regulatory effect of the A2AAR on NFkB signalling 
has been observed previously in macrophages from A2AAR
-/- mice (Lukashev et al., 2004) 
and has also been demonstrated in vitro in C6 cells where increasing expression of the 
A2AAR resulted in a severe reduction in IkB phosphorylation in response to TNFa or LPS 
(Sands  et  al.,  2004).    The  reason  for  the  lack  of  effect  of  LPS  treatment  on  IkBa 
phosphorylation in  A2AAR
-/- mice is not clear.   It could be that the  NFkB pathway is 
maximally activated even in basal conditions.  However, this cannot be concluded from 
data  presented  here  as  although  levels  of  phosphorylated  IkBa  are  clearly  elevated  in 
A2AAR mice, it is not possible to tell what percentage of total IkB levels this represents.  
This question could be addressed through the use of two-dimensional gel electrophoresis to 
fractionate  protein  samples  on  the  basis  of  charge  as  well  as  size.    This  would  allow 
separation  of  phosphorylated  IkBa  from  the  unphosphorylated  form,  thereby  allowing 
quantitation of their relative abundances. 
IKK-mediated phosphorylation of IkBa on Ser32 and Ser36 is generally thought to lead to 
its Lys48 polyubiquitination and degradation by the proteasome (Karin and Ben-Neriah, Gillian R Milne, 2008    Chapter 3, 117 
2000).  Surprisingly, despite the dramatic increases in IkBa phosphorylation observed here 
in A2AA
-/- mice, there were no differences in total levels of IkBa between different groups 
of  mice.    A  possible  explanation  for  this  is  that  in  A2AAR
-/-  mice,  negative  feedback 
mechanisms are induced or upregulated to compensate for the increased activation of the 
NFkB pathway.  IkBa is itself a target for NFkB transcriptional activity (de Martin et al., 
1993) and its resynthesis and binding to activated NFkB proteins in the nucleus is a crucial 
step  in  the  regulation  of  NFkB  signalling  (Karin  and  Ben-Neriah,  2000).    In  an  auto-
regulatory loop, newly synthesised IkBa enters the nucleus where it binds to NFkB and 
removes it from DNA, thereby terminating its transcriptional activity (Arenzana-Seisdedos 
et al., 1997).  The NFkB/IkB complex is then transported back into the cytoplasm by the 
nuclear protein CRM1 which recognises nuclear export sequences on IkB (Huang et al., 
2000; Johnson et al., 1999).  It is possible that in A2AAR
-/- mice, the efficiency of this 
pathway is upregulated and that increased degradation of phosphorylated IkB does occur 
but  is  not  detected  because  it  is  rapidly  resynthesised  resulting  in  no  net  change  in 
abundance. 
Another possible explanation for the apparent lack of IkBa degradation is that there is a 
defect in the proteasome of A2AAR
-/- mice.  Alternatively, there could be alterations in the 
activity of the enzymes which mediate ubiquitination of phosphorylated IkBa and target it 
for degradation by the proteasome.  The E3 ubiquitin ligase complex which recognises 
phosphorylated IkBa and promotes its polyubiquitination is regulated by post-translational 
modification by the ubiquitin-like protein Nedd8 (Read et al., 2000).  Neddylation of the 
cullin-1 subunit of the IkB-specific Skp1-cullin-F-Box (SCF) ubiquitin ligase is required 
for its activity while deneddylation represents a means of regulating NFkB activity by 
preventing degradation of IkB (Read et al., 2000).  This mechanism has been found to be 
activated by adenosine acting through A2BARs and to contribute to the protective effects of 
hypoxic preconditioning in mice (Khoury et al., 2007).  It is possible that in A2AAR
-/- mice, 
this protective mechanism is upregulated and neddylation of cullin-1 is reduced.  This 
would result in IkBa levels remaining constant despite increased phosphorylation.   
Other NFkB-induced feedback inhibitors which could be at work to prevent inappropriate 
activation  in  A2AAR-competent  mice  include  the  deubiquitinating  proteins  CYLD  and 
A20.  CYLD  inhibits  NFkB  by  reversing  the  K63-linked  ubiquitination  of  upstream 
signalling  molecules  such  as  TRAF2  and  TRAF6  which  is  required  for  LPS-induced 
activation of the IKK complex (Courtois, 2008).  CYLD expression has been found to be Gillian R Milne, 2008    Chapter 3, 118 
upregulated in atherosclerotic lesions and its overexpression in cultured endothelial cells 
resulted  in  inhibition  of  TNFa-induced  NFkB  activation  through  deubiquitination  of 
TRAF2 (Takami et al., 2008).  These findings suggest it could play an important role in 
suppressing  inflammation  in  the  aorta.    A20  was  originally  identified  as  regulator  of 
TNFa-induced NFkB activation with the ability to change the ubiquitination profile of RIP 
thereby targeting it for proteasomal degradation but it could also affect activation by LPS 
as it has effects on signalling from TLRs through deubiquitination of TRAF2 and IKKg 
(Heyninck and Beyaert, 2005). 
Despite the observed dysregulation of IkBa phosphorylation in A2AAR
-/- mice, no changes 
were  seen  in  the  induction  of  VCAM-1  and  ICAM-1  expression  in  response  to  LPS, 
perhaps reflecting the efficiency of feedback mechanisms induced.  However, it is also 
possible  that  increases  in  VCAM-1  and  ICAM-1  expression  were  not  detected  due  to 
increased shedding of the extracellular domains of these proteins into the circulation of 
A2AAR
-/- mice.  Increased levels of the soluble forms of VCAM-1 and ICAM-1 are found 
in  a  number  of  inflammatory  diseases  (Gearing  and  Newman,  1993).    In  this  study, 
VCAM-1 and ICAM-1 were detected in the aorta using an antibody directed against their 
N-terminal extracellular domains which would not take account of molecules which have 
shed their extracellular domains.  Total levels of VCAM-1 and ICAM-1 could be measured 
using an antibody directed against their intracellular domains or by detecting levels of shed 
molecules in serum. 
In addition to the NFkB pathway, the JAK/STAT pathway is also activated in response to 
LPS.    LPS  signalling  through  TLR4  has  not  been  reported  to  directly  activate  the 
JAK/STAT  pathway  but  rather  to  rapidly  induce  expression  of  interferons  in  order  to 
achieve optimal expression of LPS-inducible genes (Ohmori and Hamilton, 2001).  In this 
study,  STAT1  phosphorylation  in  response  to  LPS  treatment  was  elevated  in  A2AAR
-/- 
mice compared to wild-type mice.   It is tempting to suggest that this might be due to 
suppression of STAT1 phosphorylation in wild-type mice by members of the SOCS family 
as  stimulation  of  the  A2AAR  has  been  shown  to  reduce  IL-6-induced  STAT3 
phosphorylation in cultured endothelial cells through induction of SOCS3 (Sands et al., 
2006).  However, SOCS3 mediates this effect on STAT3 activation by binding to tyrosine-
phosphorylated IL-6 receptors and inhibiting the activity of associated JAKs (Sasaki et al., 
1999).  Since regulation by SOCS3 is at the level of JAK activity, it would be expected 
that  if  SOCS3  is  involved  then  both  STAT1  and  STAT3  phosphorylation  would  be 
affected in A2AAR
-/- mice.  SOCS1 also inhibits JAK activity (Yasukawa et al., 1999) and Gillian R Milne, 2008    Chapter 3, 119 
so  can  influence  phosphorylation  of  both  STAT1  and  STAT3.    Since  only  STAT1 
phosphorylation is significantly elevated in A2AAR
-/- mice, it seems unlikely that decreased 
activity of SOCS1 or SOCS3 is responsible. 
Despite  increased  STAT1  phosphorylation  in  response  to  LPS,  STAT1-regulated 
expression of TAP-1 was not altered in A2AAR
-/- mice.  However, the significance of this is 
not  clear  as  TAP-1  expression  was  not  increased  in  LPS-treated  mice.    High  basal 
expression of this protein may have masked changes occurring in response to LPS or it is 
possible  that  although  the  dose  of  LPS  used  was  sufficient  to  elicit  STAT1 
phosphorylation, it may not have activated the JAK/STAT pathway strongly enough to 
produce detectable effects downstream.  Alternatively, it may be that A2AAR-mediated 
regulation  of  STAT1-dependent  gene  expression  is  target-specific  and  examining 
expression  of  other  STAT1-regulated  genes  may  still  reveal  functional  effects  of  the 
absence of the A2AAR.  In order to investigate this possibility, attempts were made during 
this study to determine the effects of A2AAR gene deletion on expression of the inducible 
form of nitric oxide synthase (iNOS).  iNOS expression can be induced in endothelial cells 
in response to combinations of cytokines such as IFNg and TNFa (Wagner et al., 2002) or 
by IFNs and LPS (Koide et al., 2007) through activation of both STAT1 and NFkB which 
act synergistically at the iNOS promoter (Ganster et al., 2001).  However, in this study, it 
was  not  possible  to  assess  iNOS  expression  as  immunoblotting  using  an  anti-iNOS 
antibody produced multiple bands of approximately the correct size.  Attempts were made 
to obtain clearer results using a second iNOS antibody directed against a separate epitope 
and  through  use  of  different  positive  controls.    However,  it  was  still  not  possible  to 
confidently identify a single band as iNOS. 
Mice lacking the A2AAR have been shown previously to express elevated levels of pro-
inflammatory cytokines and to suffer enhanced tissue damage in response to inflammatory 
stimuli (Ohta and Sitkovsky, 2001).  The model of vascular inflammation used in this 
study revealed significant perturbations in both NFkB and JAK/STAT signalling in the 
aortae of A2AAR
-/- mice which could perhaps account for these effects.  It was of particular 
interest to study pro-inflammatory signalling pathway activation in the aorta because in a 
previous study, the NFkB pathway was found to be primed for activation in atherosclerotic 
lesion-prone  areas  of  the  aorta  in  LPS-treated  wild-type  mice  (Hajra  et  al.,  2000).    If 
A2AAR expression in the aorta can regulate NFkB activation then it may play a role in 
preventing  development  of  atherosclerosis.    However,  further  analysis  of  NFkB  and Gillian R Milne, 2008    Chapter 3, 120 
STAT-dependent  expression  of  specific  target  genes  including  VCAM-1  and  ICAM-1 
which mediate leukocyte recruitment during atherogenesis did not reveal any changes in 
protein levels in the absence of the A2AAR.  This does not however rule out a role for the 
A2AAR in regulating inflammatory events involved in atherosclerosis.  Several aspects of 
the model used in this study mean that it was not possible to fully evaluate the effects of 
the  loss  of  the  A2AAR  on  specific  events  occurring  in  the  endothelium  during 
atherogenesis.    For  example,  LPS  induces  an  acute  form  of  inflammation  while 
atherosclerosis is a chronic inflammatory condition.  Although LPS does induce expression 
of  inflammatory  mediators  and  adhesion  molecules  believed  to  be  important  in 
development  of  atherosclerosis,  the  actual  similarity  to  the  disease  is  not  known.    In 
addition, results presented here are based on samples produced from whole aortas which 
included endothelial cells but also the surrounding smooth muscle layer.  The A2AAR may 
have  specific  effects  in  the  endothelium  which  are  masked  by  responses  occurring  in 
smooth muscle cells.  Similarly, by examining the whole aorta, it was not possible to detect 
differences in inflammatory pathway activation and target protein expression specifically 
in lesion-prone areas of the aorta where regulation could be most crucial.  This problem 
could be addressed by  using immunohistochemistry to examine NFkB  and JAK/STAT 
pathway activation in particular lesion-prone areas of the intact endothelium. 
An  additional  concern  in  this  study  was  that  since  mice  were  euthanized  and  organs 
harvested  4  hours  following  LPS-treatment  it  was  only  possible  to  examine  protein 
expression in aortic tissue samples at a single time point.  The NFkB and JAK/STAT 
pathways  are  subject  to  regulation  at  many  stages  through  feedback  mechanisms  and 
through interaction with other signalling pathways.  It is likely that many changes occurred 
before the 4 hour time point or may have occurred later if the study had been continued for 
longer.  However, in order to produce samples at different time points, it would have been 
necessary  to  use  much  larger  numbers  of  mice  which  would  have  been  prohibitively 
expensive. 
Regardless of the limitations mentioned above, data presented here clearly mark out a role 
for  the  A2AAR  in  modulating  pro-inflammatory  signalling  through  the  NFkB  and 
JAK/STAT pathways in the aorta.  This not only adds to the collective evidence for a 
physiological role for the A2AAR for limiting inflammation in vivo but more importantly 
provides new evidence regarding the mechanisms behind this effect.  Future studies in 
vitro should be aimed at further analysis of the role of the A2AAR in regulating NFkB and Gillian R Milne, 2008    Chapter 3, 121 
JAK/STAT  signalling  and  will  hopefully  allow  identification  of  specific  mechanisms 
involved.  122 
4  Regulation  of  the  A2A  adenosine  receptor  by 
phosphorylation 
4.1 Introduction 
The anti-inflammatory and tissue protective effects of signalling through the A2AAR are 
well documented (Palmer and Trevethick, 2008; Sitkovsky et al., 2004; Sitkovsky, 2003).  
Elucidation of the mechanisms behind the beneficial effects of the A2AAR is a current topic 
of investigation and progress is being made in identifying means by which the A2AAR may 
modulate pro-inflammatory signalling pathways as exemplified by findings described in 
chapter 3.  In contrast, a subject that has not received much attention is how the A2AAR is 
regulated at a molecular level.  This is of particular interest since it has become apparent 
that  in  addition  to  heterotrimeric  G  proteins  and  proteins  involved  in  desensitisation, 
numerous  other  proteins  can  interact  with  the  intracellular  portions  of  GPCRs.    These 
proteins have the potential to regulate the activity of GPCRs either by directly activating 
alternative signalling pathways or by acting as adaptors or scaffolds to recruit proteins with 
the potential to modulate G protein-dependent signalling or initiate G protein-independent 
signalling events (Kristiansen, 2004; Hall and Lefkowitz, 2002; Heuss and Gerber, 2000). 
The A2AAR has an unusually long C-terminal tail in comparison to many other GPCRs and 
particularly in contrast to other adenosine receptors (122 amino acids in man compared to 
only 34 in the C-terminal tail of the A1AR; Zezula and Freissmuth, 2008).  The presence of 
numerous serine and threonine residues in this region suggests potential for regulation of 
the  A2AAR  by  phosphorylation.    Indeed,  agonist-induced  desensitisation  of  the  canine 
A2AAR  is  associated  with  rapid  phosphorylation  of  the  receptor  (Palmer  et  al.,  1994).  
Furthermore, studies using the canine A2AAR expressed in C6 glioma cells have shown 
that stimulation of protein kinase C (PKC) by phorbol 12-myristate 13-acetate (PMA) or 
endothelin-1 (ET-1) which activates PKC through endogenous ETA receptors results in 
dramatically increased phosphorylation of the A2AAR over basal levels (Palmer and Stiles, 
1999).  Through the use of inhibitors, the involvement of PKC in mediating this effect has 
been confirmed and the PKCd isoform in particular identified as being partly responsible. 
The  role  of  the  extended  C-terminal  tail  of  the  A2AAR  and  the  significance  of 
phosphorylation  events  in  this  region  has  not  been  determined.    In  fact,  it  has  been 
demonstrated that deletion of 95 amino acids from the C-terminus of the canine A2AAR Gillian R Milne, 2008    Chapter 4, 123 
which removes ten of the twelve potential phosphorylation sites has no effect on agonist-
induced  phosphorylation  or  desensitisation  of  the  receptor  (Palmer  and  Stiles,  1997).  
Similarly, using truncated forms of the human A2AAR it has been shown that the last 95 
amino  acids  of  the  C-terminal  tail  are  not  required  for  agonist-stimulated  G  protein-
coupling and stimulation of adenylyl cyclase (Palmer and Stiles, 1997).  In addition, it has 
been found that the agonist-binding properties of a mutant canine A2AAR lacking the last 
102 residues are comparable to those of the wild-type receptor (Piersen et al., 1994).  Since 
truncation of the A2AAR appears to have no effect on the classical signalling or regulatory 
mechanisms associated with GPCRs, other potential roles for the C-terminal tail must be 
considered.  A number of proteins have been reported to interact with this region of the 
A2AAR indicating that it may act as a scaffold for recruitment of proteins involved in G 
protein-independent signalling pathways (Zezula and Freissmuth, 2008).  This theory is 
supported by the finding that G-protein independent activation of ERK by the A2AAR is 
dependent on an interaction between the C-terminal tail of the A2AAR and ARF nucleotide 
site  opener  (ARNO)  which  is  a  guanine  nucleotide  exchange  factor  for  the  ADP-
ribosylation factor (ARF) family of monomeric G proteins (Gsandtner et al., 2005).  The 
cytoskeletal protein a-actinin has also been identified as a C-terminal binding partner of 
the  A2AAR.    This  interaction  has  been  found  to  be  important  for  agonist-mediated 
clustering and internalisation of the receptor (Burgueño et al., 2003).  However, a-actinin 
can also interact with components of the ERK cascade, suggesting an additional role as a 
scaffold  protein  involved  in  organisation  of  ERK  signalling  (Christerson  et  al.,  1999; 
Leinweber et al., 1999).  Translin-associated protein X (TRAX) is another protein which 
binds to the C-terminus of the A2AAR with effects on A2AAR-mediated signalling that 
appear to be both Gs and ERK-independent (Sun et al., 2006).  TRAX has been shown to 
be involved in the ability of the A2AAR to suppress proliferation of PC12 cells and restore 
nerve  growth  factor  (NGF)-induced  neuronal  differentiation  that  is  impaired  by  p53 
inactivation.  However, the mechanism by which this occurs is unclear (Sun et al., 2006).  
Yet another recently identified interaction partner of the A2AAR is the deubiquitinating 
enzyme ubiquitin-specific protease 4 (USP4).  Binding of USP4 to the C-terminus of the 
A2AAR results in deubiquitination of the receptor which is required for its export from the 
ER during synthesis (Milojević et al., 2006).  Ubiquitination status is, however, also an 
important determinant of the fate of endocytosed GPCRs (Wojcikiewicz, 2004) and so it is 
possible  that  binding  of  USP4  could  have  effects  on  the  rate  of  receptor  recycling 
following desensitisation. Gillian R Milne, 2008    Chapter 4, 124 
The list of proteins reported to interact with the C-terminal tail of the A2AAR is growing 
rapidly.    Despite  the  exaggerated  length  of  this  region  compared  to  other  adenosine 
receptors,  it  is  unlikely  that  it  is  long  enough  to  accommodate  binding  of  numerous 
interaction partners simultaneously.  Moreover, ARNO (Gsandtner et al., 2005) and a-
actinin (Burgueño et al., 2003) have been reported to bind in the same juxtamembrane 
portion of the receptor tail.  This highlights the need for regulation of binding events and 
indeed  it  has  been  suggested  that  phosphorylation  of  thr  298  which  is  present  in  the 
binding  sites  of  both  ARNO  and  a-actinin  may  be  important  for  determining  which 
interactions occur (Zezula and Freissmuth, 2006).  As mentioned above, there are twelve 
potential phosphorylation sites present within the C-terminal tail of the receptor and so it 
seems highly likely that phosphorylation events could have consequences for binding of 
particular  accessory  proteins.    This  could  provide  a  mechanism  by  which  different 
pathways can interact with the A2AAR to regulate its activity. 
The aim of the present study was to identify stimuli that induce increased phosphorylation 
of  the  human  A2AAR  and  to  determine  how  this  affects  recruitment  of  C-terminal-
interacting molecules involved in regulating A2AAR activity and downstream signalling 
events.  Information currently available in this area is derived from work using the canine 
A2AAR expressed in C6 glioma, CHO and COS cells (Palmer and Stiles, 1999).  Although 
A2AARs  have  fairly  high  species  homology  (92%  between  human  and  canine),  most 
differences occur within the C-terminal tail.  For this reason, findings from studies using 
canine receptors may not reflect mechanisms that regulate human A2AARs.  In addition, 
since C6, CHO and COS cells do not express A2AARs, they may not have the regulatory 
mechanisms in place that would be found in cells expressing endogenous receptors.  In 
order to properly understand how the human A2AAR is regulated, it is necessary to study 
human  receptors  in  human  cells  that  express  endogenous  receptors.    Therefore,  in  the 
following  experiments  receptor  phosphorylation  has  been  studied  using  a  myc-tagged 
human A2AAR expressed in human umbilical vein endothelial cells (HUVECs). Gillian R Milne, 2008    Chapter 4, 125 
4.2 Results 
The myc-tagged human A2AAR was introduced to HUVECs via adenoviral mediated gene 
transfer using an moi of 30 ifu/cell.  Successful expression of the A2AAR was confirmed by 
detection  of  the  myc  tag  of  the  receptor  by  immunoblotting  using  the  9E10  antibody 
(figure 4.1, lower panel).  Immunoblotting produced two bands at approximately 50 and 40 
kDa in samples from adA2AAR-infected cells as has been observed previously using the 
9E10 antibody to detect the myc-tagged A2AAR expressed in HUVECs using adenovirus 
(Sands et al., 2004).  A third band was detected below the 37 kDa marker in both adA2AAR 
and adGFP-infected cells and so was determined to be non-specific.   The 50 kDa band 
corresponds to the size of the native A2AAR which has been detected as a 45-46 kDa band 
using photoaffinity labelling of the A2AAR in human striatal membranes (Ji et al., 1992) 
and cardiac tissues (Marala et al., 1998).  This is likely to represent the fully glycosylated, 
full-length form of the receptor.  This has been investigated by immunoprecipitating the 
A2AAR from cells treated with biotin hydrazide to label cell-surface carbohydrate groups 
(T.M.  Palmer,  unpublished  observation).    Blotting  with  HRP-streptavidin  produced  a 
single band at approximately 50 kDa representing the glycosylated receptor.  The 40 kDa 
band  is  likely  to  represent  a  partially  processed  form  of  the  A2AAR  rather  than  a 
degradation product as degradation of the A2AAR typically involves loss of the C-terminal 
tail (Nanoff et al., 1990).  The myc tag is at the C-terminus of the receptor and thus the tail 
must be intact to be recognised by 9E10.  Furthermore, the 40 kDa band is consistent with 
the predicted molecular weight of the deglycosylated receptor and is of a similar size to the 
38  kDa  bovine  striatal  A2AAR  detected  by  photoaffinity  labelling  following 
deglycosylation (Barrington et al., 1990). 
Expression  of  the  myc-tagged  A2AAR  was  specific  to  adA2AAR-infected  cells  as 
recombinant  receptor  was  not  detected  in  adGFP-infected  cells.    Stimulation  of  the 
receptor  using  the  selective  agonist  CGS21680  produced  a  time-dependent  increase  in 
ERK phosphorylation indicating that the receptor was functional (figure 4.1, upper panel).  
ERK  phosphorylation  in  response  to  CGS216080  was  also  detected  in  adGFP-infected 
cells  but  not  to  the  extent  seen  in  adA2AAR-infected  cells  indicating  activation  of 
endogenous receptors.  Saturation binding analysis using 
3H-ZM241385 revealed that in 
adA2AAR-infected cells, the myc-tagged A2AAR had a Kd value of 1.4 ± 0.4 nM and was 
expressed at a level of 80 ± 7 pmol/mg protein (figure 4.2).  Despite detection of functional 
endogenous receptors via CGS21680 stimulation of ERK phosphorylation, no 
3H- Gillian R Milne, 2008    Chapter 4, 126 
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Figure 4.1 Adenovirus-mediated expression of the human A2AAR in HUVECs 
HUVECs  were  infected  with  A2AAR-expressing  adenovirus  (A)  or  control  adenovirus 
expressing GFP alone (G).  Cells were incubated with 10 mM CGS21680 for the times 
indicated before preparation of protein extracts.  Extracts were normalised for protein 
content prior to fractionation by SDS-PAGE on 10 % (w/v) polyacrylamide gels.  Proteins 
were  transferred  to  nitrocellulose  for  immunoblotting  using  a  phospho-specific  ERK 
antibody (pERK) and the 9E10 antibody which recognises the myc tag of the A2AAR.  
This is an example of two such experiments.  The asterisk denotes a non-specific band. Gillian R Milne, 2008    Chapter 4, 127 
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Figure 4.2 Saturation analysis of 
3H-ZM241385 binding to the myc-tagged 
human A2AAR 
HUVECs  were  infected  with  A2AAR-expressing  adenovirus  before  preparation  of 
membrane extracts for use in saturation binding assays using a range of concentrations of 
the radiolabelled A2AAR antagonist 
3H-ZM241385.  This is a representative example of 
three such experiments. 
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ZM241385  binding  was  observed  in  adGFP-infected  cells.    However,  this  lack  of 
detectable binding has been found in previous studies in HUVECs (Sands et al., 2004) and 
T-cells (Armstrong et al., 2001) using 
3I-ZM241385. 
To allow analysis of receptor phosphorylation in whole cells, it was necessary to be able to 
isolate the A2AAR from other proteins present in whole cell extracts.  This was achieved by 
immunoprecipitation using the 9E10 antibody which recognises the myc tag of the A2AAR.  
Immunoblotting  using  an  A2AAR-specific  antibody  revealed  that  the  A2AAR  was 
successfully  immunoprecipitated  from  adA2AAR-infected  cells  but  not  from  control 
adGFP-infected  cells  and  only  in  the  presence  of  the  9E10  antibody  showing  that  the 
procedure was specific for the myc-tagged A2AAR (figure 4.3).  In addition, recovery of 
the  receptor  was  good  as  immunoprecipitated  receptors  were  detected  at  levels 
proportionally comparable to total input levels of the A2AAR in whole cell lysates. 
For  initial  analysis  of  receptor  phosphorylation,  HUVECs  infected  with  adA2AAR  or 
adGFP were subjected to an intact cell phosphorylation assay in the presence or absence of 
1mM PMA which has been shown to induce phosphorylation of the canine A2AAR in C6 
cells (Palmer and Stiles, 1999).  The phosphorylated A2AAR was detected as two bands at 
approximately 45-50 kDa and 40 kDa corresponding to the bands detected in immunoblots.  
A third band above 50 kDa was also detected in some cases but appears to be non-specific 
as it is present in lanes when the other bands are not detected and is also faintly detectable 
in cells that have not been infected with adA2AAR. 
Stimulation with PMA resulted in an increase in receptor phosphorylation over basal levels 
in  adA2AAR-infected  cells  but  not  adGFP-infected  cells  showing  that  it  was  the 
phosphorylated  A2AAR  that  was  being  detected  specifically  (figure  4.4  A).    PMA 
activation of novel and conventional isoforms of PKC results in Raf- mediated activation 
of  the  ERK  pathway  (Schönwasser  et  al.,  1998)  in  manner  that  can  be  either  Ras-
dependent (Chiloeches et al., 1999) or -independent (Ueda et al., 1996).  Induction of ERK 
phosphorylation  by  PMA  was  therefore  a  useful  measure  to  confirm  PMA  activity  as 
shown in figure 4.4 B (upper panel).  The presence of the A2AAR in adA2AAR-infected 
cells but not adGFP-infected cells was confirmed by immunoblotting (figure 4.4B, lower 
panel). 
To begin to characterise phosphorylation of the A2AAR, HUVECs infected with adA2AAR 
were subjected to an intact cell phosphorylation assay in the presence of 10 mM  Gillian R Milne, 2008    Chapter 4, 129 
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Figure 4.3 Immunoprecipitation of the A2AAR 
HUVECs were infected with adenovirus expressing the myc-tagged A2AAR (adA2AAR) or 
GFP alone (adGFP).  Cell extracts were prepared and equalised for protein content before 
subjection to an immunoprecipitation protocol in the presence or absence of the anti-myc 
9E10 antibody as indicated.  Immunoprecipitated receptors and total levels of receptors in 
cell lysates (Input) were detected using SDS-PAGE followed by immunoblotting using an 
A2AAR-specific antibody. Gillian R Milne, 2008    Chapter 4, 130 
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Figure 4.4 Specific immunoprecipitation and phosphorylation of the A2AAR 
HUVECs infected with adenovirus expressing the myc-tagged A2AAR (adA2AAR) or GFP 
alone  (adGFP)  were  labelled  with 
32P  orthophosphate  for  90  minutes.    Cells  were 
incubated in the presence or absence of 1 mM PMA for 30 minutes before preparation of 
protein  extracts.    Extracts  were  equalised  for  protein  content  and  used  to 
immunoprecipitate the A2AAR using the anti-myc 9E10 antibody.  A. The 
32P-labelled 
A2AAR  was  detected  by  autoradiography  following  SDS-PAGE.    B.  Levels  of 
phosphorylated ERK (pERK) and total A2AAR expression were detected by SDS-PAGE 
and immunoblotting of protein samples prepared from experiments carried out in parallel 
using unlabelled cells.  The 9E10 antibody was used to detect the A2AAR.  Shown are 
examples of results from two replicated experiments. Gillian R Milne, 2008    Chapter 4, 131 
CGS21680, 1 mM PMA, 50 mM forskolin, 10 ng/ml TNFa, 1mg/ml LPS or 5 ng/ml IL-6.  
CGS21680 was included as GPCRs in general are phosphorylated in response to agonist 
stimulation as discussed in Section 1.5.4.1.  In addition, CGS21680 has previously been 
shown to induce phosphorylation of the canine A2AAR expressed in CHO cells (Palmer et 
al., 1994).  Forskolin stimulates AC resulting in elevation of cAMP, thereby mimicking 
one of the effects of A2AAR stimulation and so may have had the potential to activate 
feedback  mechanisms  to  induce  receptor  phosphorylation.    The  A2AAR  has  also  been 
reported to regulate activation of the NFkB pathway by TNFa and LPS (Sands et al., 
2004) and the JAK/STAT pathway by IL-6 (Sands et al., 2006; Sahfi et al., submitted for 
publication).  It was therefore of interest to include these stimuli as an effect on receptor 
phosphorylation could indicate a means of reciprocal regulation by these pathways.  As 
shown  in  figure  4.5,  only  PMA  had  a  significant  effect  on  A2AAR  phosphorylation, 
inducing a 2.5 to 5-fold increase over basal levels (p < 0.001, n = 3).  All stimuli were 
active  as  shown  by  their  ability  to  induce  ERK  phosphorylation  (figure  4.5  C,  upper 
panel).  Moreover, differences in phosphorylation levels were not due to alterations in 
receptor expression as levels of the A2AAR detected by immunoblotting were not affected 
by any of the chosen stimuli (figure 4.5 C, lower panel).  Thus, the A2AAR is strongly 
phosphorylated in response to PMA treatment but not following stimulation with agonist or 
any other stimuli tested. 
The  time-dependence  of  PMA-induced  A2AAR  phosphorylation  was  assessed  by 
performing an intact cell phosphorylation assay with adA2AAR-infected HUVECs treated 
with 1mM PMA for different times.  As shown in figure 4.6, phosphorylation was rapid, 
being detectable at the first time point tested (15 seconds).  It reached a maximum at 10 
minutes and was sustained at high levels for at least 30 minutes.  These results closely 
match the values obtained in previous studies using the canine A2AAR (Palmer and Stiles, 
1999).  However, in contrast to the canine receptor, phosphorylation of the human A2AAR 
appeared to occur in two stages, reaching a first peak at 1 minute and levelling off slightly 
until the 5 minute time point before rising to a maximum after 10 minutes.  The response 
was concentration-dependent reaching a maximum of (3.6 ± 0.4)-fold above basal at 10 
nM (figure 4.7 B) which is lower than the value previously observed for the canine A2AAR 
((11.2 ± 2.5)-fold above basal levels at 1 mM PMA; Palmer and Stiles, 1999).  Curve-
fitting of data pooled from three experiments produced an EC50 value for PMA of 1.7 nM 
(figure 4.7 B) which is consistent with published values for the affinity of phorbol esters 
for PKC (Dimitrijević et al., 1995). Gillian R Milne, 2008    Chapter 4, 132 
Figure 4.5 The human A2AAR is phosphorylated in response to PMA 
HUVECs  infected  with  adenovirus  expressing  the  A2AAR  were  labelled  with 
32P 
orthophosphate for 90 minutes prior to stimulation with 10 mM CGS21680 (CGS), 1 mM 
PMA, 50 mM forskolin (Fsk), 10 ng TNFa, 1 mg LPS or 5 ng IL-6/25 ng IL-6 sRa (IL-6) 
for  30  minutes.    Cell  extracts  were  prepared  and  equalised  for  protein  content  before 
immunoprecipitation  of  the  A2AAR.    A.  The 
32P-labelled  A2AAR  was  detected  by 
autoradiography following SDS-PAGE.  B.  Bands were quantitated by densitometry and 
values expressed as a mean fold increase ± SE as shown in the graph.  C.  Levels of 
phosphorylated  ERK  and  total  A2AAR  expression  were  detected  by  SDS-PAGE  and 
immunoblotting of protein samples prepared from experiments carried out in parallel using 
unlabelled cells (n = 2).  The 9E10 antibody was used to detect the A2AAR. Gillian R Milne, 2008    Chapter 4, 133 
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Figure 4.5 The human A2AAR is phosphorylated in response to PMA Gillian R Milne, 2008    Chapter 4, 134 
Figure 4.6 PMA induces rapid phosphorylation of the human A2AAR 
HUVECs  infected  with  adenovirus  expressing  the  A2AAR  were  labelled  with 
32P 
orthophosphate for 90 minutes prior to stimulation with 1 mM PMA for the times indicated. 
Cell extracts were prepared and equalised for protein content before immunoprecipitation 
of the A2AAR.  A. The 
32P-labelled A2AAR was detected by autoradiography following 
SDS-PAGE.  B.  Bands were quantitated by densitometry and values expressed as a mean 
percentage of the maximal response ± SE as shown in the graph.  C.  Identical experiments 
were carried out in parallel using unlabelled cells (n = 1).  Protein extracts were prepared 
for analysis by SDS-PAGE and immunoblotting using the 9E10 antibody to detect total 
levels of the A2AAR. Gillian R Milne, 2008    Chapter 4, 135 
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Figure 4.6 PMA induces rapid phosphorylation of the human A2AAR Gillian R Milne, 2008    Chapter 4, 136 
Figure  4.7  PMA  induces  phosphorylation  of  the  human  A2AAR  at  low 
concentrations 
HUVECs  infected  with  adenovirus  expressing  the  A2AAR  were  labelled  with 
32P 
orthophosphate  for  90  minutes  prior  to  stimulation  with  PMA  at  the  concentrations 
indicated for 20 minutes. Cell extracts were prepared and equalised for protein content 
before immunoprecipitation of the A2AAR.  A. The 
32P-labelled A2AAR was detected by 
autoradiography following SDS-PAGE.  B.  Bands were quantitated by densitometry and 
values expressed as a mean percentage of the maximal response ± SE as shown in the 
graph.    C.    Identical  experiments  were  carried  out  in  parallel  using  unlabelled  cells.  
Protein extracts were prepared for analysis by SDS-PAGE and immunoblotting using the 
9E10 antibody to detect total levels of the A2AAR (n = 1). Gillian R Milne, 2008    Chapter 4, 137 
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Figure  4.7  PMA  induces  phosphorylation  of  the  human  A2AAR  at  low 
concentrations 
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PMA is an activator of conventional and novel isoforms of PKC (Bell and Burns, 1991).  
To  determine  whether  A2AAR  phosphorylation  could  be  induced  by  stimulation  of 
endogenous receptors which activate PKC, adA2AAR-infected HUVECs were stimulated 
with histamine.  In HUVECs, histamine activates histamine H1 receptors (Li et al., 2003), 
which leads to stimulation of PLCb and activation of PKC (Hill et al., 1997).  Treatment of 
HUVECs  with  1  mM  histamine  stimulated  a  time-dependent  increase  in  A2AAR 
phosphorylation  (figure  4.8)  which  paralleled  the  agonist’s  ability  to  induce  ERK 
phosphorylation (figure 4.8 C, upper panel).  Histamine induced maximal phosphorylation 
at 2 minutes (70 ± 17 % above basal levels, p = 0.05, n = 4) but was not as effective as 
parallel PMA treatment which induced a 245 ± 38 % increase in stimulation (p < 0.01, n = 
4; figure 4.5).  Thus, phosphorylation of the A2AAR can be induced both through treatment 
with PMA and by stimulation of endogenous histamine H1 receptors which activate PKC 
in HUVECs. 
To begin to investigate the role of PKC in PMA-induced phosphorylation of the A2AAR, 
an intact cell phosphorylation assay was carried out using adA2AAR-infected HUVECs 
which  had  been  treated  with  increasing  concentrations  of  GF109203X,  an  inhibitor  of 
classical and novel forms of PKC (Martiny-Baron et al., 1993; Toullec et al., 1991), before 
stimulation with 10 nM PMA.  As before, PMA induced receptor phosphorylation in the 
absence of GF109203X.  However, pre-treatment with GF109203X resulted in a dose-
dependent inhibition of receptor phosphorylation with an IC50 of 200 nM (figure 4.9 A,B), 
a  value  which  is  consistent  with  concentrations  of  GF10923X  required  to  inhibit 
phosphorylation of other known substrates of novel and conventional isoforms of PKC 
(Überall et al., 1997).  PMA-stimulated ERK phosphorylation was similarly inhibited in 
GF109203X-treated  cells  (figure  4.9  C,  upper  panel).    The  reduction  in  receptor 
phosphorylation could not be explained by changes in receptor expression as shown in 
figure 4.9 C, lower panel, indicating that PMA induced phosphorylation of the A2AAR is 
dependent on the involvement of  classical or novel isoforms of PKC. 
An alternative method for analysing the involvement of PKC is to deplete cellular levels by 
chronic treatment with PMA.  Prolonged exposure to phorbol esters triggers the down-
regulation  of  PMA-sensitive  PKC  isoforms  by  increasing  the  rate  of  proteolytic 
degradation (Liu and Heckman, 1998).  The effect of PKC depletion on PMA-induced 
receptor phosphorylation was investigated by incubating HUVECs with 100 nM PMA for 
36 hours before performing an intact cell phosphorylation assay.   In cells which had not 
received chronic treatment with PMA, a 20 minute treatment with 10 mM PMA induced  Gillian R Milne, 2008    Chapter 4, 139 
Figure 4.8 The human A2AAR is phosphorylated in response to stimulation of 
endogenous histamine H1 receptors which activate PKC 
HUVECs  infected  with  adenovirus  expressing  the  A2AAR  were  labelled  with 
32P 
orthophosphate for 90  minutes prior to stimulation with 1 mM histamine for the times 
indicated.    Cell  extracts  were  prepared  and  equalised  for  protein  content  before 
immunoprecipitation  of  the  A2AAR.    A.  The 
32P-labelled  A2AAR  was  detected  by 
autoradiography following SDS-PAGE.  B.  Bands were quantitated by densitometry and 
values expressed as a mean fold increase ± SE as shown in the graph.  C.  Levels of 
phosphorylated  ERK  and  total  A2AAR  expression  were  detected  by  SDS-PAGE  and 
immunoblotting of protein samples prepared from experiments carried out in parallel using 
unlabelled cells (n = 2).  The 9E10 antibody was used to detect the A2AAR. Gillian R Milne, 2008    Chapter 4, 140 
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Figure 4.9 PKC plays a role in PMA-induced phosphorylation of the human 
A2AAR 
HUVECs  infected  with  adenovirus  expressing  the  A2AAR  were  labelled  with 
32P 
orthophosphate for 90 minutes prior to addition of the PKC inhibitor GF109203X (GFX) at 
the concentrations indicated.  After 30 minutes, cells were stimulated with 10 nM PMA (+) 
or DMSO vehicle (-) for 20 minutes. Cell extracts were prepared and equalised for protein 
content  before  immunoprecipitation  of  the  A2AAR.    A.  The 
32P-labelled  A2AAR  was 
detected  by  autoradiography  following  SDS-PAGE.    B.    Bands  were  quantitated  by 
densitometry and values expressed as a mean percentage of the maximal response ± SE as 
shown in the graph. C.  Levels of phosphorylated ERK and total A2AAR expression were 
detected  by  SDS-PAGE  and  immunoblotting  of  protein  samples  prepared  from 
experiments carried out in parallel using unlabelled cells (n = 2).  The 9E10 antibody was 
used to detect the A2AAR. Gillian R Milne, 2008    Chapter 4, 142 
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strong  phosphorylation  as  observed  in  the  experiments  described  above  (figure  4.10).  
However, in cells which had been treated with 100 nM PMA for 36 hours, this response 
was reduced by an average of 59 ± 9 % (p = 0.05, n = 3).  This was not due to effects of 
PMA  other  than  on  PKC  as  in  cells  pre-incubated  for  36  hours  with  an  equivalent 
concentration  of  the  control  drug,  4a  phorbol  which  does  not  activate  PKC,  receptor 
phosphorylation  was  detected  at  similar  levels  as  that  seen  in  cells  which  had  not 
undergone chronic treatment.  Immnoblotting using a pan-PKC antibody showed that the 
PKC-depletion protocol was effective (figure 4.10 C, upper panel).  In accordance with a 
reduction  in  PKC  activity,  PMA-induced  ERK  phosphorylation  was  reduced  or 
undetectable in cells subjected to chronic PMA treatment.  The changes in phosphorylation 
observed were not due to any effects of the drugs used on receptor expression as levels of 
the A2AAR did not vary significantly between conditions (figure 4.10 C, lower panel).  
Thus PKC depletion severely impairs the ability of PMA to induce phosphorylation of the 
A2AAR. 
Results obtained using the PKC inhibitor GF109203X and by depleting cellular levels of 
PKC indicate that PKC plays a role in mediating phosphorylation of the A2AAR.  HUVECs 
express 5 isoforms of PKC (a, d, e, q and z; Haller et al., 1996) of which all apart from z 
are activated by DAG and can be down-regulated by chronic phorbol ester treatment (Liu 
and  Heckman,  1998).    To  begin  to  investigate  which  isoform  may  be  responsible  for 
phosphorylation of the A2AAR, intact cell phosphorylation assays were carried out with 
cells treated with rottlerin which is an inhibitor of PKCd and has been shown previously to 
inhibit phosphorylation of the canine A2AAR expressed in C6 cells (Palmer and Stiles, 
1999).  Cells were treated with different concentrations of rottlerin for 30 minutes before 
stimulation with 10 nM PMA.  As shown in figure 4.11, phosphorylation of the A2AAR 
was unaffected by rottlerin except at the highest concentration used (10 mM).  At this 
concentration, rottlerin may inhibit kinases other than PKCd (Davies et al., 2000) and so it 
is unclear whether or not PKCd is responsible for phosphorylating the A2AAR. 
PKC isoforms can be differentiated on their requirement for calcium.  HUVECs express 
both calcium-dependent PKCa and calcium-independent PKCd, PKCe and PKCq (Haller 
et al., 1996).  In order to test whether a calcium-dependent isoform was involved, PMA-
induced receptor phosphorylation was assessed in cells which had been pre-incubated with 
the cell-permeable calcium chelator BAPTA/AM (10 mM) for 30 minutes.  As shown in 
figure 4.12, PMA induces receptor phosphorylation which is not affected by BAPTA/AM.  Gillian R Milne, 2008    Chapter 4, 144 
Figure 4.10 PKC depletion reduces PMA-stimulated phosphorylation of the 
human A2AAR 
HUVECs  infected  with  adenovirus  expressing  the  A2AAR  were  incubated  with  10  nM 
PMA or DMSO vehicle (-) or with 10 nM 4a-phorbol for 36 hours before stimulation with 
10 nM PMA or vehicle for 20 minutes.  Cell extracts were prepared and equalised for 
protein content before immunoprecipitation of the A2AAR.  A. The 
32P-labelled A2AAR 
was detected by autoradiography following SDS-PAGE.  B.  Bands were quantitated by 
densitometry and values expressed as a mean percentage of the response observed for cells 
treated with 4a-phorbol ± SE as shown in the graph. C.  Levels of phosphorylated ERK 
and total A2AAR expression were detected by SDS-PAGE and immunoblotting of protein 
samples prepared from experiments carried out in parallel using unlabelled cells (n = 2).  
The 9E10 antibody was used to detect the A2AAR. Gillian R Milne, 2008    Chapter 4, 145 
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Figure  4.11  PKCd d d d  does  not  appear  to  be  involved  in  PMA-induced 
phosphorylation of the human A2AAR 
HUVECs  infected  with  adenovirus  expressing  the  A2AAR  were  labelled  with 
32P 
orthophosphate  for  90  minutes  prior  to  addition  of  the  PKCd  inhibitor  rottlerin  at  the 
concentrations indicated.  After 30 minutes, cells were stimulated with 10 nM PMA (+) or 
DMSO vehicle (-) for 20 minutes. Cell extracts were prepared and equalised for protein 
content  before  immunoprecipitation  of  the  A2AAR.    A.  The 
32P-labelled  A2AAR  was 
detected  by  autoradiography  following  SDS-PAGE.    B.    Bands  were  quantitated  by 
densitometry and values expressed as a mean percentage of the maximal response ± SE as 
shown in the graph. C.  Levels of phosphorylated ERK and total A2AAR expression were 
detected  by  SDS-PAGE  and  immunoblotting  of  protein  samples  prepared  from 
experiments carried out in parallel using unlabelled cells (n = 2).  The 9E10 antibody was 
used to detect the A2AAR. Gillian R Milne, 2008    Chapter 4, 147 
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Figure 4.12 Effect of calcium chelation on PMA-induced phosphorylation of 
the human A2AAR 
HUVECs  infected  with  adenovirus  expressing  the  A2AAR  were  labelled  with 
32P 
orthophosphate for 90 minutes prior to addition of 10 mM BAPTA/AM.  After 30 minutes, 
cells  were  stimulated  with  10  nM  PMA,  1mM  ionomycin  or  DMSO  vehicle  (-)  as 
indicated.  Cell  extracts  were  prepared  and  equalised  for  protein  content  before 
immunoprecipitation  of  the  A2AAR.    A.  The 
32P-labelled  A2AAR  was  detected  by 
autoradiography following SDS-PAGE.  B.  Bands were quantitated by densitometry and 
values expressed as a mean percentage of the maximal response ± SE as shown in the 
graph. C.  Levels of phosphorylated ERK and total A2AAR expression were detected by 
SDS-PAGE and immunoblotting of protein samples prepared from experiments carried out 
in  parallel  using  unlabelled  cells  (n  =  2).    The  9E10  antibody  was  used  to  detect  the 
A2AAR. Gillian R Milne, 2008    Chapter 4, 149 
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To  confirm  that  BAPTA/AM  was  effective,  cells  were  treated  with  the  ionophore 
ionomycin which mobilises intracellular calcium stores (Liu and Hermann, 1978).  This 
results in calcium-dependent ERK activation via activation of calmodulin and calmodulin 
binding proteins which can modulate Ras activity (Agell et al., 2002).  Calcium chelation 
was judged to be successful as calcium-dependent activation of ERK induced by treating 
cells  with  1  mM  ionomycin  for  20  minutes  was  reduced  in  cells  pre-incubated  with 
BAPTA/AM (figure 4.12 C, upper panel).  It should be noted that in cells treated with 
ionomycin, receptor expression was reduced (figure 4.12 C, lower panel).  However, since 
the extent of the reduction was similar for both BAPTA/AM-treated and untreated cells, 
the effect of BAPTA/AM on ERK phosphorylation was still considered relevant.  Thus, 
A2AAR phosphorylation appears to be mediated by a calcium-independent isoform of PKC 
which  rules  out  the  involvement  of  PKCa.    Excluding  PKCd,  the  remaining  calcium-
independent, PMA-sensitive isoforms expressed by HUVECs are PKC e and q. 
Although many PKC inhibitors exist, their selectivity for different isoforms is limited.  A 
more specific approach to achieve inhibition of individual PKC isoforms is to use siRNA 
gene silencing.  To assess the involvement of PKCe in A2AAR phosphorylation, siRNAs 
targeted against human PKCe, non-targeted control siRNA or PKCa were introduced into 
HUVECs  prior  to  infection  with  adA2AAR.    PKCa  siRNA  was  included  as  a  relative 
kinase control to show that effects observed were specific to PKCe and that PKCa was not 
involved.  As before, PMA induced phosphorylation of the A2AAR (figure 4.13 A).  No 
decrease in this response was observed in cells transfected with siRNAs directed against 
PKCe, PKCa or control siRNA suggesting that PKCe is not required for PMA-mediated 
A2AAR phosphorylation.  This also corroborated findings presented above which indicated 
that  calcium-dependent  isoforms  such  as  PKCa  are  not  required  for  PMA-induced 
phosphorylation.  As shown in figure 4.13 B (top panel) PKCe was effectively depleted in 
cells transfected with PKCe-targeted siRNA while levels were constant in untransfected 
cells  and  those  transfected  with  PKCa,  confirming  the  effectiveness  of  the  technique.  
PKCa  expression  was  also  significantly  reduced  specifically  in  cells  transfected  with 
PKCa-targeted siRNA (figure 4.13 B, centre panel).  Expression of the A2AAR remained 
constant between conditions (figure 4.13 B, bottom panel).  Thus, PKCe does not appear to 
be required for PMA-induced A2AAR phosphorylation. 
It  was  one  of  the  aims  of  this  study  to  determine  which  region  of  the  A2AAR  was 
phosphorylated in response to PMA.  To begin to address this question, cells were  Gillian R Milne, 2008    Chapter 4, 151 
Figure 4.13 Effect of PKCe e e e and PKCa a a a siRNA gene silencing on PMA-induced 
A2AAR phosphorylation 
HUVECs were transfected with siRNA targeted against PKCe or PKCa and infected with 
adenovirus expressing the A2AAR.  Cells were labelled with 
32P orthophosphate for 90 
minutes prior to stimulation with 1 mM PMA for 20 minutes.  Cell extracts were prepared 
and equalised for protein content before immunoprecipitation of the A2AAR.  A. The 
32P-
labelled  A2AAR  was  detected  by  autoradiography  following  SDS-PAGE  (n  =  2).    B. 
Identical experiments were carried out in parallel using unlabelled cells.  Protein extracts 
were prepared for use in SDS-PAGE and immunoblotting to confirm successful siRNA-
mediated knock-down of PKCe and PKCa using PKC isoform-specific antibodies and to 
show total levels of A2AAR expression using the 9E10 antibody (n = 2). Gillian R Milne, 2008    Chapter 4, 152 
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transfected with one of two A2AAR truncation mutants in order to assess which regions of 
the C-terminal tail were required for phosphorylation.  One construct (1-360) lacked five 
potential  phosphorylation  sites  from  the  receptor  tail  and  the  other  (1-311),  the  most 
severely truncated, lacked eleven sites (Klinger et al., 2002b, figure 4.14).   HUVECs do 
not respond well to transfection protocols and attempts to express the receptor constructs 
proved to be unsuccessful (data not shown).  For this reason, experiments were initially 
carried out using CHO cells which are a more tractable cell line. 
Transfection of CHO cells was successful as shown in figure 4.15 A, upper panel.  Wild-
type A2AAR was detected as two bands between 37 and 75 kDa, while the 1-360 and 1-311 
truncated forms are represented as bands of lower molecular mass owing to the absence of 
50 or 100 amino acids respectively.  However, in intact cell phosphorylation assays using 
transfected cells stimulated with 10 mM CGS21680 or 1 mM PMA, no phosphorylation of 
the  wild-type  or  truncated  receptors  was  detected  (figure  4.15  B).    This  was  despite 
confirmation that the CGS21680 and PMA were active as shown by their ability to induce 
ERK  phosphorylation  (figure  4.15  A,  lower  panel).    The  lack  of  detectable  A2AAR 
phosphorylation  was  not  due  to  a  failure  in  the  immunoprecipitation  procedure  as  the 
A2AAR  was  detected  by  immunoblotting  immunoprecipitated  samples  with  an  A2AaR-
specific antibody (figure 4.15 C).  Thus, it appears that the human A2AAR is not subject to 
PMA-induced phosphorylation in CHO cells, raising the possibility that this is a cell type-
specific phenomenon.  To further investigate this possibility, phosphorylation was assessed 
in HEK 293 and C6 cells transfected with the wild-type or truncated forms of the A2AAR.  
Immunoblotting revealed that the wild-type A2AAR was expressed in HEK 293 cells at 
easily detectable levels while the 1-311 and 1-360 truncated forms were present at lower 
levels (figure 4.16 A (i), upper panel).  Stimulation with CGS21680 and PMA induced 
ERK  phosphorylation  (figure  4.16  A  (i),  lower  panel)  but  did  not  result  in  receptor 
phosphorylation  (figure  4.16  A  (ii)).    The  wild-type  and  truncated  A2AARs  were  also 
successfully expressed in C6 cells but detection by immunoblotting was hindered by a 
strong band at approximately 60 kDa possibly representing endogenous myc (figure 4.16 B 
(i), upper panel).  Again, PMA induced ERK phosphorylation (figure 4.16 B (i)) but did 
not result in detectable receptor phosphorylation (figure 4.16 B (ii)).  Therefore, it appears 
that phosphorylation of the human A2AAR in response to PMA only occurs in certain cell 
types including HUVECs but not CHO, HEK 293 or C6 cells. 
Previous studies have shown that a large part of the A2AAR tail is dispensable for agonist 
binding (Piersen et al., 1994), desensitisation (Palmer and Stiles, 1997) and G-protein  Gillian R Milne, 2008    Chapter 4, 154 
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 Figure  4.14  Sequences  of  the  C-terminal  tail  of  DNA  constructs 
representing the wild-type and truncated forms of the human A2AAR 
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Figure  4.15  Expression  of  wild-type  and  truncated  forms  of  the  A2AAR  in 
CHO cells 
CHO  cells  were  transfected  with  plasmids  encoding  a  myc-tagged  WT  human  A2AAR 
(WT) or one of two myc-tagged carboxyl-terminus truncation mutants (1-311 and 1-360).  
A.  Cells were stimulated with 10 mM CGS21680, 1 mM PMA or DMSO vehicle for 20 
minutes  before  preparation  of  protein  extracts.    Extracts  were  normalised  for  protein 
content prior to fractionation by SDS-PAGE and immunoblotting using a phospho-ERK 
(pERK)-specific antibody or the 9E10 antibody which recognises both WT and truncated 
forms of the A2AAR (n = 2).    B.  Transfected cells were labelled with 
32P for 90 minutes 
prior to stimulation with 10 mM CGS21680, 1 mM PMA or DMSO vehicle for 20 minutes.  
Cell  extracts  were  prepared  and  equalised  for  protein  content  before  subjection  to  an 
immunoprecipitation  protocol  using  the  9E10  antibody.    Samples  were  fractionated  by 
SDS-PAGE and dried gels were exposed to film to allow detection of any 
32P-labelled 
receptor (n = 3).  C.  CHO cells were left untransfected (control) or were transfected with 
the WT A2AAR.  Cell extracts were prepared  and equalised for protein content before 
subjection  to  an  immunoprecipitation  protocol  in  the  presence  or  absence  of  the  9E10 
antibody as indicated.  Immunoprecipitated receptors and total levels of receptors in cell 
lysates  (Input)  were  detected  using  SDS-PAGE  followed  by  immunoblotting  using  an 
A2AAR-specific antibody (n = 2). Gillian R Milne, 2008    Chapter 4, 156 
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Figure 4.16 Expression of wild-type and truncated forms of the A2AAR in HEK 
293 and C6 cells 
HEK 293 (A) or C6 cells (B) were transfected with plasmids encoding a myc-tagged WT 
human A2AAR (WT) or one of two myc-tagged carboxyl-terminus truncation mutants (1-
311 and 1-360).  (i) Cells were stimulated with 10 mM CGS21680, 1 mM PMA or DMSO 
vehicle for 20 minutes before preparation of protein extracts.  Extracts were normalised for 
protein content prior to fractionation by SDS-PAGE and immunoblotting using a phospho-
ERK  (pERK)-specific  antibody  or  the  9E10  antibody  which  recognises  both  WT  and 
truncated forms of the A2AAR (n = 2).  (ii)  Transfected cells were labelled with 
32P for 90 
minutes prior to stimulation with 10 mM CGS21680, 1 mM PMA or DMSO vehicle for 20 
minutes.  Cell extracts were prepared and equalised for protein content before subjection to 
an immunoprecipitation protocol using the 9E10 antibody.  Samples were fractionated by 
SDS-PAGE and dried gels were exposed to film to allow detection of any 
32P-labelled 
receptor (n = 3).   
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coupling (Klinger et al., 2002b).  Therefore, the significance of phosphorylation events in 
this region is unclear.  However, the A2AAR has been reported to interact with a number of 
accessory  proteins,  including  14-3-3  proteins  and  TRAX  (Gsandtner  and  Freissmuth, 
2006), prompting the question of whether phosphorylation of the  A2AAR tail could be 
important for determining which proteins bind.  It was of interest to determine whether 
PMA-induced phosphorylation observed in this study had an effect on such interactions.  
This was investigated using pull-down assays to detect interactions in vitro between the 
A2AAR and 14-3-3t or TRAX under conditions where the A2AAR would or would not be 
phosphorylated.  To perform these assays, it was necessary to obtain purified GST fusion 
proteins.    GST-14-3-3t  and  GST-TRAX  were  expressed  in  E.  coli  and  purified  on 
glutathione Sepharose beads.  GST-14-3-3t was successfully expressed and was detected 
by Coomassie staining as shown in figure 4.17 A by a clean band at approximately 55 kDa.  
TRAX was expressed at reasonable levels as shown by the strong band at approximately 
60 kDa present 4 hours after induction (figure 4.17 B) although the weaker bands detected 
at  later  points  show  that  significant  amounts  of  TRAX  protein  were  lost  during  the 
purification process. 
Purified GST-tagged 14-3-3t and TRAX were used in pull-down assays with cell lysates 
produced  from  adA2AAR-infected  cells  which  had  been  incubated  in  the  presence  or 
absence of 1mM PMA for 20 minutes to induce optimal receptor phosphorylation (figure 
4.18).  As shown in figure 4.18 A, the A2AAR was detected in samples from pull-down 
assays  using  GST-14-3-3t  regardless  of  PMA  treatment  confirming  that  14-3-3t  does 
interact with the A2AAR in this cell system.  However, since there was no change in levels 
detected when cells had been stimulated with PMA, it does not appear to be dependent on 
PMA-induced  A2AAR  phosphorylation.    No  receptor  was  detected  when  parallel  pull-
downs were performed with GST alone indicating that observations were not a result of 
non-specific interactions.  The A2AAR was also detected when pull-downs were performed 
with unstimulated cells in the presence of GST-TRAX.  Strikingly, levels of the A2AAR 
were  drastically  reduced  in  samples  from  PMA-stimulated  cells  (71  ±  17  %  reduction 
compared to unstimulated, p < 0.0001, n = 3) indicating that the interaction of TRAX with 
the A2AAR may be dependent on phosphorylation status of the A2AAR tail. 
In summary, data presented here shows that phosphorylation of the human A2AAR can be 
induced in HUVECs by treatment with PMA or by stimulation of endogenous histamine 
H1 receptors.  A role for PKC was indicated by the ability of both a PKC inhibitor and Gillian R Milne, 2008    Chapter 4, 161 
Figure 4.17 Expression and purification of GST-tagged 14-3-3t t t t and TRAX.   
E. coli were transformed with plasmids encoding either GST-14-3-3t or GST-TRAX.  A. 
Expression of GST-14-3-3t was induced by incubation of bacterial cultures with 1 mM 
IPTG for 4 hours at 37 °C and recombinant protein was purified by immobilisation on 
glutathione Sepharose beads.  Bound proteins were eluted from beads and protein analysed 
by SDS-PAGE and Coomassie staining.  B. GST-TRAX protein expression was induced 
by addition of 0.5 mM IPTG for 16 hours at 25 °C and recombinant protein was purified 
by immobilisation on glutathione Sepharose beads.  Eluted protein and samples taken from 
cultures at each hour following induction and from whole cell lysates (a), sonicated lysates 
(b) and cleared lysates (c) were analysed by SDS-PAGE and Coomassie staining. 
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Figure 4.18 14-3-3t t t t and TRAX interact with the human A2AAR 
HUVECs infected with adenovirus expressing the A2AAR were incubated with or without 
1 mM PMA for 20 minutes.  Cell extracts were prepared and used in a pull-down assay 
using GST-fusion protein glutathione Sepharose beads representing 20 mg of either GST, 
GST-14-3-3t or GST-TRAX.  A. Protein complexes eluted from beads and samples of 
untreated  and  PMA-treated  cell  lysates  (input)  were  subjected  to  SDS-PAGE  and 
immunoblotting  using  the  9E10  antibody  to  detect  the  A2AAR.    B.  Interactions  of  the 
receptor with (i) GST-14-3-3t and (ii) GST-TRAX were quantitated by densitometry of 
immunoreactive bands and values were expressed as a mean percentage of the maximum 
A2AAR detected ± SE. Gillian R Milne, 2008    Chapter 4, 164 
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chronic  PMA-mediated  PKC  depletion  to  inhibit  receptor  phosphorylation.    Initial 
investigations showed that this effect is mediated by a calcium-insensitive isoform of PKC 
as  chelation  of  intracellular  calcium  had  no  effect  on  levels  of  PMA-induced 
phosphorylation.  An siRNA gene silencing approach confirmed that PKCa is not required 
and also indicated that PKCe is not required for PMA-induced phosphorylation but it was 
not possible to identify the specific isoform responsible.  Notably, through the use of pull-
down assays, it was possible to detect in vitro interactions between 14-3-3t and TRAX and 
the A2AAR.  Most interestingly, while the interaction between 14-3-3t and the A2AAR was 
detected in both basal conditions and following PMA treatment when the receptor would 
be phosphorylated, the interaction of TRAX was drastically reduced when cells had been 
treated  with  PMA,  indicating  that  the  phosphorylation  status  of  the  receptor  may 
negatively regulate TRAX binding. Gillian R Milne, 2008    Chapter 4, 166 
4.3 Discussion 
Several proteins have been reported to interact with the long C-terminal tail of the A2AAR 
prompting the suggestion that it may act as a scaffold upon which signalling complexes 
can be assembled (Zezula and Freissmuth, 2008).  However, the question of how these 
interactions might be regulated has not been addressed.  A number of serine and threonine 
residues are present within this region of the A2AAR suggesting potential for regulation by 
phosphorylation.  The canine A2AAR has been shown to be phosphorylated in response to 
activation  of  PKC  but  unlike  other  GPCRs,  this  is  not  associated  with  heterologous 
desensitisation  (Palmer  and  Stiles,  1999).    It  was  therefore  of  interest  in  this  study  to 
investigate whether phosphorylation of the C-terminal tail of the A2AAR could play a role 
in regulating the binding of interacting proteins.  Importantly, this question was addressed 
using human receptors expressed in HUVECs which express low levels of endogenous 
receptors as phosphorylation of the A2AAR has only been examined previously using the 
canine receptor heterologously expressed in rat C6 glioma cells. 
In the present study, it was found that phosphorylation of the human A2AAR is rapidly 
elevated over basal levels following activation of PKC either by treatment with PMA or 
through activation of endogenous histamine H1 receptors.  This effect was significantly 
reduced  in  the  presence  of  the  PKC  inhibitor  GF109203X  or  following  depletion  of 
cellular levels of PKC, thereby confirming the involvement of PKC.  The specific isoform 
of PKC responsible for PMA-induced phosphorylation of the A2AAR was determined to be 
calcium-insensitive and through the use of siRNA gene silencing a role for PKCe was 
eliminated,  leaving  PKCd  and  PKCq  as  potential  candidates.    Previously  reported 
interactions between the A2AAR and TRAX and 14-3-3t were confirmed in vitro by GST 
pull-down  assay.    Binding  of  14-3-3t  to  the  A2AAR  was  detected  at  similar  levels  in 
samples  from  PMA-treated  compared  to  untreated  cells.    However,  A2AAR  complex 
formation with TRAX was significantly reduced in samples from PMA-stimulated cells 
indicating that receptor phosphorylation may regulate the interaction with TRAX. 
In  order  to  study  phosphorylation  of  the  A2AAR,  recombinant  adenovirus  was  used  to 
introduce  the  myc-tagged  human  receptor  into  HUVECs.    Data  obtained  from  ligand-
binding  studies  showed  that  expression  of  the  receptor  was  very  high  compared  to 
endogenously expressed receptors (80 ± 7 pmol/mg compared to 0.95 pmol/mg previously 
reported for the A2AAR in porcine striatum; Klinger et al., 2002b).  However, in this study, Gillian R Milne, 2008    Chapter 4, 167 
it was necessary to achieve high expression in order to detect receptor phosphorylation.   
This allowed identification of mechanisms which may potentially regulate the activity of 
the A2AAR.  Further studies can be carried out in future to assess the functional relevance 
of these events in cells expressing endogenous receptors. 
Phosphorylation of the human A2AAR was induced by low nanomolar concentrations of 
PMA and in a short time frame as previously described for the canine receptor (Palmer and 
Stiles, 1999).  However, the human receptor was not as strongly phosphorylated reaching 
only (3.6 ± 0.4)-fold above basal levels compared to the canine receptor which reached 
(11.2  ±  2.5)-fold  above  basal  levels.    In  addition,  in  contrast  to  the  canine  receptor, 
phosphorylation of the human A2AAR appeared to be bi-phasic, perhaps suggesting the 
existence of two separate phosphorylation events.  Activation of histamine receptors also 
resulted in increased phosphorylation of the A2AAR indicating that this is a physiologically 
relevant event.  However, in contrast to studies using the canine receptor expressed in C6, 
CHO and COS cells (Palmer and Stiles, 1997; Palmer et al., 1994), phosphorylation in 
response to agonist stimulation was not detected.  This is perhaps surprising as agonist-
induced  phosphorylation  by  GRKs  represents  the  major  mechanism  for  homologous 
desensitisation of many GPCRs (Krupnick and Benovic, 1998).  It is possible that basal 
levels of phosphorylation are higher in HUVECs than in CHO cells, making small agonist-
induced changes difficult to detect compared to the strong response elicited by PMA.  An 
alternative  explanation  is  that  recruitment  of  GRKs  to  the  A2AAR  may  require  prior 
phosphorylation  of  the  receptor  by  second  messenger-dependent  kinases.    A  specific 
consensus sequence for  phosphorylation by GRKs has not been defined.  However, in 
studies  using  synthetic  peptides,  GRK2  has  been  found  to  preferentially  phosphorylate 
peptides  with  negatively  charged  amino  acids  to  the  N-terminal  side  of  a  serine  or 
threonine residue (Onorato et al., 1991; Benovic et al., 1990).  Indeed, replacement of 
specific acidic residues with uncharged amino acids in a peptide representing a GRK2 
phosphorylation site in the a2-adrenergic receptor completely abolished phosphorylation 
(Onorato et al., 1991).  It is possible that in the A2AAR, serine and threonine residues are 
not present in regions sufficiently rich in negatively charged residues to allow recruitment 
of GRK2.  However, introducing negative charges through PMA-induced phosphorylation 
could  potentially  provide  this  requirement  and  increase  the  affinity  of  the  receptor  for 
GRK2, thereby allowing subsequent agonist-induced phosphorylation. 
Initial investigations into the role of PKC in mediating phosphorylation of the A2AAR were 
made using the PKC inhibitors GF109203X and rottlerin.  A potential problem with this Gillian R Milne, 2008    Chapter 4, 168 
approach is that many PKC inhibitors are non-selective as they inhibit PKC via its ATP 
binding  site,  a  domain  which  is  highly  homologous  between  different  protein  kinases.  
Despite this, GF109203X has been shown to be a potent and selective inhibitor of classical 
and  novel  isoforms  of  PKC  (Toullec  et  al.,  1991)  and  so  its  ability  to  inhibit 
phosphorylation of the A2AAR does indicate a role for PKC in this process.  Rottlerin, 
which has been reported to inhibit PKC with some selectivity for PKCd (Gschwendt et al., 
1994), did not inhibit phosphorylation of the A2AAR except at the highest concentration 
tested.    However,  the  value  of  this  finding  is  questionable  as  in  more  recent  studies 
rottlerin was found to be a very poor inhibitor of PKCd with the ability to inhibit other 
unrelated kinases with much greater potency (Davies et al., 2000).  Further studies using 
siRNA  to  specifically  knock  down  expression  of  PKCd  will  be  important  to  more 
accurately assess the role of PKCd. 
The ability of GF109203X to inhibit phosphorylation indicated the involvement of a novel 
or classical isoform of PKC.  These can be differentiated based upon their requirement for 
calcium for activation.  In this study, the calcium chelator BAPTA/AM failed to block 
PMA-induced  phosphorylation  indicating  that  one  of  the  novel  calcium-insensitive 
isoforms of PKC present in HUVECs (either PKCe, d or q) was responsible.  However, 
these results are difficult to interpret as cells treated with ionomycin in control experiments 
to  confirm  the  activity  of  BAPTA/AM  appeared  to  suffer  toxic  effects.    Without 
confirmation that BAPTA/AM was active, it is not possible to firmly conclude that the 
phosphorylation  response  is  calcium-independent  as  similar  results  would  have  been 
obtained using an inactive drug.  To obtain more reliable results, this experiment could be 
repeated using an alternative ionophore such as A23187 which may be less toxic than 
ionomycin. 
In contrast to the use of PKC inhibitors, siRNA-mediated gene silencing provided a very 
specific method for examining the contribution of individual isoforms of PKC to PMA-
induced phosphorylation of the A2AAR.  Expression of PKCe and PKCa was efficiently 
downregulated  as  determined  by  immunoblotting  but  this  had  no  effect  on  levels  of 
phosphorylation achieved providing strong evidence that these isoforms are not involved.  
Attempts were made to assess the role of PKCq in a similar fashion.  However, PKCq 
proved  extremely  difficult  to  detect  by  immunoblotting  which  made  it  impossible  to 
determine  whether  PKCq  expression  had  been  successfully  downregulated  by  RNA 
interference.    Optimisation  of  immunoblotting  procedures  perhaps  through  the  use  of Gillian R Milne, 2008    Chapter 4, 169 
alterative anti-PKCq antibodies will be required to allow the use of RNA interference to 
determine whether PKCq is involved in regulating PMA-induced phosphorylation of the 
A2AAR. 
Although the above findings strongly suggest a role for PKC in regulating phosphorylation 
of the A2AAR, it is not clear whether PKC phosphorylates the receptor directly or whether 
an intermediate kinase is involved.  This is an important consideration as PMA has been 
shown to activate several other targets in addition to PKC including the PKD family of 
serine/threonine kinases (Brose and Rosenmund, 2002).  In common with PKCs, PKDs 
have a DAG-binding site termed the C1 site which can also bind phorbol esters (Valverde 
et  al.,  1994).    Following  stimulation  with  PMA,  PKD  is  translocated  to  the  plasma 
membrane where it has the potential to interact with other signalling proteins (Matthews et 
al., 2000).  PKD is then activated through direct interaction with and phosphorylation by 
PKC (Waldron and Rozengurt, 2003; Zugaza et al., 1996).  Several isoforms of PKC have 
been implicated in the activation of PKD including all novel isoforms which is consistent 
with an effect that would be inhibited by GF109203X as observed in this study (Wang, 
2006).    PKD  phosphorylates  serine  residues  within  the  consensus  motif 
(LXR(Q/K/E/M)(M/L/K/E/Q/A)S),  the  most  critical  residue  being  leucine  at  the  -5 
position (Döppler et al., 2005; Nishikawa et al., 1997).  There are two serine residues 
(Ser329 and Ser370) in the C-terminal tail of the A2AAR with leucine at the -5 position.  
However, the intervening residues do not conform to the consensus sequence and so it is 
not clear whether the tail of the A2AAR could act as a substrate for phosphorylation by 
PKD.    Interestingly,  another  potential  phosphorylation  site  (Ser213)  bearing  a stronger 
resemblance  to  the  PKD  substrate  consensus  sequence  is  present  within  the  third 
intracellular loop of the receptor.  However, this is in the region implicated in G protein 
coupling and since phosphorylation has no effect on the ability of the receptor to stimulate 
AC  (Palmer  and  Stiles,  1999),  it  seems  unlikely  that  PMA-induced  phosphorylation  is 
occurring  at  this  site.  Unfortunately,  there  are  no  specific  PKD  inhibitors  available  at 
present which could be used to test the involvement of PKD in phosphorylation of the 
A2AAR  and  so  further  investigations  would  require  the  use  of  siRNA  to  suppress 
expression of each of the four isoforms of PKD. 
The  failure  to  detect  phosphorylation  of  the  A2AAR  in  cell  types  other  than  HUVECs 
presented a major problem during this study and prevented evaluation of the effects of 
receptor truncation on the response.  Detection of phosphorylation in HUVECs required 
that  the  A2AAR  be  overexpressed  at  high  levels  (80  ±  7  pmol/mg)  which  was  readily Gillian R Milne, 2008    Chapter 4, 170 
achievable  through  the  use  of  recombinant  adenovirus.    DNA  constructs  encoding  the 
wild-type and truncated forms of the A2AAR were introduced to C6, CHO or HEK 293 
cells by the less efficient process of transfection.  It must therefore be considered that 
receptor phosphorylation was not detected in these cells because the receptors were not 
expressed at sufficiently high levels.  Initial determination of receptor expression was in 
itself complicated by the presence of multiple non-specific bands in immunoblots.  This 
problem could have been avoided by including samples from mock-transfected cells for 
comparison as these would display only non-specific bands and not those representing the 
different forms of the receptor.  Despite the difficulties in identifying specific bands, it did 
appear that the 1-311  mutant in particular was expressed at lower levels than the WT 
receptor and the 1-360 mutant although this could perhaps be explained by the fact that the 
1-311 mutant lacks the binding site for USP4.  USP4 is thought to promote cell surface 
expression  of  the  A2AAR  following  synthesis  by  deubiquitinating  it  and  preventing  its 
degradation by the proteasome (Milojević et al., 2006).  Therefore, it seems likely that a 
truncated form of the receptor that does not bind USP4 would be retained in the ER and 
degraded.  However, USP4 is reported to bind within the last 50 amino acids of the A2AAR 
(Milojević et al., 2006) which are missing from both the 1-311 and the 1-360 mutants and 
so it might be expected that both mutants would be expressed at similarly low levels.  
Thus, there may be additional reasons for the poor expression of the 1-311 mutant.  For 
example,  the  additional  truncated  residues  may  be  important  for  proper  folding  of  the 
receptor, meaning that 1-311 is more prone to misfolding and therefore more likely to be 
degraded before reaching the cell surface.  The requirement for high levels of expression of 
the A2AAR to allow detection of phosphorylation could be tested by using adenovirus to 
increase expression of the receptor in C6 or CHO cells.  It would also be useful to transfect 
cells with the canine receptor in parallel with cells transfected with the human A2AAR to 
assess  phosphorylation  in  response  to  PMA  treatment.    Since  PMA-induced 
phosphorylation of the canine receptor has been observed previously in C6 and CHO cells, 
this would provide a positive control to highlight any failings in experimental procedures.  
An alternative explanation for the lack of response could be that the wild-type and mutant 
constructs encoded receptors which were not fully functional.  However, this is unlikely as 
the  ability  of  these  receptors  to  stimulate  AC  activation  and  ERK  activation  has  been 
confirmed in a previous study using the same DNA constructs (Klinger et al., 2002b).  It is 
possible that PMA-induced phosphorylation of the human A2AAR was only observed in 
HUVECs because it requires the presence of a PKC isoform or other kinase which is not 
present in C6, CHO or HEK 293 cells.  For example, CHO cells do not appear to express 
PKCq (Megson et al., 2001; Tippmer et al., 1994) which was one of the isoforms of PKC Gillian R Milne, 2008    Chapter 4, 171 
identified as a potential candidate for mediating phosphorylation of the receptor in this 
study. 
During this study, previously identified interactions between 14-3-3t and the A2AAR and 
TRAX and the A2AAR were observed in vitro using pull-down assays.  The A2AAR-TRAX 
interaction  has  been  confirmed  in  intact  cells  by  immunoprecipitating  the  A2AAR  and 
immunoblotting using an antibody directed against TRAX and also by colocalisation of 
these two proteins in the brain using double-immunohistochemical staining (Sun et al., 
2006).  Similar studies should be carried out to confirm the interaction between A2AAR 
and 14-3-3t in intact cells.   
The  finding  that  14-3-3t  interacted  with  the  A2AAR  independently  of  PMA-induced 
receptor phosphorylation was surprising as a major determinant for 14-3-3 binding to many 
ligands is the presence of a phosphorylated serine or threonine residue (Aitken, 2006).  14-
3-3 proteins exist as dimers, each monomer containing a binding pocket that can interact 
with proteins with either RSXpSXP and RXfXpSXP binding motifs (Yaffe et al., 1997; 
Muslin et al., 1996).  Data from crystal structures in complex with peptides indicates that a 
cluster of basic residues within an amphipathic groove of each 14-3-3 monomer mediates 
the interaction with phosphorylated residues in partner binding proteins (Aitken, 2006).  It 
is  possible  that  in  this  study,  14-3-3t  bound  to  serine  residues  of  the  A2AAR  that  are 
phosphorylated in basal conditions and this is why no changes were detected in response to 
PMA treatment.  However, it is also possible that the interaction occurred independently of 
phosphorylation as occurs in the case of some other 14-3-3-binding proteins.  For example 
the inositol polyphosphate 5-phosphatase forms a complex with 14-3-3z that appears to be 
mediated by a non-phosphorylated RSESEE motif (Campbell et al., 1997).  It is thought 
that the presence of negatively charged Asp and Glu residues may compensate for the lack 
of phosphorylated serine residues, thereby allowing binding to the amphipathic groove of 
14-3-3z in a similar way to phosphorylated ligands.  In another example, 14-3-3 proteins 
have  been  found  to  interact  with  the  Pseudomonas  aeroginosa  ADP-ribosyltransferase 
toxin exoenzyme S in a completely different fashion involving hydrophobic rather than 
electrostatic interactions (Ottmann et al., 2007).  In this case, binding requires the presence 
of four leucine residues.  Further studies will be required to ascertain whether any of these 
modes of binding are employed in the interaction between the A2AAR and 14-3-3t.  There 
are  no  aspartic  acid  or  leucine-rich  motifs  which  stand  out  in  the  sequence  of  the  C-
terminal tail of the A2AAR.  However, other amino acids with similar properties may allow Gillian R Milne, 2008    Chapter 4, 172 
similar interactions to occur.  Identification of the region of the A2AAR involved in binding 
to 14-3-3t will be important in determining whether this is the case.  Firstly, to determine 
whether  a  conventional  phosphorylated  binding  site  is  used,  it  would  be  useful  to 
immunoprecipitate  the  A2AAR  and  perform  an  immunoblot  using  a  phospho-14-3-3 
substrate  antibody.      If  the  antibody  does  not  react  with  the  A2AAR,  indicating  that  a 
conventional binding site is not being used, then to begin to investigate which part of the 
receptor is involved in the interaction, pull-downs or co-immunoprecipitation studies with 
wild-type and truncated forms of the A2AAR could be used to see if the deleted parts of the 
truncated receptors are necessary for binding.  Similarly, the effect of truncation of the 
receptor on colocalisation of 14-3-3t and the A2AAR could be assessed.  More detailed 
analysis of the binding site involved could be achieved by detecting binding of purified 14-
3-3t to peptide arrays constituting the C-terminal tail region of the A2AAR. 
It is also not clear what functional role 14-3-3t binding to the A2AAR may play.  14-3-3 
proteins have been ascribed diverse roles in many physiological processes including cell 
signalling,  cell  cycle  progression,  intracellular  trafficking,  cytoskeletal  structure  and 
transcription (Fu et al., 2000).   In the context of cell signalling, their ability to act as 
scaffolding proteins is of particular interest.  Since 14-3-3 proteins exist as dimers, they are 
able to bind two interaction partners simultaneously (Tzivion et al., 2001).  It is therefore 
possible  that  14-3-3t  could  recruit  signalling  molecules  to  the  tail  of  the  A2AAR  and 
facilitate initiation of different signalling pathways.  14-3-3 proteins have been reported to 
bind several signalling molecules including Raf kinases, MEKKs, PKC and PI-3 kinase 
(Tzivion et al., 2001).  The interaction between 14-3-3 and Raf-1 has been particularly 
well studied and appears to play a critical regulatory role in Ras-mediated activation of 
Raf-1 during initiation of the ERK cascade (Fu et al., 2000).  There are conflicting reports 
regarding the precise role of 14-3-3 proteins in this process.  However, this may be due 
largely to the fact that Raf-1 contains two phosphoserine-dependent binding sites (pSer259 
and pSer621) and one phosphate-independent binding site for 14-3-3 proteins, each with 
different roles.  Interactions at the pSer259 site negatively regulate Raf-1 activity while 14-
3-3 proteins bound at the pSer621 site have been suggested to either act as cofactors for 
Raf-1 kinase activity or alternatively to stabilise Raf-1 in a confirmation that promotes its 
activation  (Fu  et  al.,  2000).    The  ability  of  14-3-3  proteins  to  regulate  Raf-1  activity 
prompts  the  question  of  whether  binding  of  14-3-3t  to  the  A2AAR  could  influence 
initiation  of  ERK  signalling  from  the  receptor.    This  has  been  suggested  for  the  a2-
adrenergic receptors which bind 14-3-3z via their third intracellular loops (Prezeau et al., Gillian R Milne, 2008    Chapter 4, 173 
1999).  Since a2-adrenergic receptors activate ERK via Ras and Raf, it was proposed that 
binding of Raf to inactive receptors via 14-3-3z could poise it for immediate activation 
following agonist stimulation.  It is possible that 14-3-3t could play a similar role in ERK 
activation by the A2AAR in endothelial cells where G protein-independent activation of 
ERK is believed to occur through activation of Ras (Seidel et al., 1999). 
A major finding in this study was that interaction of the A2AAR with TRAX was severely 
inhibited under conditions when the A2AAR would be phosphorylated.  Future studies to 
determine the functional consequences of this effect can make use of the discovery that 
TRAX mediates the ability of the A2AAR to induce cell cycle arrest and differentiation of 
PC-12 cells that is impaired in the absence of functional p53 (Sun et al., 2006).  First it will 
be important to define the binding site for TRAX in the A2AAR C-terminal tail.  Initially, 
the truncated forms of the A2AAR could be used in pull-down experiments to determine 
which region of the receptor is involved.  More detailed analysis could be achieved by 
constructing  peptide  arrays  based  on  the  tail  of  the  A2AAR  and  testing  the  ability  of 
purified TRAX to bind to different stretches of amino acids.  If the residues required for 
binding of TRAX to the A2AAR can be identified, then peptides based on this sequence 
could be constructed and modified with lipids to allow introduction into PC-12 cells.  If the 
interaction  of  TRAX  with  the  A2AAR  is  dependent  on  the  receptor  being 
unphosphorylated, then these peptides will displace TRAX from the A2AAR and this will 
result in a reduced ability of the A2AAR to induce neurite differentiation in the absence of 
functional  p53.    Treating  cells  with  PMA  to  induce  receptor  phosphorylation  and 
dissociation  from  TRAX  would  be  expected  to  have  a  similar  effect.    Together,  these 
experiments would show whether or not phosphorylation of the receptor is a significant 
factor in regulating downstream functional effects of A2AAR signalling. 
In summary, during this study, it was found that the human A2AAR is phosphorylated in 
response to activation of PKC either by treatment with PMA or through stimulation of 
endogenous histamine H1 receptors.  In HUVECs this effect appeared to be mediated by 
PKCd and/or PKCq although the involvement of an intermediate kinase could not be ruled 
out.  Importantly, a potential functional role for these phosphorylation events was indicated 
by the  finding that in vitro binding of the C-terminal-interacting protein TRAX to the 
A2AAR  was  significantly  reduced  under  conditions  when  the  receptor  would  be 
phosphorylated  while  the  interaction  with  14-3-3t  was  unaffected.    This  suggests  that 
phosphorylation  of  the  A2AAR  may  be  important  in  regulating  binding  of  particular 
proteins  to  the  C-terminal  tail  of  the  receptor.    This  is  significant  in  the  light  of  the Gillian R Milne, 2008    Chapter 4, 174 
increasing  number  of  proteins  that  are  being  identified  as  able  to  interact  with  the  C-
terminal tail of the A2AAR.  Regulation by phosphorylation may provide a mechanism by 
which different proteins can be recruited in order to initiate different signalling pathways 
in different cellular contexts. 
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5  Final discussion 
The  production  of  adenosine  in  response  to  metabolic  stress  represents  a  critical 
endogenous mechanism for preventing excessive inflammation and limiting tissue injury 
(Haskó and Cronstein, 2004).  The central role of the A2AAR in mediating these responses 
has been demonstrated in numerous studies using adenosine and A2AAR selective agonists 
to inhibit the inflammatory responses in a variety of cell types in vitro as well as in in vivo 
models  of  inflammatory  disease  and  in  studies  using  A2A-deficient  mice  (Palmer  and 
Trevethick,  2008;  Haskó  and  Cronstein,  2004;  Sitkovsky,  2003).    As  an  endogenous 
mediator of anti-inflammatory responses, the A2AAR represents a particularly attractive 
subject for study.  Increasing understanding of how the body naturally deals with excessive 
inflammation may reveal mechanisms of limiting inflammation and tissue damage that 
could  be  harnessed  to  create  novel  therapies  for  major  inflammatory  diseases  such  as 
atherosclerosis, sepsis and cancer. 
Despite  the  plethora  of  evidence  regarding  the  anti-inflammatory  effects  of  signalling 
through the A2AAR, the mechanisms behind these effects are only just beginning to be 
elucidated.  Findings from in vitro studies using endothelial cells have indicated that the 
ability  of  the  A2AAR  to  exert  such  wide-ranging  anti-inflammatory  effects  could  be 
explained by its ability to regulate pro-inflammatory signalling pathways (Sands et al., 
2006; Sands et al., 2004).  The aim of the study described in Chapter 2 of this thesis was to 
investigate  the  physiological  relevance  of  these  findings  by  assessing  the  role  of  the 
A2AAR in regulating activation of the NFkB and JAK/STAT pro-inflammatory signalling 
pathways in the aortae of A2AAR-deficient mice.  Data presented here show that in mice 
lacking  the  A2AAR,  LPS-induced  pro-inflammatory  cytokine  production  is  markedly 
enhanced compared to wild-type mice.  Consistent with this observation, activation of the 
JAK/STAT pathway in response to LPS was potentiated in the aortae of these animals as 
shown by elevated levels of phosphorylated STAT1.  Similarly, heightened activation of 
the NFkB pathway was detected by the presence of increased levels of phosphorylated 
IkBa  in  A2AAR
-/-  mice  regardless  of  LPS-treatment.    However,  evaluation  of  the 
significance of this finding will require further study as no change was detected in the 
expression of the STAT1 and NFkB-regulated genes, VCAM-1, ICAM-1 and TAP-1. 
The lack of effect of increased NFkB and JAK/STAT pathway activation on downstream 
signalling  and  gene  expression  was  unexpected  but  can  perhaps  be  explained  by  the Gillian R Milne, 2008    Chapter 5, 176 
upregualtion of negative regulatory mechanisms in A2AAR-deficient mice.  This may have 
been a result of using a mouse model in which the A2AAR gene had been disrupted in all 
tissues.  Many unknown compensatory genetic changes could have occurred that might 
mask the effects of expressing a non-functional A2AAR.  A more useful method to analyse 
specific effects of the A2AAR in the vascular endothelium would be to use tissue-specific 
gene deletion to target the A2AAR only in endothelial cells.  Another approach to assess the 
importance of adenosine receptor signalling in regulating pro-inflammatory signalling in 
the endothelium would be to examine NFkB and JAK/STAT pathway activation in mice 
lacking endothelial CD73 or CD39.  These enzymes enable the endothelium to produce a 
significant  amount  of  adenosine  that  is  critical  for  maintenance  of  endothelial  barrier 
function  during  acute  inflammatory  responses  (Lennon  et  al.,  1998).    If  adenosine 
signalling through the A2AAR is a significant mechanism for regulating pro-inflammatory 
signalling in the endothelium then it might be expected that CD73 or CD39-deficient mice 
would display similar perturbations in NFkB and JAK/STAT signalling to A2AAR
-/- mice. 
In this study, pro-inflammatory signalling pathway activation was examined specifically in 
the  aorta  in  an  attempt  to  characterise  mechanisms  which  may  allow  the  A2AAR  to 
suppress  the  development  of  vascular  inflammation  and  atherosclerosis.    LPS-induced 
sepsis was used as a model of vascular inflammation.  However, LPS treatment produces 
acute inflammation while atherosclerosis is a chronic inflammatory disease with plaques 
developing over several years or decades (Hansson, 2005).  In order to understand changes 
in the endothelium during atherosclerosis, it would be useful to carry out studies using a 
model  of  chronic  inflammation  such  as  collagen-induced  arthritis  which  develops  over 
several weeks.  This may produce quite different effects on pro-inflammatory signalling 
owing  to  changes  in  the  cytokines  present  during  chronic  inflammation  and  the 
involvement of different cell types, particularly T cells. 
A particularly striking difference between wild-type and A2AAR
-/- mice observed in this 
study was the increased level of IkBa phosphorylation detected in A2AAR
-/- mice even in 
the absence of LPS treatment.  It would be interesting to investigate the mechanisms which 
prevent IkBa phosphorylation and therefore inappropriate activation of the NFkB pathway 
in A2AAR-competent mice.  This could occur at several steps in the pathway leading to 
NFkB activation.  For example, through negative regulation of IKK phosphorylation or by 
inactivation  of  upstream  components  such  as  TAK1,  RIP  or  TRAF  proteins.    These 
signalling  factors  rely  on  Lys63  polyubiquitination  for  activation  and  are  subject  to 
negative  regulation  by  DUBs  such  as  A20  and  CYLD  (Sun  et  al.,  2008).    Therefore Gillian R Milne, 2008    Chapter 5, 177 
modulation  of  DUB  activity  represents  a  likely  mechanism  for  regulation  of  their 
activation status.  A2BAR activation has already been shown to promote deneddylation of 
the Cul-1 subunit of the IkBa E3 ligase complex (Khoury et al., 2007).  Perhaps A2AAR 
activation  in  wild-type  mice  suppresses  NFkB  activation  in  the  absence  of  stimuli  by 
promoting the deubiquitination of signalling components upstream of IKK. 
The  effects  of  the  A2AAR  on  endothelial  cells  are  of  particular  interest  since  vascular 
dysfunction is central to development of atherosclerosis.  In this study, it was hypothesised 
that the presence of the A2AAR might suppress pro-inflammatory pathway activation in the 
endothelium  and  therefore  protect  against  development  of  vascular  disease.    However, 
these effects may not be specific to endothelial cells and it would be interesting to see if 
signalling in other cell types is affected by A2AAR activation.  T cells and NKT cells, for 
example,  represent  interesting  targets  as  they  are  both  involved  in  the development  of 
atherosclerosis (Hansson, 2005) and have their pro-inflammatory functions suppressed by 
A2AAR stimulation (Sevigny et al., 2007; Lappas et al., 2006). 
Another  subject  for  future  studies  might  be  to  investigate  the  effect  of  A2AAR  gene-
deletion on signalling pathways other than the NFkB and JAK/STAT pathways.  Although 
these  are  generally  considered  to  be  the  major  pro-inflammatory  signalling  pathways, 
others  such  as  the  JNK  and  p38  pathways  are  also  involved  in  activation  of  the 
endothelium and so may represent targets for regulation by the A2AAR (Sumara et al., 
2005; Hoefen and Berk, 2002). 
In summary, findings presented in Chapter 2 of this thesis indicate that signalling through 
the A2AAR represents a significant endogenous mechanism for suppressing activation of 
the NFkB  and JAK/STAT pro-inflammatory signalling pathways in the aorta.  Further 
studies will be required to assess the consequences of this for downstream gene expression 
and  development  of  vascular  inflammation.    Future  studies  aimed  at  identifying 
mechanisms by which the A2AAR regulates pro-inflammatory signalling may reveal novel 
targets for therapeutic intervention.  This could allow specific modulation of inflammatory 
events  occurring  in  the  endothelium  to  limit  the  progression  of  diseases  such  as 
atherosclerosis, sepsis and cancer. 
While data presented in Chapter 2 of this thesis add to the large body of evidence regarding 
the physiological effects of signalling through the A2AAR, findings described in Chapter 3 
pertain to the lesser studied question of how the receptor is regulated at a molecular level.  Gillian R Milne, 2008    Chapter 5, 178 
This subject has become of particular interest recently since it has become apparent that in 
addition to heterotrimeric G proteins and proteins involved in desensitisation, several other 
proteins can interact with the long C-terminal tail of the A2AAR (Zezula and Freissmuth, 
2008).  However, the question of how these interactions might be regulated has not been 
addressed.    Previous  studies  have  shown  that  the  canine  A2AAR  is  phosphorylated  in 
response to activation of PKC.  However, unlike in the case of other GPCRs, this is not 
associated with heterologous desensitisation of receptor-G protein coupling (Palmer et al., 
1999),  indicating  that  PKC-mediated  phosphorylation  may  have  a  previously 
unappreciated role in regulating A2AAR activity.  The aim of this study was to determine 
whether  the  human  A2AAR,  like  the  canine  receptor,  is  subject  to  regulation  by 
phosphorylation and whether phosphorylation events in the C-terminal tail of the A2AAR 
could play a role in regulating the binding of interacting proteins.  Data presented here 
indicate that the human A2AAR is indeed phosphorylated in response to PKC activation.  
Interestingly this modification appears to have consequences for the binding of C-terminal 
interacting proteins as 14-3-3t was found to bind to the A2AAR in the presence or absence 
of PKC-activating stimuli while TRAX bound only to the unphosphorylated receptor.  This 
suggests  that  PKC-mediated  phosphorylation  may  represent  a  selective  means  of 
controlling binding of individual interacting proteins. 
In addition to 14-3-3t and TRAX, several other proteins have been reported to interact 
with the C-terminal tail of the A2AAR including ARNO (Gsandtner et al., 2005), a-actinin 
(Burgueño et al., 2003) and USP4 (Milojević et al., 2006).  To determine whether PKC-
mediated phosphorylation represents a general mechanism of regulating interactions with 
the A2AAR, it would be interesting to repeat pull-down experiments carried out in this 
study with ARNO, a-actinin and USP4.  It would also be interesting to find out if any of 
these  proteins  can  bind  simultaneously  and  whether  the  phosphorylation  status  of  the 
receptor dictates which combination of proteins can bind at one time.  For example, while 
phosphorylation  of  the  A2AAR  inhibits  the  interaction  with  TRAX,  dissociation  from 
TRAX may enable another protein to bind.  To properly characterise these interactions, it 
will be important to identify the binding sites of each of the interacting proteins.  This can 
be achieved by assessing binding of recombinant proteins to peptide arrays representing 
the C-terminal tail of the A2AAR.  Alanine scanning mutagenesis could then be used to 
identify  the  role  of  individual  amino  acids  in  dictating  interactions  in  co-
immunoprecipitation and pull-down assays. Gillian R Milne, 2008    Chapter 5, 179 
The finding that 14-3-3t binds to the A2AAR indicates that other 14-3-3 proteins may also 
be A2AAR interactors as members of this family are highly homologous (Aitken, 2006).  It 
would be interesting to test whether this is the case as different isoforms of 14-3-3 proteins 
may be present in different cell types.  It would also be interesting to find out whether they 
share a common binding site as the A2AAR C-terminal tail does not contain any classical 
14-3-3 consensus binding motifs. 
Future studies should be directed at determining the functional significance of interactions 
occurring  at  the  C-terminal  tail  of  the  A2AAR  and  the  consequences  of  receptor 
phosphorylation.    USP4  has  been  assigned  a  role  in  promoting  A2AAR  cell-surface 
expression by regulating its ubiquitination status (Milojević et al., 2006) while a-actinin 
appears to be important for A2AAR internalisation (Burgueño et al., 2003) and ARNO is 
involved  in  G-protein-independent  activation  of  the  ERK  pathway  by  the  A2AAR 
(Gsandtner et al., 2005).  If receptor phosphorylation is found to regulate the interactions 
of  any  of  these  proteins  with  the  tail  of  the  A2AAR,  it  would  be  interesting  to  see  if 
phosphorylation  results  in any  changes in these functions.  This could  be achieved by 
introducing  cell-permeable  peptides  based  on  either  the  phosphorylated  or 
unphosphorylated form of the receptor tail to displace the interacting proteins followed by 
assessment of downstream effects.  The role of 14-3-3t binding to the A2AAR has not yet 
been identified but could be investigated using gene targeting to generate mice lacking 14-
3-3t and then examining the resultant phenotypes for changes that might relate to aberrant 
A2AAR function.  The likelihood that other 14-3-3 proteins could compensate for the lack 
of 14-3-3t might limit the usefulness of this approach. 
In  summary,  findings  presented  here  show  that  the  human  A2AAR  is  subject  to  PKC-
mediated phosphorylation and this appears to play a role in controlling which proteins can 
bind to the C-terminal tail of the receptor.  The functional significance of this regulation 
remains to be examined but it could represent a means of selectively recruiting different 
proteins to the receptor to allow initiation of distinct signalling pathways, thereby enabling 
the A2AAR to induce the appropriate responses in particular cellular contexts. 180 
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